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Introduction 
Primary open-angle glaucoma (PO A G) is a clinically and genetically heterogeneous 
eye disease, which involves the death of retinal ganglion cells and their axons due to 
an apoptotic process. Clinically, this neurodegeneration is characterised by an exca-
vation of the optic nerve, referred to as glaucomatous optic neuropathy (GON), 
and a glaucomatous visual field defect (GVFD), in combination with open and 
normal anterior chamber angles. The prevalence of POAG varies around 1% in 
subjects 55 years and older in the western world, increasing from 0.1 °/o in persons 
aged 55 to 2°/o in those over age 80.1-4 
It is generally acknowledged that POAG is a complex disease. 5-7 In the majority 
of patients, POAG is thought to be the result of a combination of multiple generic 
and non~generic risk factors.C1 Different combinations of risk factors result in a 
heterogeneous group of disorders, together classified as POAG. Only in a small 
subset of families, POAG is caused by mutations in a single gene. The aim of this 
thesis is to investigate the role of several potential risk factors in the etiology of 
POAG, using a genetic~epiderniological approach. 
Risk factors and pathogenesis~current status 
Besides age, well-known risk factors for POAG include myopia, African descent, an 
elevated rops,, The latter factor has been described extensively'" and most therapy 
is presently directed at lowering the IOP, as it is the major risk factor that can be 
influenced. However, is has been shown in population-based studies, that in 30-
500/o of patients the lOP is within the statistically normal range.1.3,10 In addition, the 
proportion of patients whose visual fields deteriorate despite treatment varies from 
5°/o to 80%, with an average of approxi1nately 10°/o per year.11 .12 These observations 
point to other factors involved in the development of glaucomatous damage. 
One hypothesis is that a decreased blood flow leads to ischemia of the optic 
nerve head. Much has been written on the factors responsible for a decreased blood 
flow. Various vascular characteristics such as blood pressure, perfusion pressure, 
antihypertensive treatment, and vasospasms, have been studied extensively.13,14 
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However, data are contradictory and difficult to interpret. Moreover, most data 
available are clinic-based and few data are available from population-based 
studies.l3·19 
The recent finding that the loss of ganglion cells was caused by the process of 
programmed cell death (apoptosis) introduced a new area of research into 
glaucoma.2° Following this innovative insight, alternative management of this 
disease may develop. In the future, neuroprotective therapy might be directed at 
preseDling ganglion cells from death, independent of the level of IOP.12 
A major risk factor is a positive family history of glaucoma.21 •22 Individuals with 
a first-degree relative with POAG have a nine times increased risk over those who 
do not have an affected relative,23 and monozygotic twin pairs were shown to be 
more often simultaneously affected than dizygotic ones.24 The identification of the 
first glaucoma disease gene (myocilin (MYOC), GLC1A) gave a new impulse to the 
research of POAG. This gene was originally identified in a family with juvenile 
onset POAG, segregating in an autosomal dominant manner.25 However, it has 
been shm.vn in clinic-based studies, that fvfYOC mutations were present in 3-5°/o of 
adult onset POAG patients.25,26 Phenotypes, resulting from different mutations in 
this gene appeared to vary among patients.r Even in patients carrying the same 
mutation, different intrafarniliar phenotypes were described, which suggest the 
involvement of other factors than J\fYOC mutations alone in the development of 
POAG2B~9 
Since the identification of J\fYOC, five other genomic regions have been linked 
to POAG in independent families (GLC1B to GLC1F) 311 These five additional 
POAG loci have been found in families where the disease segregated as an 
autosomal dominant trait and where the disease started in adult patients. The level 
of lOP was high in most POAG patients for all loci except GLClE, where 12 of 15 
POAG patients in this family had an lOP < 21 mm Hg. Because of the hetero-
geneous character of POAG, it is expected that even more disease genes will be 
identified. 
Clinical, epidemiological and genetic investigations into POAG 
Glaucoma studies are difficult to compare due to the lack of an internationally 
accepted definition of POAG. Often, POAG is discussed as a single disease, 
although it is generally acknowledged, that it is actually a group of diseases. It would 
be a step fon.vard in classifying POAG according to aetiology, when we know 
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which genes are involved. As a consequence, one would expect that in the corning 
years part of the POAG group will not be named POAG any more but e.g. 
myocilin-based open-angle glaucoma (OAG). 
Although a classification based on clinical features is unsatisfactory at the 
moment, clinical phenotyping is in itself an important step on the way to identifying 
genes. Until a more exact classification according to aetiology is reached, a world-
wide-accepted clinical definition is necessary. In the Rotterdam Study, we proposed 
to define POAG as a combination of a GON with a GVFD4 The GON criteria 
were based on the distributions of optic disc characteristics in the population. This 
definition may be fine-tuned when incidence data become available. 
In the subset of POAG families in which linkage with specific genomic regions 
(GLClA to GLC!F) was found, POAG is segregating as an autosomal dominant 
trait. However, the majority of POAG families do not reveal a clear-cut 11endelian 
inheritance pattern. The heterogeneous character of POAG complicates research 
into the genetic causes, because one phenotype may be caused by different genetic 
factors. Reversibly, one genetic defect may cause different phenotypes with differ-
ent levels of penetrance. Additionally, genetic and non-genetic factors may 
influence the expression of a gene. 
Another problem complicating the genetic dissection of POAG is the late age of 
onset. It is difficult to identify individual families "\Vith a sufficient number of 
affected relatives for linkage studies, because parents and siblings are often 
deceased and children have not reached the age of onset yet. This implies that other 
methods than traditional linkage analysis will have to be pursued in the search for 
POAG disease genes. 
Outline of thesis 
In the first part of this thesis, potential environmental and genetic risk factors for 
POAG are examined in the Rotterdam Study, a prospective population-based 
cohort study among subjects 55 years and older. In its second part, the population 
of a genetic isolate is investigated, using a combined test for linkage and linkage 
disequilibrium. 
Glaucoma cases with pseudoexfoliation were not specifically excluded in the 
baseline phase of the Rotterdam Study. Investigators disagree about whether pseu-
doexfoliative glaucoma should be named POAG and prevalence figures in 
glaucoma populations are reported up to 66°/o in Scandinavia, but also 12°/o in the 
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US and Australia.B1 As we did not see any pseudoexfoliation during follow up, and 
because we specifically excluded pseudoexfoliative glaucoma in the POAG patients 
from the genetically isolated population, we refer to the disease status as POAG in 
this thesis. 
In chapter 2.1, a proposal for an international definition of POAG is presented 
as well as the prevalence of POAG in the Rotterdam Study based according to this 
definition. The association between early menopause and POAG is described in 
chapter 2.2, suggesting the involvement of hormonal factors in the disease etiology. 
In chapter 2.3, we investigate the relation bet\veen blood pressure, arterial stiffness, 
and POAG. A new method to estimate the genetic risk in an individual is demon-
strated in chapter 3. This study was performed in a family study based on case and 
control probands derived from the Rotterdam population. In chapter 4, the 
prevalence of lvf'YOC mutations was studied in a sample of POAG cases from the 
population-based Rotterdam Study. In addition, we described a family retrieved 
from this population, where POAG co-segregated with a mutation in this gene. 
The exclusion of POAG candidate loci in a sample of patients from a genetically 
isolated population was reported in chapter 5.1. In chapter 5.2, a genome scan per-
formed in this sample is described, two regions are proposed, and possible 
candidate genes are selected. 
Finally, the main findings and methodological issues of all studies described in 
this thesis are discussed in chapter 6, with recommendations for future research. 
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2 
EPIDEMIOLOGICAL STUDIES 
IN THE ROTTERDAM STUDY 

2.1 
Definitions and prevalences of primary open-angle 
glaucoma in the Rotterdam Study 
Abstract 
PURPOSE- To create a quantitative basis for diagnostic criteria for primary 
open-angle glaucoma (POAG), and to propose an epidemiologic definition 
for POAG based on these, and to determine the prevalence of POAG in a 
general white population. 
METHODS- Of the 7,983 subjects 55 years of age or older participating in the 
population-based Rotterdam Study, 6,756 subjects participated in the 
ophthalmic part of this study (6,281 independently living subjects and 475 in 
nursing homes). The criteria for the diagnosis of POAG were based on 
ophthalmic and semi-automated Imagenet estimations of the optic disc such 
as vertical cup-to-disc ratio (VCDR), minimal width of neural rim, or asym-
metry in VCDR between both eyes, and visual field testing with kinetic 
Goldmann perimetry. All criteria for the diagnosis of POAG were assessed 
in a masked way independently of each other. 
RESULTS- Mean VCDR on ophthalmoscopy was 0.3 and with Imagenet 0.49, 
and the 97.5th percentile for both was 0.7. The prevalence of glaucomatous 
visual field defects was 1.5%. Overall prevalence of definite POAG in the 
independently living subjects was 0.8% (95% confidence interval [CI] 0.6, 
1.0; 50 cases). Prevalence of POAG was double that in women (odds ratio 
2.1, 95% CI 1.2, 3.6). Different commonly used criteria for diagnosis of 
POAG resulted in prevalence figures ranging from 0.1% to 1.2o/o. 
CONCLUSI00J- The overall prevalence of POAG in the present study was 
comparable to most population-based studies. However, prevalence figures 
differed by a factor of 12 when their criteria for POAG were applied to this 
population. ll. definition for definite POll.G is proposed: a glaucomatous 
optic neuropathy in eyes with open angles in the absence of history or signs 
of secondary glaucoma characterized by glaucomatous changes based on the 
97.5 percentile for this population, together with glaucomatous visual field 
loss. In the absence of the latter or of a visual field test, it is proposed to 
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speak of probable POAG based on the 99.5'h or possible POAG based on 
the 97,5th percentiles of glaucomatous disc changes for a population under 
study. 
Introduction 
Primary open-angle glaucoma (POAG) ranks third among causes of incurable 
visual impairment in the W' estern world. 1-3 Despite prevalence figures in white sub-
jects ranging from 0.8°/o to 3.0°/o1• 4-14, little is known about its etiology. This may be 
partly due to the lack of a worldwide epidemiologic definition of, or standard for 
diagnosis of POAG1· 15 (Table 1). As a result many (epidemiologic) studies are diffi-
cult to compare, because of the different criteria and methods used for diagnosis, 
hampering meta-analyses and the search for risk factors. 
It is nowadays generally accepted that POAG is an optic neuropathy character-
ized by cupping of the optic nen'e head, with corresponding nerve fiber loss and 
visual field defects but that there is no consensus about cut-off points for normal 
disc measurements. An elevated intraocular pressure (IOP) is considered to be a 
risk factor for POAG, as well as the presence of a first-degree relative with 
glaucoma. 16 For the diagnosis POAG congenital forms of glaucoma have to be ex-
cluded, as well as secondary causes of glaucoma such as pseudoexfoliation. 
The aim of the present study was to quantify in a masked way the prevalence of 
determinants of POAG in a white population, to propose diagnostic criteria for 
POAG, and to study the influence of various diagnostic criteria for POAG on the 
prevalence of POAG. Although pseudoexfoliative glaucoma was not excluded at 
baseline, we refer to the disease status as POAG, because pseudoexfoliation was 
not observed at follow up. 
Materials and methods 
Population 
The present study was performed as the ophthalmic part of the Rotterdam Study, a 
prospective cohort study of all residents, 55 years of age and older.17 Results of a 
prevalence study in a subset of the examined population using different criteria for 
POAG have been published previously.!O The study was performed according to 
12 
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Table 1 
Different criteria for primary open-angle glaucoma 
Baltimore Eye Survey 7 
Definite, probable and uncertain classification. Best available from eight, sometimes 
not quantified, different disc criteria (CDR;::: 0.8, or difference between OU :2: 0.3 or 
0.4). VF defect not explainable by other causes. l'io lOP criterion. 
Barbados Eye study9 
VF, optic disc, and ophthalmic examination criteria. Seven combinations possible. 
Definite: at least on succession 2 abnormal VF together \Vith 2 of 3 of following 
criteria: CDR 2:: 0.7, asymmetry;::: 0.2, rim width::::; 0.1, notching, disc hemorrhage. If 
not: suspect. IOP no criterion. 
Beaver Dam Eye Studys 
At least two of the follmving criteria: VF defect not explainable by other causes, CDR 
2':: 0.8, or an asymmetry in CDR 2':: 0.2, lOP;::: 22 mm Hg, or lOP-lowering treatment. 
Blue Mountains Eye Studyll 
GVFD not explainable by other causes, combined with VCDR;::: 0.7, or asymmetry in 
VCDR bet\:veen both eyes;::: 0.3. 
Egna-Neumarkt study13 
At least 2 of the following criteria with open angle: GVFD, lOP;::: 22 mm Hg and 1 of 
the follmving disc criteria: CDR;::: 0.7, asymmetry> 0.2, difference in VCDR and 
HCDR > 0.2, notching, disc hemorrhage, excavation reaching disc margin. 
Framingham Study23 
VF defect not explainable by other causes (only in selected part of the population), 
combined with VCDR;::: 0.6, or asymmetry in VCDR bet\veen both eyes;::: 0.2. 
Melbourne visual impairment project14 
No strict criteria due to uncertainty of diagnostic criteria. Panel discussion with 6 
ophthalmologists grading in none, possible, probable, or definite POAG. Criteria: 
past POAG history, lOP > 21 mm Hg, VF defect including enlarged blind spot, 
CDR ;::: 0. 7 or asymmetry ;::: 0.3. 
Ponza Glaucoma study12 
GVFDs and 1 of the following criteria: lOP > 20 mm Hg, CDR;::: 0.5, or asymmetry 2':: 
0.2. Suspect if questionable VF loss. 
Rotterdam Study (2000 criteria) 
If present in at least 1 eye \Vith open angle and no history or sign of secondary 
glaucoma. No lOP criteria. 
Definite POAG: GVFD combined with at least possible GO'\i: VCDR e: 0.7, or 
asymmetry between both eyes ;::: 0.2 or a minimal rim width < 0.1. 
Probable POAG: (1) GVFD without possible GON or (2) absence of GVFD or of any 
VF test with probable GOl\J: VCDR;::: 0.9, or asymmetry;::: 0.3, or minimal rim width 
< 0.05. 
Possible POAG: possible GO'\i and no GVFD. 
CDR: cup-disc ratio; GON: glaucomatous optic neuropathy; GVFD: glaucomatous visual field defect; 
HCDR: horizontal cup-disc ratio; lOP: intraocular pressure; OD: right eye; OD: left eye; OU: both 
eyes; POAG: primary open angle glaucoma; VCDR: vertical cup-disc ratio; VF: visual field. 
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the declaration of Helsinki and was approved by the Medical Ethics Committee of 
the Erasmus University. Written informed consent was obtained from all partici-
pants. All residents were asked to participate in an extensive home interview, after 
which an appointment was made for a medical examination, including a complete 
ophthalmologic one. 
Ophthalmologic examination 
The ophthalmologic examination was performed by three ophthalmologic residents 
and two technicians (Table 2). After perimetry, mydriatic drops were administered 
in both eyes, irrespective of the anterior chamber angle depth or history of 
glaucoma,1S for lens and fundus examination, and photography. At the end of the 
first phase a miotic was administered in both eyes to counteract the mydriasis. 
Optic disc measurements 
Stereo transparencies from both eyes of all individuals were digitized and analyzed 
by t\vo technicians with the semiautomated Topcon Image Analyzer (Imagenet), 
using the module for the retinal nerve fiber layer height. The system's hardware, its 
softv..rare modules and reproducibility of measurements have been described previ-
ously.19·20 For both ophthalmoscopy and Imagenet the distribution of the measure-
ments of the vertical cup-disk ratio (VCDR) and the asymmetry of the VCDR 
between both eyes together with their 97.Sth and 99.5th percentiles \Vere determined. 
The neural rim width was only determined with Imagenet and was defined as the 
proportion of the diameter of the rim section, measured at each of 36 equally 
spaced points on the optic disc border, in relation to the total optic disc diameter. 
Proposed definitions for probable and possible glaucomatous optic neuropathies 
Because cupping of the optic nerve head is the hallmark for glaucomatous optic 
neuropathy (GON), we chose to use this term. However, it does not imply that a 
person with GON definitely has glaucoma. 
Probable GON was defined as the presence of at least one of the following 
characteristics: a VCDR, or asymmetry in VCDR between both eyes, or minimum 
width of the neural rim equal to or surpassing the 99.5ch percentile of the popula-
tion concerned. Possible GON was defined as the above and greater than or equal 
to the 97.5'h but less than the 99.5cl' percentile of the population. 
14 
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Table 2 
Ophthalmologic examination and Open-Angle Glaucoma screening: 
The Rotterdam Study, 1990-1993 
Examination type/method/tool 
Phase I 
Autorefraction 
Best corrected visual acuity 
Kcratometry 
Slit-lamp examination 
Chamber angle slit-lamp 
estimation 
IOP measurement 
Visual field screening of 
both eyes separately 
11ydriatic drops 
Color transparencies macular area 
Stereo simultaneous color 
transparencies optic disc 
Ophthalmoscopy 
i\fiotic drop 
Phase II: 
Visual field screening 
Phase Ill: 
Visual field determination 
IOP measurement 
Gonioscopy (Shaffer) 
lOP: intraocular pressure 
VF: visual field 
VF A: visual field analyzer 
*Tokyo Optical Co, Tokyo, Japan 
t Haag Streit, Bern, S\.vitzerland 
t Zeiss, Oberkochen, Germany 
Manufacturer/Method 
Reference/Specifications 
Topcon Rcv!A 2000* 
Lighthouse Visual Acuity Chart (2nd edition) 
Topcon Ofvf-4 Ophthalmometer* 
Topcon SL-3E slitlamp* 
Van Herick29 
Goldmann applanation tonometer30· t 
modified 52-point supra threshold screening test 
central24o radius (Humphrey VFA):j: 
Tropicamide 0.5% and phenylephrine 5% 
35o field; TRC-SOVT camera* in mydriasis 
20° field; TRC-SS2 camera* in mydriasis 
Direct and indirect (AusJ ena ophthalmoscope, 
Zeiss bonoscope) in mydriasis 
One drop of thymoxamine-hydrochloride 0.5% 
As in phase I in case of unreliable or defective VF 
In case of unreliable or defective VF in phase II: 
kinetic Goldmann perimetl)i, experienced 
perimetrist 
Goldmann applanation tonometer 30• t 
Goldmann 3-mirror contactlenst 
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Visual field screening and determination 
The visual field (VF) screening during the first phase (Table 2) reduced examination 
time and the chance of rim artifacts. Three or more contiguously missed points on 
the screening test (2: 4 when blind spot was included) were taken as evidence for a 
VF defect. In case of a defective or unreliable VF test, VFs were retested with the 
same screening test in the second phase, about 2 weeks later. Subjects with a VF 
defect or unreliable test in the second phase of the study, underwent kinetic Gold-
mann perimetry on both eyes, performed by a skilled perimerrist in the third phase, 
some weeks later. Also, in cases with a Goldmann VF defect gonioscopy was per-
formed to exclude cases with narrow angles. All subjects with glaucomatous VF 
defects had normal open anterior chamber angles. VF testing was unreliable or im-
possible in the institutionalized subjects, mainly due to physical and mental 
disabilities. 
All Goldmann VF charts were independently graded by six different graders 
(three senior ophthalmologists, t\VO residents, one perimetrist) according to a 
special grading protocol. Graders were at first masked to all clinical data and optic 
disc appearances. Classification of the defects was solely based on the shape and 
localization of the defect. With regard to glaucomatous VF defects (GVFDs) 
special attention was put on a nasal step, paracentral defects, arcuate scotomas, 
central rests, remaining peripheral islands, and temporal nerve fiber bundle defects. 
For fields with inconsistent classifications (30%) a consensus was reached among 
the graders. The fundus and optic disc transparencies were examined in a masked 
way for clues for retinal causes of VF defects and, if present, for the expected loca-
tion of the VF defect. For exclusion of other nonglaucomatous causes of VF 
defects all other data available in the Rotterdam Study was used, including ques-
tionnaire data on and neurologic examination of all subjects, and (history) data 
from general practitioners including reports from all medical specialists who had 
treated the subject in the past. 
Definition of glaucomatous visual field loss 
Glaucomatous VF defect was defined as any Goldmann VF defect for which no 
other (neur)ophthalmologic cause could be found (see previous paragraph), thus 
excluding, for example, hemianopias and quadrantanopias. 
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Definitions for definite, probable, and possible POAGs, ocular hypertension, and elevated 
IOP 
The following POAG definitions hold for a subject in whom in one or both eyes an 
open angle was present in the absence of a history or signs of angle closure or 
secondary glaucoma. 
Definite POAG is the presence of a GVFD in combination with at least 
possible GON. 
Probable POAG is either the presence of a GVFD in the absence of a GON or 
the absence of a GVFD with a probable GON. 
Possible POAG is the presence of possible GON in the absence of either a 
GVFD or a VF test. 
For logistic reasons subjects underwent a glucose tolerance test (GTT; by the 
cardiovascular research group) approximately 20 minutes before lOP measurement 
in the first testing phase. This GTT was carried out by giving an oral glucose load 
of 75g in 200 ml of water, and was performed on all nondiabetic subjects who had 
not had a gastrectomy. 
The lOP was not used in the definition of POAG, neither was the use of lOP-
lowering medication or the performance of an lOP-lowering (laser) operation in 
the absence of our criteria for POAG. Ocular hypertension was defined as an lOP 
> 21 mm Hg (or ~ 21 mm Hg with any form of lOP-lowering treatment) in the 
absence of a GVFD or a GON. lOP values were adjusted for the lOP-lowering 
effect of the GTT. 
Data analysis 
Although the distribution of lOP and VCDR was not completely gaussian we 
thought it sound to assume a normal distribution of the large numbers in our study. 
Their 97.5th and 99.5th percentiles, also corrected for disc area quartiles and age 
strata, were parametrically calculated for each eye separately for the whole cohort, 
including the POAG cases. These percentiles were rounded up or down to the 
closest one decimal (for the minimum neural rim width to two decimals), in an 
attempt to include all POAG cases. In analyses in which Imagenet data were com-
bined with ophthalmoscopic data, the latter was only used when the Imagenet data 
were missing or unreliable (n = 84). 
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Table 3 
Response figutes of the Rotterdam Study, 1990-1993 
Age category, y 55-59 60-64 65-69 70-74 75-79 80+ Total 
Inrlependenb living sul:jects: 
Total eligibles 1480 1761 1737 1606 1286 1291 9161 
Total examined 1172 (79.2) 1421 (80.7) 1327 (76.4) 1157 (72.0) 834 (64.9) 583 (45.2) 6494 (70.9) 
()phthalmologically examined 1162 (78.5) 1399 (79.4) 1278 (73.0) 1108 (69.0) 795 (61.8) 594 (41.8) 6281 (68.6) 
J\t!en 483 (75.1) 616 (79.1) 594 (75.7) 452 (69.5) 315 (63.0) 166 (44.0) 2626 (70.5) 
\X! omen 679 (81.0) 783 (79.5) 684 (70.8) 656 (68.6) 480 (61.1) 373 (40.8) 3655 (67.2) 
~rttning hoJJJeJ: 
Total eligibles 1 4 14 29 125 941 1114 
Total examined 1 (100) 3 (75.0) 12 (85.7) 20 (69.0) 72 (57.6) 527 (56.0) 635 (570) 
Ophthalmolog.ically examined II (0.0) 1 (25.0) 8 (57.1) 12 (41.4) 60 (48.0) 394 (41.9) 475 (42.6) 
Men 0 (0.0) 0 (0.0) 4 (50.0) 4 (50.0) 18 (48.6) 93 (54.7) 119(53.1) 
\V'omcn 0 (0.0) 1 (33.3) 4 (66.7) 8 (38.1) 42 (47.7) 301 (39.0) 356 (40.0) 
Numbers in parentheses are percenlages of the number of eligible subjects in each category. 
POAG: definitions and prevalences 
Prevalence figures of GVFDs; definite, probable, and possible POAGs; elevated 
IOP; and ocular hypertension were calculated by 5-year age-categories and by 
gender. Prevalence figures of definite, probable, and possible POAGs were calcu-
lated using disc data obtained by ophthalmoscopy, by Imagenet and both. To esti-
mate the influence of age and gender on these prevalence figures, logistic regression 
analysis was used. The odds ratio (OR) was used in these analyses as an approxima-
tion of the relative risk. Sensitivity, specificity, and predictive values of different 
cut-off points for VCDR for the presence of a GVFD and, thus, POAG were cal-
culated. All analyses were adjusted for age and gender when appropriate and were 
performed separately for the independently living subjects and for those living in 
nursing homes. 
Finally, definitions of definite POAG used in other population-based studies 
(fable 1) were, as far as available and common to those in our study, applied to our 
data. 
Results 
Population 
Interview data were collected for 78% (n = 7,983) of the eligible persons (n = 
10,275; independently living subjects plus nursing home subjects). The overall 
response rate for the center visit was 69% (n = 7,129). A total of 6,756 subjects 
participated in the ophthalmic part of the study. Table 3 shows the response 
figures, focused on the ophthalmologic examinations. The availability of ophthal-
mologic data in nursing homes was limited. 
Distribution of optic disc dimensions 
The distribution of the optic disc dimensions in the independently living subjects, 
determined by Imagenet and ophthalmoscopy, is shown in Table 4. The mean 
VCDR for ophthalmoscopy was 0.3, for Imagenet 0.49. Mean VCDR was signifi-
cantly higher with Imagenet than with ophthalmoscopy. JYfean VCDR, its asymme-
try bet\veen both eyes, and mean minimal rim width were not significantly different 
in independently living subjects and those in nursing homes (data not shown). The 
influences of disc area and age on those disc measures are given in Tables 5 and 6, 
respectively. The 97.5'h percentile of the VCDR was similar for 
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Table 4 
Distribution of optic disc dimensions in independently living subjects 
determined by Imagenet and ophthalmoscopy 
MeanVCDR 
Median asymmetry in VCDR 
Mean minimal neural rim width 
Disc dimension VCDR 2::: 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
Asymmetry in VCDR 2:: 
0.2 
0.3 
0.4 
Minimal neural rim width < 
0.25 
0.20 
0.15 
0.10 
0.05 
See Table 1 for abbreviations 
Table 5 
lmagenet (SE) 
n = 5,681 
0.49 (0.0018) 
0.06 
0.17 (0.001) 
Percentage 
of subjects 
76.7 
55.0 
26.5 
5.1 
0.4 
0.0 
7.5 
1.3 
0.1 
80.5 
58.2 
26.2 
4.1 
0.1 
Ophthalmoscopy (SE) 
n=6,199 
0.30 (0.0024) 
0.00 
not assessed 
Percentage 
of subjects 
43.2 
19.6 
9.0 
4.0 
1.6 
0.7 
5.8 
1.6 
0.6 
~ot assessed 
Influence of disc area measured by Imagenet on 97 .5th percentile of 
vertical cup-disc ratio, separately for right and left eyes 
Right Eyes Left Eyes 
Disc area (quartiles) VCDR Disc area (quartiles) VCDR 
< 2.11 mm2 <: 0.68 < 2.07 mm2 <: 0.68 
2.11 - 2.39 mm2 <: 0. 71 2.07 - 2.36 mm2 <: 0. 71 
2.39- 2.71 mm2 <: 0.73 2.36- 2.68 mm2 <: 0.73 
2::2.71 mm2 
Overall 
<: 0.76 
<: 0.73 
2::2.68 mm2 
Overall 
<:0.75 
<:0.73 
POAG: definitions and prevalences 
right and left eyes and differed 0.05 between the lowest and highest quartiles of disc 
area. Subjects 75 years of age or older had on ophthalmoscopy on average a 0.1 
higher VCDR than those between 55 and 75 years of age. Table 7 shows the 97.5ch 
and 99.5'h percentiles for VCDR, asymmetry in VCDR and minimal neural rim 
width together with the chosen cut-off points for criteria for GON, based on the 
findings in Tables 4, 5, and 6. The 97.5ch percentile of the VCDR for both 
Table 6 
Influence of age on 97.5th percentile of VCDR and asymmetry in it between both 
eyes both for ophthalmoscopy and Imagenet 
Age 
(years) 
55-64 
65-74 
75-84 
85+ 
VCDROD 
Imagenet Ophthal-
moscoEY 
0.72 0.7 
0.73 0.7 
0.74 0.8 
0.77 0.8 
VCDROS 
Imagenet Ophthal-
moscoey 
0.72 0.7 
0.72 0.7 
0.74 0.8 
0.74 0.8 
See Table 1 for abbreviations. Al data indicate greater than or equal to. 
Table 7 
Asymmetry 
Imagenet Ophthal-
moscoey 
0.26 0.2 
0.26 0.2 
0.30 0.2 
0.31 0.2 
Percentiles of optic disc dimensions in independently living subjects and derived 
cut-off points leading to criteria for probable and possible glaucomatous optic disc 
neuro athy 
Imagenet Ophthalmoscopy 
n=5,619 n=6,199 
Percentiles 97.5 99.5 97.5 99.5 
VCDR?: 0 oo .i:J 0.78 0.7 0.9 
Chosen cut-off point :2:: 0.7 0.8 0.7 0.9 
Asymmetry in VCDR :2:: 0.26 0.34 0.2 0.3 
Chosen cut-off point :2:: 0.2 0.3 0.2 0.3 
1.tlinimal neural rim width :2:: 0.08 0.05 not assessed 
Chosen cut-off oint< 0.1 0.05 
Cut-off points derived from Tables 4,5, and 6. 
Probable GON ·was defined as based on the 99.5rh percentiles: a disc '\Vith a VCDR ;;:::_ 0.9 with 
ophthalmoscopy or;;:::_ 0.8 for Imagenet, or an asymmetry in VCDR ;;:::_ 0.3 bet\veen both eyes either on 
ophthalmoscopy or with lmagenet, or a minimal neural rim '\Vidth < 0.05 on lmagenet. 
Possible GON was defined as a VCDR ;;:::_ 0.7, or an asymmetry;;:::_ 0.2 bet\veen both eyes either on 
ophthalmoscopy and lmagenet, or a minimal rim '\vidth < 0.1 with Imagenet. 
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ophthalmoscopy and Imagenet was 2: 0.7 (as it was in a different substudy on this 
population for the Heidelberg Retina Tomograph). The cut-off point for asymme-
try in VCDR between both eyes was 2: 0.2 for both ophthalmoscopy and Imagenet. 
The chosen cut-off points for definitions of GON derived from Table 7, thus were 
used for definitions ofPOAG in the Rotterdam Study (Table 1). 
Prevalence of glaucomatous visual field defects 
The prevalence of glaucomatous visual field defects is sho\vn in Table 8. The odds 
for men to have a GVFD were twice higher than for women (OR 2.0, 95% CI 1.3, 
3.1). GVFDs were present in 8.6% of all subjects with a VCDR :< 0.7. This preva-
lence increased to 38% in subjects with a VCDR 2: 0.8, and to 60% in subjects with 
a VCDR 2: 0.9. 
Prevalence of definite, probable, and possible POAG 
Table 9 shows the overall prevalence of definite, probable, and possible POAGs 
for the various age groups derived from combined Imagenet and ophthalmoscopic 
data. \Xlhen Imagenet was not available or unreliable, ophthalmoscopic data were 
used. Tables 10 and 11 show the data derived when these techniques were sepa-
rated. Benveen the cases in Tables 10 and 11 there was overlap but not complete 
concordance. Of the independently living subjects, 50 had definite POAG (0.8%, 
95% Cl 0.6, 1.0%) with an OR of 2.1 (95% Cl1.2, 3.6) for men versus women. The 
risk estimates between POAG, age, and gender remained the same when the 
POAG cases defined with Imagenet or with ophthalmoscopy were analyzed sepa-
rately or by pooling (see Tables 9 through 11 ). 
Table 8 
Prevalence of glaucomatous visual field defects 
Age (years) Men(%) Women(%) 
55-59 214 7 4 (0.4) o I 668 (0.0) 
60-64 51602 (0.8) 4/763 (0.5) 
65-69 111579 (1.9) 71658 (1.1) 
70-74 131424 (3.1) 11/628 (1.8) 
75-79 81282 (2.8) 71444 (1.6) 
80+ 101149 (6.7) 91312 (2.9) 
Total 4912510 (2.0) 3813473 (1.1) 
Numbers indicate subjects. 
Glaucomatous visual field defect '\vas defined as any Goldmann VF defect 
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Total(%) 
211142 (0.2) 
911365 (0.7) 
1811237 (1.5) 
2411052 (2.3) 
151726 (2.1) 
191461 (4.1) 
87 I 5983 (1.5) 
Table 9 
Prevalence ofPOAG: The Rotterdam Study, 1990-1993--Imas:enet data combined with O£hthalmoscop-ic data 
Independentb living stt!?)eds 
Age, y J\len Definite Probable POAG Possible \'\/omen Definite Probable POAG Possible Total Definite Probable POi\G Possible 
(n) POAG GVFD GON POAG (n) POAG GVPD GON POi\G P01\G GVFD GON POJ\G 
55-59 483 1 (0.2) 1 (0.2) 7 (1.4) 72(14.9) 679 0 (0) 0 (0) 10 (1.5) 94 (13.8) 1162 1 (01) 1 (01) 17(1.4) 166(14.2) 
60-64 616 4 (0.6) 1 (0.2) 10 (1.6) 83 (13.5) 783 1 (0.1) 3 (0.4) 10 (1.3) 114 (14.6) 1399 5 (0.4) 4 (0.3) 20 (1.4) 197 (14.1) 
65-69 594 5 (0.8) 6 (1.0) 6 (l.O) 98 (16.5) 684 6 (0.9) 1 (0.1) 17(2.5) 105 (15.4) 1278 11 (0.8) 7 (0 . .1) 23 (1.8) 203 (15.9) 
70-74 452 6 (1.3) 7 (1.5) 5 (1.1) 57 (12.6) 656 7 (l.l) 4 (0.6) 8 (1.2) 97 (14.8) 1108 13 (1.2) 11 (1.1) 13 (1.2) 154 (13.9) 
75-79 315 6 (1.9) 2 (0.6) 11(1.1) 51 (16.2) 480 3 (0.6) 4 (0.8) 16 (3.3) 70 (14.6) 795 9(1.1) 6 (0.8) 27 (3.4) 121 (15.2) 
SO+ 166 6 (3.6) 4 (2.4) 5 (3.0) 39 (23.5) 373 5 (1.3) 4(1.1) 10 (2.7) 60 (16.1) 539 11 (2.0) 8 (1..1) 15 (2.8) 99 (18.4) 
Total 262() 28 (1.1) 21 (0.8) 44 (1.7) 400 (15.2) 3655 22 (0.6) 16 (0.4) 71 (1.9) 540 (14.8) 6281 50 (0.8) 37 (0.6) 1 IS (1.8) 940 (15.0) 
SEi'vf 0.0020 o.oow 0.0025 0.0069 0.0013 0.0011 0.0022 0.0058 0.0011 0.0010 0.0017 0.0044 
Dependentb living sui?Jects* 
55-59 0 0 0 
60-64 0 
65-69 4 4 8 
70-74 4 1 (25.0) 8 1 (12.5) 12 2 (16.7) 
75-79 18 3(11>.7) 42 2 (4.8) 6 (14.3) 60 2 (3.3) 9 (1.1.0) 
80+ 93 4 (4.3) 21 (22.6) 301 18 (6.0) 42 (14.0) 394 22 (5.6) 63 (16.0) 
Total 119 4 (3.4) 25 (21.0) 356 20 (5.6) 49 (13.8) 475 24(5.1) 74(1.1.1>) 
SEM 0.0165 0.0375 0.0122 0.0183 0.0100 0.0166 
Relative risk esrimates for ddJnite POAG in independently living subjects: gender (men compared with women), adjusted for age (OR 1.99; 9S% Cl 1.13, 
3.51) and age (per year increase), adjusted for gender (OR 1.09; 95(Yu CI LOS, 1.12). 
* In nursing homes no VF testing \Vas performed. Thus, only probable and possible POAGs could be diagnosed. 
Probable POAG GON: probable POAG based on probable GON; probable POAG GVFD: probable POAG based on GVFD. 
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Table 10 
Prevalence ofPOAG: The Rotterdam Study, 1990~1993-0phthalmic disc: data only 
Independentb living JN~jects 
Age, y :Men Definite Probable POAG Possible \Vomen Definite Probable POAG Possible Total Definite Probable POAG Possible 
(n) POAG GVFD GON POAG (n) PCJAG GVFD GON POAG POAG GVFD GON POAG 
.15-.19 483 0 (0) 2 (0.4) 4 (0.8) 31 (6.4) 679 0 (0) 0 (0) 10 (1.5) 40 (S.Y) 1162 0 (0) 2 (0.1) 14 (1.2) 71 (6.1) 
60-64 616 3 (0..1) 2 (0.3) 10 (1.6) 41 (6.7) 783 1 (0.1) 3 (0.4) 7 (0.9) 58 (7.4) 1399 4 (0.3) 5 (0.4) 17 (1.2) 99 (7.1) 
65-69 594 5 (0.8) 6 (1.0) 6 (LO) 45 (7.6) 684 6 (0.9) 1 (0.1) 10 (LI) 55 (8.0) 1278 11 (0.9) 7 (0.5) 16 (1.3) 100 (7.8) 
70-74 452 9 (2.0) 4 (0.9) 10 (2.2) 19 (4.2) 656 8 (1.2) 3 (0.5) 10 (LI) 53 (8.1) 1108 17 (1.5) 7 (0.6) 20 (1.8) 72 (6.5) 
75-79 315 3 (1.0) .I (1.6) 10 (3.2) 26 (8.3) 480 2 (0.4) .I (1.0) 10 (2.1) .19 (8.1) 795 .I (0.6) 10 (1.3) 20 (2.5) 65 (8.2) 
80+ 166 6 (3.6) 4 (2.4) 2 (1.2) 22 (13.3) 373 4 (1.1) .I (1.3) 7 (1.9) 33 (8.8) 539 10 (1.9) 9 (1.7) 9 (1.7) 55 (10.2) 
Total 2626 26 (1.0) 23 (0.9) 42 (1.6) 184 (7.0) 3655 21 (0.6) 17 (0.5) 54 (1.5) 278 (7.6) 6281 47 (0.7) 40 (0.6) 96 (1.6) 462 (7.4) 
SE1\l ll.0019 0.0018 lUl024 0.0050 0.0013 0.0011 0.0020 0.0044 lUl011 0.0010 0.0015 0.0(133 
Dependent/)' liPing su~jectr* 
55-59 0 0 0 
60-64 0 
65-6lJ 4 4 8 
70-74 4 8 12 
75-79 18 2 (11.1) 41 2 (4.9) 3 (7.3) 59 2 (34) 5 (8.5) 
80+ 93 6 (6.5) 7 (7.5) 297 13 (4.4) 22 (7.4) 390 19 (4.9) 29 (7.4) 
Total 119 6 (5.0) 9 (7.6) 351 15 (4.3) 2.1 (7.1) 470 21 (4.5) 34 (7.2) 
SEM 0.0201 OJJ243 0.0108 0.0138 0.009.1 0Jl120 
Relalive risk estimates for definite POAG in independently living subjects: gender (men compared with women), adjusted for age (OR 1.94; 95% Cl 1.08, 
3.47) and age (per year increase), adjusted for gender (OR 1.09; 95t!ll Cll.OS, 1.12). 
* ln nursing homes no Vl' testing was performed. Thus, only probable and possible POt\Gs could be diagnosed. 
See Tables 1 and 9 for definitions and abbreviations. 
Table 11 
Prevalence ofPOAG: The Rotterdam Study, 1990-1993-Imag:cnct data only 
lndependmtb lit;ing ml:fedr 
Age, )' j\'len Definite Probable POAG Possible \'(/omen Definite Probable POAG Possible Total Definite Probable POAG Possible 
(n) POAG GVPD GON POAG (n) PO!\G GVI'D GON POAG PO/\G GVFD GON PO!\G 
55-59 483 I (0.2) I (0.2) 6 (1.4) 67 (15.4) 620 0 (0) 0 (0) 7 (1.1) 85 (13.7) 1054 1 (0.1) 1 (0.1) 1.1 (1.2) 152 (14.4) 
60-64 616 4 (0.7) I (0.2) 8 (1.4) 80 (14.2) 722 0 (0) 4 (0.6) 6 (0.8) 108 (15.0) 1285 4 (0.3) 5 (0.4) 14 (1.1) 188 (14.6) 
65-69 594 2 (0.4) 9 (1.7) 5 (0.9) 90 (16.7) 626 4 (0.6) 3 (0.5) 14 (2.2) 100 (16.0) 1165 6 (0.5) 12 (10) 19 (1.6) 190(11>.3) 
70-74 452 3 (0.8) I 0 (2.5) 0 (0) 55 (13.8) 592 4 (0.7) 7 (1.2) 7 (1.2) 93 (15.7) 991 7 (0.7) 17 (1.7) 7 (0.7) 148 (14.9) 
75-79 315 4 (16) 4 (16) 6 (2.4) 44 (17.5) 399 3 (0.8) 4 (10) 15 (3.8) 64 (16.0) 651 7 (1.1) 8 (1.2) 21 (3.2) 108 (16.6) 
BO+ 166 2 (16) 8 (6.6) 5 (4.1) 36 (29.5) 2()2 4 (15) 5 (19) 7 (2.7) 49 (18.7) 384 6 (1.6) 13 (3.4) 12 (3.1) 85 (22.1) 
Total 2626 16 (0.7) 33 (1.4) 30 (1.3) 372 (16.1) 3221 15 (0.5) 23 (0.7) 56 (1.7) 499 (15.5) 5530 31 (0.6) 56 (10) 86 (LG) 871 (15.8) 
SEM 0.0017 0.0025 0.0024 0.0077 0.0012 0.0015 0.0023 (),()064 0.0010 0.0013 0.0017 0.0049 
Dependmt6' livtl(g .r~tb;ed.r* 
55-59 0 0 0 
60-64 0 
65-69 4 2 6 
70-74 4 I (25JJ) 7 I (14.3) 11 2 (18.1) 
75-79 18 3 (23.1) 24 5 (20.8) 37 8 (21.6) 
80+ 93 1 (18) 17 (29.3) 16lJ 8 (4.7) 33(19.5) 226 9 (3.9) 50 (22.1) 
Total 119 1 (1.3) 21 (26.9) 203 8 (3.9) 39 (19.2) 281 9 (3.2) 60 (21.4) 
SEM 0.0128 0.0506 0.0137 0.0277 O.ll105 0.0245 
Relative risk estimates for definite POAG in independently living subjects: gender (men compared with women), adjusted for age (OR 1.63; 95% CI 0.80, 
3.32) and age (per year increase), adjusted for gender (OR Ul9; 95% Cl 1.04, 1.13). 
*In nursing homes no VF testing was performed. Thus, only probable and possible P01\Gs could he diagnosed. 
See Tables 1 a11d 9 for definitions and abbreviations. 
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In nursing homes no VFs \Vcre tested. In these subjects only probable or possible 
POAG could be diagnosed based on optic disc appearance. The prevalence of 
possible POAG was comparable to prevalence figures of possible POAG in the 
independently living subjects in the same age categories. 
IO P distribution in this population 
.AJthough lOP was not used for the diagnosis of POAG in this study, we will 
present our data on lOP here for comparison with other studies. Our lOP data 
were influenced by the GTT. The lOP-lowering effect of the GTT was studied by 
comparing the lOPs of subjects who had undergone a GTT with those of subjects 
who had not (those who refused and diabetic subjects). Subjects with a GTT had a 
significantly lower mean lOP (-1.13 mm Hg, 95% Cl -1.41, -0.84) than subjects 
without GTT (similar in diabetic subgroup and refuser subgroup). Unadjusted for 
the effect of the GTT the mean lOP (subjects with lOP-lowering treatment were 
excluded) was 14.5 mm Hg (95% Cl 14.46, 14.61). After correction for the lOP-
lowering effect of the glucose solution, the mean lOP was 15.6 mm Hg (95°/o CI 
15.48, 15.64). The cumulative distribution of lOP (adjusted for the GTI) is shown 
in Figure 1. There were no significant IOP differences bet\:veen independently 
living subjects and subjects in nursing homes (p = 0.185, adjusted for age and 
gender), or between men and women, and there was no clinically significant change 
in IOP with increasing age. 
The prevalence figures of elevated lOP (> 21 mm Hg) are shown in Table 12 
for the independently living subjects. The OR for men to have an lOP > 21 mm 
Hg compared with women was 1.35 (95% CI 1.10, 1.66). Ocular hypertension was 
present in 5.6°/o of participants and also v.ras more prevalent in men than in women 
(OR 1.26; 95% Cl 1.02, 1.56). Again, the prevalence of ocular hypertension in 
subjects in nursing homes was not significantly different from the prevalence in 
independently living subjects (p = 0.48, adjusted for age and gender). 
Of the 50 diagnosed POAG cases (using the combined lmagenet and ophthalmo-
scopy data) 23 subjects (OR 46.0%; 95% Cl 45.9, 46.1) were previously known to 
have POAG and received lOP-lowering treatment. Of the remaining 27 POAG 
cases, only three had an lOP > 21 mm Hg. 
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Figure 1 
Cumulative distribution of the lOP adjusted for influence of a preYiously taken GTT in 
5977 independently living subjects \Vithout IOP-lo\vering therapy. The 2 . .5111 percentile 
corrected for the GTT \vas both for right and left eyes < 10 mm Hg, the 97 .5th percentile > 
22 mm Hg. Uncorrected for the GTT these were < 9 mm Hg and 21mm Hg, respectively. 
On the other hand, of the 242 independently living subjects with lOP-lowering 
treatment, only 13 (OR 8.7%, 95% CI 5.1, 12.2) had definite POAG when using 
only ophthalmoscopic data, and 23 (9.5'/'o, 95% Cl 5.8, 13.2) subjects had definite 
POAG using the combined lmagenet and ophthalmoscopy data. The sensitivity of 
elevated IOP for detection of POAG was calculated only in the newly diagnosed 
POAG cases (because the lOPs at the time of diagnosis of the known POAG cases 
were not available). The sensitivity was 11.1% (3 of 27 cases had an elevated IOP) 
and the specificity 98.0% (5,827 of 5,943 subjects had no definite POAG). The 
predictive value of an IOP > 21 mm Hg for the detection of POAG was onlv 
2.5%; the predictive value of an IOP :':: 21 mm Hg for its absence was 99.6%. 
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Figure 2 
Variation in pteYalence figures of POAG in the Rotterdam Study \Vhen different criteria for the 
definition ofPOAG, as used by other population-based studies, were applied to the Rotterdam data. 
Figure 2 shows the variation in prevalence of POAG by age in our study, when 
POAG definitions from other large population-based studies were applied to our 
data. This resulted in prevalence figures varying between 0.1 °/o and 1.4°/o in the 
youngest age-categories to prevalence figures between 0.9°/o and 5.9°/o in the oldest 
ones. 
Discussion 
In this article we have given the rationale for the follo-wing proposal for an interna-
tional definition of POAG in epidemiologic research: POAG is a disorder charac-
terized by a GVFD, in combination with probable or possible GON based on cut-
off points approximating the 99.5th and 97.5th percentiles, respectively, in that 
population in at least one eye of a subject with open chamber angle, and no history 
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or sign of angle closure or secondary glaucoma. Thus an algorithm may be created 
leading to the diagnosis of definite, probable, or possible POAG (see addendum). If 
other research groups use a similar approach, one 1s free to pool definite and 
probable POAG or not. 
\\/hen looking at Table 1 and reference 15, it seems that we have not made 
much progress in defining glaucoma since Donders coined the term glaucoma 
simplex in 1861.21 It, thus, seems like a risky enterprise to start defining criteria for 
POAG nearly 150 years later. On the other hand, it is clear also from Figure 2 that 
there is a need for valid comparisons between studies. Current variations in defini-
tion allo"\v wide variations in prevalence data, as well as justification for treatment. 
In this study, we define cut-off values for POAG determinants based on statistical 
grounds. This means that on arbitrary statistical grounds a division is made between 
normal and abnormal discs. \X/ e realize that this might be artificial and that some 
subjects may falsely be defined as healthy or abnormal. However, because of the 
large variation in POAG definitions in epidemiologic and/ or clinical research, we 
think that it is for the time being a good starting point to use such a definition for 
better c01nparison and pooling of study results. In due time further refinement of 
the definition may become possible \Vhen more incidence data become available. 
"Using 97.Sth or 99.5th percentiles to define abnormality does not mean that we used 
these criteria to define someone as being diseased. Only in combination with other 
signs we propose tbe term definite POAG. We felt that our database allowed for 
the definition of POAG on statistical grounds and that such an approach may 
become a starting point for future diagnostic fine-tuning. This may not be too far 
away because some large population-based studies are working on incidence data 
onPOAG. 
Although pseudoexfoliative glaucoma was not excluded at baseline, we refer in 
this version of the manuscript to the disease status as POAG, because pseudoexfo-
liation was not observed at follow up.ll,J3 In the published version, we refer to the 
disease status with OAG. 
In this study we present prevalence figures for POAG combining GON data 
obtained by Imagenet and ophthalmoscopy. We think the Imagenet data are the 
more reliable data, especially for follow-up and risk factor analyses. However, 
because the Imagenet module for the optic disc is not available any more, and 
neither is the simultaneous stereoscopic Topcon TRC-SS2 camera, also essential for 
this module, we also present prevalence figures based on only ophthalmoscopic 
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optic disc data for comparison with other studies. \Xlc found in a substudy that 
Imagenet and the Heidelberg Retina Tomograph had much higher correlations for 
the estimation of the VCDR than ophthalmoscopy, showing that ophthalmoscopy 
is less reliable than these semiautomated apparatus, even carried out by trained 
examiners. Still we felt that in daily practice ophthalmoscopy will be the method of 
choice during the coming years. Therefore, in choosing cut-off points for the 
VCDR and other disc measures we looked primarily at feasibility, and tried to 
choose cut-off points that were also ophthalmoscopically assessible. Thus, to create 
as simple as possible a definition for POAG, based on GVFD and optic 
neuropathy, we propose as a cut-off point for a statistically abnormal, and thus 
arbitrarily pathologic, possible GON a VCDR e: 0.7, asymmetry in VCDR between 
both eyes e: 0.2, or neuroretinal rim width < 0.1 for data obtained by ophthalmo-
scopy. The latter was not assessed in this study by ophthalmoscopy but would 
probably be necessary in other studies to detect discs with local notching of the 
rim. From Tables 5 and 6 one may see that for the largest discs the cut-off for 
pathologic VCDR might have been chosen as 0.8, and the same holds for those 75 
years of age and older. All these subdivisions make the definition more and more 
complicated and that is why we propose to keep as the cut-off point for a possible 
GON a VCDR e: 0.7. 
Hitherto, some studies did not specify whether one used information on lOP or 
disc measures to grade VF defects as glaucomatous.2•8·13 T\.vo were masked in this 
respect9,1I and one was not. 14 Similarly, before deciding whether a subject had 
POAG, all studies mentioned in Table 1 looked at the combined data of a case 
while we tried to do so by combining strictly defined determinants without 
subjective overall evalution at the end. \\le believed that this would lead to less 
assessment bias. On the other hand, this resulted in small differences in prevalence 
of POAG when the Imagenet or ophthalmoscopy data were used. 
Our overall prevalence of definite POAG of 0.8% (with combined use of 
Imagenet and ophthalmoscopic data; 0. 7% \.Vhen only using ophthalmoscopic data) 
and its rise with age is comparable to prevalence figures of the Framingham Study24 
(1.2%), of the Baltimore Eye Survey' (1.1 %), and among the white subjects of the 
Barbados Eye Study' (0.8%). The Beaver Dam Eye Study and the Blue Mountains 
Eye Study, on the other hand, found a higher overall prevalence, 2.1°/os and 3.0°/o,11 
respectively. The prevalence of definite plus probable POAG in the Rotterdam 
Study was 3.2°/o and this may explain the gap. Several more reasons for these 
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differences exist. All studies mentioned in Table 1 but the Egna·Neumarkt and the 
Rotterdam Study used for final assignment to glaucoma diagnosis a review of all 
data by one or more principal investigators, glaucoma specialists, or ophthalmolo-
gists. In this study we combined the VF and optic disc data, and this led straight-
fonvard to one of three diagnostic categories (apart from normals) without addi-
tional influence on the final results. The discrepancy with the Beaver Dam Study 
could be explained by their wider criteria for POAG. Other sources for differences 
between studies include sampling and perimetry techniques, screening methods for 
glaucoma, subjective interpretation of examination data, diagnostic criteria, age 
distributions, and real geographic contrasts in prevalence due to differences in 
lifestyle or genetic drift. 
The VF screening and grading procedure in our study resulted in a prevalence of 
l.S'Yo of GVFDs compatible with POAG. This is comparable with the findings of 
the Framingham Study (1.4%, screening in a subset only, enlargement of blind spot 
excluded),'' but lower than that found in Australia (3.1 %)11 The Blue Mountains 
Eye Study used, after screening, Humphrey full threshold perimetry (C30-2), which 
is more sensitive than kinetic Goldmann perimetry,26 especially in glaucoma where 
it might detect up to 21% more defectsP Full threshold automated perimetry is 
no\vadays considered to be the gold standard for VF examination, but at baseline in 
1990 we felt that especially in older subjects it may create more false-positive errors 
compared \.vith Goldmann perimetry. This might be because of poor tlxation that 
accounted for 9°/o of inadequate Humphrey fields versus 2% at the Goldmann 
perimeter.27 Between threshold Humphrey perimetry and kinetic Goldmann 
perimetry there is 88°/o concordance \vhen both tests appeared reliable. 27 Because 
the Humphrey algorithms also have changed in the meantime and because \Ve now 
perform both Humphrey 30-2 and Goldmann perimetry in a follow-up study, a 
more valid comparison bet\veen both methods will be possible within 1 year from 
now. It also has been shown that supra threshold perimetry identities about rum 
thirds of all cases identitled by full-threshold perimetry.2S L sing this latter test our 
prevalence of definite POAG might have risen to approximately 1.4°/o. Even then 
there still would have been a t\vofold difference in prevalence by comparison with 
the Blue 11ountains Eye Study. Given the variation in techniques and differences 
bet\vecn various studies we believe that conclusions on geographic differences are 
for the time being not justifiable. 
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Our study differed from other large population-based studies with regard to the 
use of Imagenet to assess the optic nerve. Imagenet used strict criteria for defining 
the cup margins, based only on topographic data, thus reducing variation due to 
different obsenrers. This makes it also particularly interesting for follow-up 
studies.21 \X/e found a higher mean VCDR on Imagenet measurements (0.49) 
compared \Vith studies using other methods for examining the optic disc (mean 
VCDR 0.285, 0.3H1 using ophthalmoscopy by several examiners, 0.368 and 0.4311 by 
grading of photographs). As a result, the prevalence of an enlarged VCDR was also 
higher in our study than in other studies (VCDR :2: 0.4: 76.7% compared with 
27.1%5, 37.0%8). However, our prevalence of a VCDR :2: 0.7 (5.1%) was only 
slightly different from the findings of the Blue Mountain Eye Study (5.0%), which 
examined stereo transparencies with a viewer. 11 Also, asymmetry in VCDR between 
both eyes \vas more prevalent in our study, compared with findings of other studies 
(4.6% asymmetry :2:0.223,0.7% asymmetry :2: 0.311). 
The relation bet\veen POAG and gender is still controversial. ln Framinghams 
and Barbados9 a higher prevalence of POAG was found in men, which matchdour 
finding. However, in the Blue Mountains Eye Study a (borderline significant) higher 
OR of 1.55 for POAG was found for women,11 and in Baltimore' and Beaver 
Dam8 no difference was found. It might be that in younger subjects the association 
between POAG and gender is not yet present. It would seem possible that if the 
study cohort had a greater proportion of younger the gender risk would disappear. 
Our study did not show any correlation bet\veen age, gender or IOP. This is in 
contrast This is in contrast to previously published results, 1•4.29 but is in agreement 
with others.LS,s Our findings do agree with prevalence data on lOP and VCDR in 
nursing home inhabitants.3° However, the response in the nursing homes was low, 
especially in the older subjects, increasing the risk of selection bias. This could 
explain our lower POAG prevalences contrasting findings with that study.3° One 
could adjust the prevalence rates for probable and possible POAGs in the nursing 
homes by raising them by 25°/o similar to the lo'\ver response rates in these homes 
than in the independently living subjects. 
In conclusion, the overall prevalence of definite POAG in the Rotterdam Study 
was 0.8°/o, which is comparable to findings of other population-based studies on 
whites. The OR for men to have POAG was higher than for women. There was a 
significant increase in prevalence of POAG with increasing age. The overall preva-
lence of POAG varied 12-fold with different criteria and screening algorithms. \Xle 
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hope that standardizing diagnostic procedures and our proposed definitions will 
improve future (epidemiologic) glaucoma research. 
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Addendum: 
Decision tree for classifying primary open-angle glaucoma 
in subjects who have at least in one and the same eye an open anterior chamber angle and 
no history or signs of angle closure or secondary glaucoma 
The diagnosis POAG depends on the presence or absence of a glaucomatous optic 
neuropathy (GON) and/ or a glaucomatous visual field defect (GVFD). Because a GON 
usually appears earlier and is easier to assess than a G\lFD, the decision tree starts with 
GO~ and afterv.rards includes presence or absence of a GVFD. 
The diagnosis of GON is based on the 97.Sth and 99.5111 percentiles of the various disc 
measures in the population concerned. 
Category of GO~ VCDR Asymmetry in VCDR Minimal neural 
bct\veen both eyes rim width 
Possible GON (97.5Lh percentile) 0.1 0.2 0.1 
Probable GON (99.5'h percentile) 0.8 0.3 0.05 
Definite POAG is the presence of a GVFD in combination \vith a probable or possible 
GON. 
Probable POAG is the presence of a GVFD in absence of a GON or the presence of a 
probable GO;..;J in the absence of a GVFD or of any VF test. 
Possible POAG is the presence of a possible GON in the absence of a GVFD. 
POAG classification 
yes -------definite POAG 
---GVFD no --------probable POt\G 
no VF test probable POAG 
G00;<Y" 
no------------ GVfD ~~~~--------~~0~~~-:~~0AG ~no VF test no PO/\G 
GON: glaucomatous optic neuropathy; GVFD: glaucomatous visual field defect. 
See text for explanation 
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Primary open-angle glaucoma and age at menopause 
Abstract 
The authors examined the association between age at menopause and 
primary open-angle glaucoma among 'WOmen aged ;.:::: 55 years in the 
population-based Rotterdam Study (1990-1993). Information on age and 
type of menopause was obtained by interview. Subjects (n = 3,078) were 
stratified into three categories according to age at menopause: < 45 years, 
45-49 years, and ~ 50 years, with the last group serving as the reference 
group. Diagnosis of primary open-angle glaucoma was based on the presence 
of a glaucomatous visual field defect and glaucomatous optic neuropathy. 
Primary open-angle glaucoma was diagnosed in 78 women with a natural 
menopause and 15 women with an artificial menopause. In the category of 
natural menopause, v.romen who went through menopause before reaching 
the age of 45 years had a higher risk of primary open~angle glaucoma than 
the reference group (odds ratio = 2.6; 95% confidence interval: 1.5, 4.8), 
after adjustment for age and use of hormone replacement therapy. Among 
\.vomen who went through menopause bet\veen the ages of 45 and 49 years, 
the odds ratio was 1.1 (95% confidence interval: 0.7, 2.0). These findings 
suggest that early menopause is associated with a higher risk of primary 
open-angle glaucoma. 
Introduction 
Primary open-angle glaucoma (POAG) is characterized by a progressive loss of 
ganglion cells and their axons, resulting in glaucomatous optic neuropathy in 
combination with corresponding visual field defects. In the \Y.;' estern world, primary 
open~angle glaucoma is the third largest cause of irreversible visual impairment. 1 
Despite the important implications of visual field loss, little is known about the 
pathogenesis and etiology of POAG. Elevated intra~ocular pressure (lOP) is an 
important risk factor,2·' but in 30-50 percent of POAG patients lOP is witbin the 
normal range; therefore, other causative factors must be present.s 
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Following our observation that the prevalence of POAG \vas n·vice as high in 
men as in women,4 we hypothesized that one of the possible explanations for this 
difference is a protective effect of female sex hormones. This hypothesis is 
strengthened by the finding that lOP is higher among postmenopausal women than 
among men of the same age6·7 and premenopausal \Vomen.s Furthermore, hormone 
replacement therapy has been suggested to lower IOP.9,1D 
To our kno\vledge, no population-based study has been performed to investi-
gate this possible protective effect of female sex hormones, of which age at 
menopause is one indicator, on POAG. Thus, the purpose of the current study "\vas 
to test our hypothesis and to determine \vhether age at menopause is associated 
with the prevalence of POAG. 
Materials and methods 
Population 
The Rotterdam Study is a population-based prospective follow-up study of 
residents of a suburb of Rotterdam, the C\letherlands, aged ~ 55 years in which 
chronic cardiovascular, neurologic, locomotor, and ophthalmologic diseases are 
being investigated. 11 The present cross-sectional study was performed with baseline 
data, which were collected from 1990 to mid-1993. The study was approved by the 
.i\{edical Ethics Committee of Erasmus Vniversity (Rotterdam), and written 
informed consent was obtained from all participants. 
Of all eligible residents (n = 1 0,275) who were invited to take part in the study, 
7,983 subjects (78 percent) participated in an extensive home interview (Table 1). 
Because the ophthalmic part of the Rotterdam Study started later than the other 
three sections, 6,872 subjects were eligible for the ophthalmologic study. Of the 
6,756 subjects who participated in the eye examination, 4,032 were female. Nursing 
home residents (n = 366) were excluded, because visual field testing could not be 
carried out. Independently living women for whom we had no data on optic disc 
parameters (n = 24) or on visual field testing of at least one eye (n = 111) were also 
excluded. In addition, women who were premenopausal or who could not remem-
ber the date or cause of their last menstrual period (n = 189) were excluded. 
Complete menopausal and ophthalmologic data were available on 3,342 women. 
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Table 1 
Procedure used to select the study population in the baseline phase of the 
Rotterdam Study, 1990-1993 
Study group 
Eligible persons 
Participants in 
Rotterdam Study 
Persons eligible for 
ophthalmologic 
study 
Persons examined 
ophthalmologically 
Females 
Persons "\Vith complete 
ophthalmologic data 
Postmenopausal 
\\'Omen 
Final study group 
No. Exclusions 
10,275 2,292 nonparticipants 
7,983 1,111 with no physical 
examination or before 
start of ophthalmologic 
study 
6,872 116 "\Vith no eye examination 
6,756 2,724 males 
4,032 135living independendy 
366 living in nursing home 
3,531 189 premenopausal or age 
or cause of menopause 
unknown 
3,342 173 with menopause after 
cessation of contraceptive 
use 
3,078 
91 with menopause 
induced by medication 
Characteristics of 
subgroup 
24 with no data on 
optic disc 
111 with no perimetry 
or incomplete 
screening 
No perimetry 
2,469 with natural 
menopause 
609 '\Vith artificial 
menopause 
576 with menopause 
induced by surgery 
33 with menopause 
induced by 
irradiation 
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In the present study, women who reported experiencing menopause after 
stopping the use of oral contraceptives (n = 173) were excluded, because for these 
\.VOmen true age at menopause was not known. \X/ omen who stopped menstruating 
after taking medication (n = 91) were also excluded, because data on the use and 
effects of medications \Vith a specific influence on menopause \\rere not available at 
the time of the analyses. The present analysis included 2,469 women who 
experienced a natural menopause and 609 women \vho experienced menopause 
after surgery or irradiation therapy. 
IntervieJv 
Data on menopause, menarche, and use of hormone replacement therapy were 
obtained by self-report during the home intervie\v, \Vhich \Vas conducted by a 
trained research assistant. For \llOmen with natural menopause, age at menopause 
was defined as self-reported age at the time of last menstruation. For all women 
reporting menopause after gynecologic surgery or radiation therapy· and for those 
reporting any other operations before age 50 that might have led to menopause, 
information on the exact date and type of operation was verified using general 
practitioners' records, which included correspondence from medical specialists. 
Data on the use of hormone replacement therapy were likewise validated. Age at 
menarche was defined as age at the date of the first menstrual period, and duration 
of exposure to endogenous sex hormones was defined as the difference in years 
between menarche and menopause. 
J\1easurements 
The complete eye examination included testing of visual acuity, ocular refraction, 
and visual fields, measurement of lOP, and slit-lamp examination, as well as 
indirect ophthalmoscopy.4 For lOP, three measurements were taken and the 
median \Vas used. 12 For assessment of the optic disc, stereo transparencies from 
both eyes were digitized and anillyzed using the module for retinal nerve fiber layer 
height of the Topcon image analyzer Imagenet.4,13 Disc area, vertical cup-disc ratio, 
and the smallest neural rim width were automatically calculated from the 
topographic data. 14 Visual field testing \.VaS performed as described by \\lolfs et al.4 
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Vim a! field ,grading and classification 
Six graders (three senior ophthalmologists, t\vo residents, and one perimetrist) 
independently graded all Goldmann visual field charts according to shape and 
localization of the defect.4 The graders "\vere masked with regard to other clinical 
data such as medical history or optic disc characteristics. The cause of the visual 
field defect was determined using data from the home interview, ophthalmologic 
examination, and neurologic assessment and additional information obtained from 
the medical records of general practitioners and specialists. Glaucomatous visual 
field loss was defined as a visual field defect compatible with nerve fiber bundle 
defects (nasal step, paracentral defect, arcuate scotoma, temporal nerve fiber bundle 
defect, remaining peripheral island and a central remnant) after exclusion of other 
retinal or neuroophthalmologic causes. 
Diagnosis 
Although pseudoexfoliative glaucoma was not specifically excluded in the baseline 
phase of the study, we refer to the disease status as POAG, because at follow up no 
cases with pseudoexfoliative glaucoma were found. POAG "\Vas classified into three 
categories: definite, probable, and possible.4 For the current analysis, we included 
only patients with definite and probable POAG. 
Definite POAG was defined as the presence of a glaucomatous visual field 
defect in combination with a possible or probable glaucomatous optic neuropathy, 
based on the 97.5th and 99.5th percentiles of the distributions of the measurements 
in this population, respectively. The 97 .5th percentile for vertical cup-disc ratio \Vas 
0.7, that for asymmetr.y beru.reen the vertical cup-disc ratios of both eyes \Vas 0.2, 
and that for minimal neural rim width was 0.1 0. For the 99.5th percentile, these 
values were 0.8, 0.3, and 0.05, respectively. Probable POAG was defined either as 
the presence of glaucomatous visual field loss in the absence of a possible glauco-
matous optic neuropathy or as a probable glaucomatous optic neuropathy, without 
glaucomatous visual field loss. 
lOP was not included in our criteria for the diagnosis of POAG, but elevated 
lOP was included in the analysis because of its importance as a risk factor for 
POAG. 15 \Xie considered the lOP ele·vated when applanation ton01netry was over 
21 mm Hg in one or both eyes or when treatment had been given to lower the 
lOP. 
41 
Chapter 2.2 
Data analysis 
\~'e studied the association bet\veen age at menopause and POAG in the following 
ways. First, we compared baseline characteristics between the women included in 
the analysis and those excluded from the analysis because of missing data. For this, 
both logistic and linear multi\'ariate regression analyses were used. ::--.J ext, \vomen 
were stratified into three categories according to age at menopause: < 45 years, 45-
49 years, and ;;::: 50 years. The last group was regarded as the reference group. Odds 
ratios and 95 percent confidence intervals were calculated for definite and POAG 
and for elevated IOP, by age at menopause, using multivariate logistic regression 
analysis. 
Relative risks v.rere then calculated for \Vomen who had experienced either 
natural or artificial menopause. To examine the effect of ovarian estrogen produc~ 
tion, we made a distinction in the artificial menopause group bet\veen \vomen 
whose menopause started after irradiation therapy or bilateral oophorectomy and 
those whose menopause resulted from hysterectomy with or without unilateral 
oophorectomy. In all analyses, adjustments were made for age, hypertension, 
diabetes mellitus, use of hormone replacement therapy at any time, and duration of 
hormone replacement therapy (in months). 15 
Results 
Baseline characteristics of the women who were included in the analyses and those 
who were excluded from the analvses are shown in Table 2. Excluded women were 
older. In these women, systolic blood pressure was higher after age adjustment, and 
percentage of women who had ever used hormone replacement therapy \vas lower. 
11ean age at menopause, mean vertical cup-disc ratio in the right eye, and duration 
of use of hormone replacement therapy did not differ between the groups. 
Characteristics of women \vho experienced a natural menopause are given by 
age category in Table 3. Age at the time of examination ranged from 55 years to 
94.5 years (mean = 68.8 years), and age at menopause varied from 30 years to 60 
years (mean = 49.7 years). \Xlomen whose menopause occurred before age 45 were 
older; a higher percentage of them had used hormone replacement therapy at some 
time, and a higher percentage had used it for at least 1 year. In these women, the 
prevalence of definite and probable POAG and of elevated lOP was higher. 
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Table 2 
Age-adjusted baseline characteristics of women included in analyses and women 
excluded from analyses (because of complete and incomplete ophthalmologic and 
rnenopausa] data, respectively), The Rotterdam Study, 1990-1993 
Characteristjc 
..\Jean age (years) 
1Jean age at menopause (years) 
Mean time since menopause (years) 
Mean duration of exposure to 
endogenous hormones (years) 
%with ever use ofHRTt 
0/r1 \Vith use of HRT for 2: 1 year 
i\Iean systolic blood pressure (mm Hg) 
i\Tean diastolic blood pressure (mm Hg) 
ty;) with hypertension 
::\lean intraocular pressure in right eye 
(mm Hg) 
Included women 
(n = 3,342) 
fvlean SDt 
or 0/o 
68.1 
48.8 
19.3 
35.2 
7.9 
139.2 
73.3 
40.6 
15.7 
8.1 
4.9 
9.5 
5.2 
22.4 
11.1 
3.1 
tYc1 \.Vith elevated intraocular pressure 10.4 
l\-Iean vertical cup: disc ratio in right C\'C 0.50 0.1 
* p < 0.05. 
t SD, standard deviation; HRT, hormone replacement therapy. 
Table 3 
Excluded women 
(n = 699) 
Mean SDt 
or% 
80.7* 
48.7 
32.5 
34.7 
2Y 
143.5* 
72.0 
36.7 
15.5 
11.4 
0.50 
10.1 
5.8 
11.0 
6.2 
25.1 
13.8 
4.3 
0.1 
Characteristics of women with natural menopause, by age group, The Rotterdam 
Study, 1990-1993 
Characteristic>< 
J\.fean age (years) 
(Yo with ever use of HRT:j: 
0/o with use of HRT for 2': 1 vear 
% with definite open-angle glaucoma 
%with probable POAGj:, based 
on a glaucomatous visual field defect 
%with probable POJ\G:j:, based 
:?: 50 
(n = 1,555) 
68.4 (8.4)t 
6.8 
2.4 
0.4 
0.4 
Age group (years) 
45-49 
(n = 650) 
69.2 (8.4) 
6.5 
3.0 
0.6 
0.3 
< 45 
(n = 264) 
70.0 (7.6) 
7.4 
5.4 
1.1 
2.3 
on a glaucomatous optic neuropathy 1.9 2.0 3.4 
%with elevated intraocular pressure 10.4 8.9 13.3 
* see text for definitions and criteria. 
t Numbers in parentheses, standard deviation. 
4: HRT, hormone replacement therapy; t POi\G, primary open-angle glaucoma. 
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Definite (n = 13) and probable POAG based on either a glaucomatous visual field 
defect (n = 14) or a glaucomatous optic neuropathy (n =51) was diagnosed in 78 
subjects (Table 4). Women who experienced menopause before the age of 45 years 
had a significantly higher risk of POAG (odds ratio (OR) = 2.6; 95 percent 
confidence interval (CI): 1.5, 4.8) than the reference group. Women who 
experienced menopause bet\veen the ages of 45 and 49 years did not have a signifi-
cantly increased odds ratio (OR= 1.1; 95 percent CI: 0.7, 2.0). Wben we considered 
the small number of cases with definite open-angle glaucoma (n = 13), the odds 
ratio for women with menopause before age 45 was 3.5 (95 percent CI: 0.8, 14.8) 
and that for women with menopause between ages 45 and 49 was 1.8 (95 percent 
CI: 0.5, 6. 7). 
\Xle next examined the relation bet\veen age at menopause and probable POAG, 
based on a glaucomatous visual field defect or a glaucomatous optic neuropathy 
(Table 5). The odds ratio for women with menopause before age 45 was 2.5 (95 
percent CI: 1.3, 4.8) and that for women with menopause at age 45-49 years was 
1.0 (95 percent CI: 0.6, 1.9), in comparison with the reference group. 
Duration of lifetime exposure to endogenous sex hormones ranged from 15 
years to 49 years (mean = 36.1 years). The odds ratio for POAG decreased signifi-
cantly by 5 percent per year of exposure to endogenous sex hormones (OR::.::: 0.95; 
95 percent CI: 0.90, 0.99) and by 6 percent per year for each year of age at 
menopause (OR = 0.94; 95 percent CI: 0.90, 0.99). Additional adjustment for use 
of hormone replacement therapy did not markedly change our estimates. 
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Table 4 
Odds ratios for definite and probable* primary open-angle glaucoma, by 
age at natural menopause, The Rotterdam Study, 1990-1993 
Age at Primary o:een-angle glaucoma Odds 95% 
menopause 
Absent Present ratiot 
confidence 
·ears) interval 
2: 50 1,276 41 l.Oj: 
45-49 541 19 1.1 0.7, 2.0 
< 45 210 18 2.6 1.5, 4.8 
* Probable primary open-angle glaucoma was based on either a glaucomatous visual field 
defect or a glaucomatous optic neuropathy. 
t Adjusted for age and use of hormone replacement therapy. 
:j: Reference category. 
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Table 5 
Odds ratios for probable* open-angle glaucoma, by age at natural 
menopause, The Rotterdam Study, 1990-1993 
Age at Prirnarv o:een-aogle glaucoma Odds 95°/ri 
menopause Absent Present ratiot 
confidence 
(vears interval 
:::::50 1,276 35 1.0:1: 
45-49 541 15 1.0 0.6-1.9 
< 45 210 15 2.5 1.3-4.8 
"' Probable primary open-angle glaucoma was based on either a glaucomatous visual field 
defect or a glaucomatous optic neuropathy. 
t Adjusted for age and use of hormone replacement therapy. 
:j: Reference category. 
There were 609 women who had experienced an artificial menopause. Among 
women who had experienced menopause after irradiation therapy or bilateral 
oophorectomy with or without hysterectomy (n = 209), definite or probable 
POAG was diagnosed in seven women: four women with menopause at or after 
age 50 and three \vomen with 1nenopause between ages 45 and 49 years. POAG 
\vas not present in the women who had experienced menopause before age 45. In 
the category of women who had undergone a hysterectomy with or without 
unilateral oophorectomy (n = 400), these numbers were one, two, and five, 
respectively. Numbers were too small among women with an artificial menopause 
to calculate odds ratios. \\/hen we analyzed all women, regardless of cause of 
menopause (n = 3,078), the odds ratio for POAG was 1.8 (95 percent CI: 1.0, 3.0) 
among women with menopause before age 45 and 1.1 (95 percent CI: 0.7, 1.9) 
among women with menopause at age 45-49, in comparison with the reference 
group. In all analyses, additional adjustments for use of hormone replacement 
therapy, hypertension, diabetes, and elevated IOP did not markedly change our 
results. 
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Table 6 
Odds ratios for elevated intraocular pressure, by category of age at 
natural menopause, for women with natural menopause and women 
who experienced artificial menopause after undergoing irradiation 
therapy or a bilateral oophorectomy, The Rotterdam Study, 1990-1993 
Age at Elevated intraocular pressure Odds 95% 
menopause Absent Present confidence Ratio* (vears) inten'al 
;, 50 
45-49 
< 45 
1,450 
659 
293 
172 
62 
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J.Ot 
0.8 
1.2 
*Adjusted for age, hormone replacement therapy and hypertension. 
t Reference category. 
0.6·1.1 
0.8-1.8 
Hormone replacement therapy 
Among women with natural menopause or menopause after irradiation therapy or 
bilateral oophorectomy (n = 2,678), 188 women had taken hormone replacement 
therapy for some period of time . .0..fean duration of use was 2.5 years (maximum = 
24 years). Of\-vomen who used hormone replacement therapy, three had definite or 
probable open-angle glaucoma. The risk of POAG was lower in \-vomen who had 
used hormone replacement therapy than in women who never had, but this 
estimate was not significant (OR= 0.54 (95 percent CI: 0.17, 1.74), adjusted for age 
and age at menopause). 
Intraocular pressure 
The odds ratio for elevated lOP among women who experienced either natural or 
artificial menopause before age 45 years was 1.2 (95 percent CI: 0.8, 1.8), and the 
odds ratio among those with menopause benveen ages 45 and 49 years was 0.8 (95 
percent CI: 0.6, 1.1), in comparison with the reference group (Table 6). Additional 
adjustments for hypertension and hormone replacement therapy did not change the 
odds ratios. 
Discussion 
In this population-based study, women who experienced an early natural 
menopause had an increased risk of POAG. In interpreting this finding, some 
methodological issues must be addressed. 
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Women included in the present analysis may have differed from those excluded. 
We excluded subjects with incomplete ophthalmologic or menopausal data; these 
women were mostly older and living in a nursing home, where visual field screening 
was not possible. After we adjusted for age, there was no difference in most 
baseline characteristics beru.reen the two groups, but the percentage of use of hor-
mone replacement therapy was lower and the mean systolic blood pressure was 
higher in the group of excluded subjects. Since age is an important risk factor for 
POAG, exclusion of an older set of women probably causes underestimation of the 
prevalence of the disease. :\.Iean age at menopause and mean vertical cup-disc ratio 
\Vtte comparable in the t\vo groups; therefore, "\VC do not think selection bias had a 
large effect on our results. 
Data on age and cause of menopause were self-reported. The distribution of 
ages at menopause in our study \Vas comparable to the distributions reported by 
t\vo leading studies on age at menopause in the )Jetherlands. 16,17 Still, misclassifica-
tion could have occurred because of the time period bet\veen age at menopause and 
age at examination. Since we have no reason to assume that women with POAG 
would have reported an earlier age at menopause, misclassification "\Vould have been 
non-differential, and this would have given an underestimation of the true effect. 
The main finding of our study \Vas that women "\vho had a natural menopause 
before the age of 45 had a significantly higher risk of POAG than those who had a 
natural menopause at age 50 or above. This is in agreement with our hypothesis 
that female endogenous sex hormones protect against PO_AG. However, the risk 
was not significantly elevated among \vomen who experienced menopause bet\veen 
the ages of 45 and 49 years. This can be explained by a smaller contrast in hormo-
nal status bet\veen the t\vo groups. Probably only very early menopause is relevant 
for an increased risk of POAG. We cannot exclude the possibility that the small 
number of cases rendered our findings insignificant. \X::'hen we considered only 
definite POAG, both in women who had menopause before age 45 and in those 
who had menopause benveen ages 45 and 49, the odds ratios were increased. The 
small number of cases probably explains the lack of significance in this analysis. 
Another variable of possible importance is the interval between menarche and 
menopause. \\le studied the relation between menarche and POAG (1-year-later 
menarche: OR= 1.05; 95 percent Cl: 0.92, 1.19). The reason for such a small effect 
and wide confidence intetYals could be misclassification due to inaccurate assess-
ment of age at menarche. Possibly, in contrast to cessation of hormonal activity 
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during middle age, the start of hormonal activity in youth has no effect or a weaker 
effect on risk of open-angle glaucoma. \X/e also studied the interval bet\veen 
menarche and menopause, but this gave us results similar to those for age at 
menopause. For these reasons, we chose age at menopause as our indicator of 
exposure to endogenous female hormones. For analyses including other parameters 
of endogenous or exogenous exposure to hormones, such as artificial menopause 
and use of hormone replacement therapy, the data should be interpreted with care, 
since the numbers of cases in these categories were small. 
There was no significant difference in risk of elevated lOP between women in 
different categories of age at menopause. This finding was expected from our 
hypothesis. No appreciable difference in risk was predicted, because any hypothe-
sized lOP-lowering effect of estrogens and progestogens would be a direct effect, 
independent of age at menopause. In the literature, evidence is found for a direct 
effect of endogenous hormonal changes on aqueous humor circulation: J\{ost 
authors agree that in pregnancy, with altered hormonal status, intraocular pressure 
decreases significantly. 18-2U This reversible effect is most likely explained by an 
increased outflow facility through the trabecular meshwork.19 
The relation between POAG and gender is still controversiaL In the Baltimore 
Eye Survey,21 the Beaver Dam Eye Study,22 and the Blue Niountains Eye Study,23 
no significant difference \vas found between prevalences of primary open-angle 
glaucoma in men and women. However, in the Framingham Eye Study,24 the 
Barbados Eye Study,3 and the Rotterdam Study,< up to a twofold higher prevalence 
was found in men. Many differences between these studies have been discussed.4 
The change over time in use of hormone replacement therapy, and thus a protec-
tive effect of exogenous sex hormones, could explain the gender difference. 
Several biologic mechanisms could explain the association benveen early 
menopause and POAG. It may be assumed that the decrease in estrogen and 
progesterone levels after menopause may play a key role, and therefore biologic 
mechanisms influenced by these hormones may be involved. It is known that 
estradiol increases endothelial nitric oxide levels by enhancing the activity of the 
enzyme nitric oxide synthase III.25-2~ Several investigators have reported that nitric 
oxide induces a decrease in IOP--for example, by relaxation of the trabecular 
meshwork.29-32 fvforeover, as a vasodilator, nitric oxide may have an effect on the 
blood supply of the optic nerve and the basal vascular tone in uveal, retinal, and 
choroidal circulation. 32-37 
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There is evidence that progesterone has the properties of a glucocorticoid 
antagonist.JS Glucocorticoids are known to elevate IOP.39.4D Progesterone may 
inhibit the ocular hypertensive effect of endogenous glucocorticoids by competing 
for the receptor-binding site. These receptors have been located in human 
trabecular mesh"\vork cells41 and rabbit iris-ciliary body cells,42 binding both 
glucocorticoids and progesterone. 
In the population-based Rotterdam Study, age at natural menopause \Vas 
associated with the presence of POAG. For both etiologic and therapeutic reasons, 
further research into the effects of endogenous and exogenous exposure to female 
sex hormones would be of interest. 
References 
1. Klaver CC, \'\/olfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence 
and causes of blindness and visual impairment in an older population: the Rotterdam 
Study. Arch Ophthalmology 1998;116:653-658. 
2. Leske J\fC. The epidemiology of open-angle glaucoma: a revie\v. Am] Epidemiol 1983; 
118:166-191. 
3. Leske :VIC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence 
of open angle glaucoma. Arch Ophthalmol 1994;112:821-829. 
4. \"'17olfs RC, Borger PH, Ramrattan RS, I<Javer CC, Hulsman CA, Hofman A et al. 
Changing views on open-angle glaucoma: definitions and prevalences-The Rotterdam 
Study. Invest Ophthalmol Vis Sci 2000;41:3309-3321. 
5. Broadway DC, Nicolela ;\JT, Drance SJ\..L Optic disk appearances in primary open-angle 
glaucoma. Surv Ophthalmol 1999;43:S223-S243. 
6. Armaly, {vf. F. On the distribution of applanation pressure. Arch Ophthalmol 1965;73: 
11-18. 
7. Bankes JL, Perkins ES, Tsolakis S, Wright JE. Bedford glaucoma survey. Br Med J 1968; 
1:791-796. 
8. Qureshi IA. Ocular hypertensive effect of menopause with and without systemic 
hypertension. Acta Obstet Gynecol Scand 1996;75:266-269. 
9. Sator MO, Joura EA, Frigo P, Kurz C, ;\fetka 1.1, Hammer A et al. Hormone 
replacement therapy and intraocular pressure. 1-hturitas 1997;28:55-58. 
10. Sa tor NIO, Akramian J, Joura EA, Nessmann A, \V'edrich A, Gruber D et al. Reduction 
of intraocular pressure in a glaucoma patient undergoing hormone replacement therapy. 
Maturitas 1998;29:93-95. 
11. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease 
and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-
422. 
49 
Chapter 2.2 
12. Dielemans I, Vingerling JR, Hofman A, Grobbce DE, de Jong PT. Reliability of 
intraocular pressure measurement '\Vith the Goldmann applanation tonometer m 
epidemiological studies. Graefes Arch Clin Exp Ophthalmology 1994;232:141-144. 
13. Varma R, Steinmann \XlC, Spaeth GL, \\Tilson RP. Variability in digital analysis of optic 
disc topography. Graefes Arch Clin Exp Ophthalmology 1988;226:435-442. 
14. Ramrattan RS, \\iolfs RC, Jonas JB, Hofman A, de Jong PT. Determinants of optic disc 
characteristics in a general population: The Rotterdam Study. Ophthalmology 1999;106: 
1588-1596. 
15. Dielemans I, Vingerling JR, A.lgra D, Hofman A, Grobbee DE, de Jong PT. Primary 
open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general 
elderly population. The Rotterdam Study. Ophthalmology 1995;102:54-60. 
16. den Tonkelaar I. Validity and reproducibility of self-reported age at menopause in 
·women participating in the DOM-project. J\.hturitas 1997;27:117-123. 
17.Jaszmann L, Van Lith ~D, Zaat JC. The age of menopause in the Netherlands. The 
statistical analysis of a survey. Intj Fcrtil1969;14:106-117. 
18. Becker. Clinical aqueous outflow. Arch Ophthalmol1953;50:557-571. 
19. Green K, Phillips CI, Cheeks L, Slagle T. Aqueous humor flow rate and intraocular 
pressure during and after pregnancy. Ophthalmic Res 1988;20:353-357. 
20. Ziai ~. Ory SJ, Khan AR, Brubaker RF. Beta-human chorionic gonadotropin, 
progesterone, and aqueous dynamics during pregnancy. Arch Ophthalmol 1994;112:801-
806. 
21. Tielsch jl\.t!, Sommer A, Katz J, Royall fu\J, Quigley HA, J avitt J. Racial variations in the 
prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. jAi\1A 1991; 
266:369-374. 
22. Klein BE, I<Jein R, Sponsel \\?E, Franke T, Cantor LB, l\hrtone J et al. Prevalence of 
glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-1504. 
23. ivlitchell P, Smith '1//, Attebo K, Healey PR. Prevalence of open-angle glaucoma in 
Australia. The Blue 1-tfoumains Eye Study. Ophthalmology 1996;103:1661-1669. 
24. Kahn HA, Leibowitz H~1, Ganley JP, Kini J\{i\1, Colton T, I':ickerson RS ct al. The 
Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 
1977;106:17-32. 
25. Rosselli ~1, Imthurm B, Macas E, Keller PJ, Dubey RK. Circulating nitrite/ nitrate levels 
increase '\Vith follicular development: indirect evidence for estradiol mediated I\:0 
release. Biochem Biophys Res Commun 1994;202: 1543-1552. 
26. Hayashi T, Yamada K, Esak.i T, Kuzuya M, Satake S, Ishikawa T et aL Estrogen 
increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res 
Commun 1995;214:847-855. 
27. Ruehlmann DO, 11ann GE. Actions of oestrogen on vascular endothelial and smooth-
muscle cells. Biochem Soc Trans 1997;25:40-45. 
28. Van Buren GA, Yang DS, Clark KE. Estrogen-induced uterine vasodilatation is 
antagonized by L- nitroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am J 
Obstet Gynecol1992;167:828-833. 
50 
POAG and earfy menopause 
29. Nathanson JA, McKee l\J. Identification of an extensive system of nitric oxide-
producing cells in the ciliary muscle and outflmv pathway of the human eye. InYest 
Ophthalmol Vis Sci 1995;36J765-1773. 
30. \Y'iederholt lvi, Sturm A, Lepple-\"X'ienhucs A. Relaxation of trabecular mcsh"\vork and 
ciliary muscle by release of nitric oxide. InYest Ophthalmol Vis Sci 1994;35:251 S-2520. 
31. Becker B. Topical 8-bromo-cyclic G).1P lowers intraocular pressure in rabbits. InYest 
Ophthalmol Vis Sci 1990;31:1647-1649. 
32. Becquet F, Courtois Y, Goureau 0. J\'itric oxide in the eye: multifaceted roles and 
diYerse outcomes. Surv Ophthalmol 1997;42:71-82. 
33. Neufeld AH, Hernandez 1.1R, Gonzalez 1L ~itric oxide synthase in the human 
glaucomatous optic nerve head. Arch Ophthalmol1997;115:497-503. 
34. Chakravarthy U, Stitt A\Y/, McNally J, Bailie JR, Hoey EM, Duprex P. ~itric oxide 
synthase activity and expression in retinal capillary endothelial cells and pericytes. Curt 
Eye Res 1995;14:285-294. 
35. Goldstein Ii\J, Osl:\vald P, Roth S. ~itric oxide: a reYie"\V of its role in retinal function 
and disease. Vision Res 1996;36:2979-2994. 
36. Kobayashi K, Kobayashi H, Ueda 11, Honda Y. Estrogen receptor expression in bovine 
and rat retinas. Invest Ophthalmol Vis Sci 1998;39:2105-2110. 
37. Ogueta SB, Sch\vartz SD, Yamashita CK, Farber DB. Estrogen receptor in the human 
eye: influence of gender and age on gene expression. Invest Ophthalmol Vis Sci 1999; 
40:1906-1911. 
38. Gagne D, Pons NI, Crastes dP. Analysis of the relation between receptor binding affinity 
and antagonist efficacy of antiglucocorticoids. J Steroid Biochem 1986;25:315-322. 
39. Armaly M, F. and Becker, B. Intraocular pressure response to topical corticosteroids. 
Fed Proc 1965;24:1274-1278. 
40. Garbe E, LeLorier J, BoiYin JF, Suissa S. Risk of ocular hypertension or open-angle 
glaucoma in elderly patients on oral glucocorticoids. Lancet 1997;350:979-982. 
41. \\leinreb RJ\', Bloom E, Baxter JD, Alvarado J, Lan N, O'Donnell] et al. Detection of 
glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci 
1981 ;21 :403-407. 
42. \\/einstein Bl, Altman K, Gordon GG, Dunn .i\1, Southren AL. Specific glucocorticoid 
receptor in the iris--ciliary body of the rabbit. Invest Ophthalmol Vis Sci 1977;16:973-
976. 
51 

Abstract 
2.3 
Blood pressure, arterial stiffness, 
and primary open-angle glaucoma 
The association between blood pressure and primary open-angle glaucoma is 
still debated, as results are inconsistent between studies. \Xle investigated 
blood pressure and arterial stiffness in relation to primary open-angle 
glaucoma among 5,732 subjects of the population-based Rotterdam Study. 
Primarv open-angle glaucoma cases "\vere classified into those "\Vith and 
without an intraocular pressure > 21 mm Hg (high-tension and normal-
tension primary open-angle glaucoma, respectively). Arterial stiffness \vas 
determined by pulse "\vave velocity and common carotid distensibility. 
i\ssociations were evaluated "\Vith logistic regression analysis, adjusted for 
age, gender, body mass index, education and smoking. Positive associations 
with high-tension primary open-angle glaucoma "\vere found for systolic 
blood pressure(> 160 mm Hg: odds ratio: 2.9, 95% confidence interval: 1.1-
7.6 compared to the reference group) and pulse pressure(> 80 m1n Hg: odds 
ratio: 4.5, 95(Yo confidence interval: 1.6-12.8), in subjects without treatment 
for systemic hypertension, and for low diastolic blood pressure (< 65 mm 
Hg: odds ratio: 3.0, 95'% confidence interval: 1.1-8.2) and low diastolic perfu-
sion pressure (< 50 mm Hg: odds ratio: 4.8, confidence interval: 1.3-17.7) in 
subjects treated for systemic hypertension. Increased arterial stiffness was 
associated with an increased risk of high-tension primary open-angle 
glaucoma, (relative risk (95% confidence interval) for the highest tertile of 
pulse wave velocity: 2.2 (0.9-5.5), and for the lowest tertile of distensibility: 
2.7 (1.0-7.4), compared to their reference categories). No association was 
observed for normal-tension primary open-angle glaucoma. The findings of 
this study show that high systolic blood pressure, high pulse pressure, low 
diastolic blood pressure, and arterial stiffness are related to high-tension 
primary open-angle glaucoma. 
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Introduction 
The vascular etiology of primary open-angle glaucoma (POAG) has been studied 
extensively. Still, the relation bet-;veen risk factors such as systemic hypertension, 
systolic and diastolic blood pressure (BP), and POAG remains controversial. 
Studies have found associations between highl-3 and low'-" levels of BP and POAG, 
while others did not find any relation. 5J' Reasons for these contradictory results may 
be the complexity of the mechanisms possibly involved, the difference in design of 
studies, and the difference in definitions of POAG used in studies. 
In the elderly, S)rstolic hypertension is the most observed type of hypertension, 
\vhich is found to be associated with the phenomenon of arterial stiffness. Recently, 
it has been suggested that arterial stiffness is not an innocent process in ageing, but 
may be related to ischemic heart disease and stroke. 7·8 
The objective of the present study was to examine systolic and diastolic BP, 
pulse pressure, as well as arterial stiffness, in relation to POAG. 
Methods 
Study population 
The Rotterdam Study is a prospective cohort study among 7,983 subjects aged 55 
years and older9 The baseline examination phase took place from 1990 to 1993 and 
the third phase between 1997 and 1999. The study was approved by the Medical 
Ethics Committee of the Erasmus University and written informed consent was 
obtained from all participants. 
i\!Ieasurements 
1\ standardized eye examination was performed during the baseline phase of the 
study.lO Optic disc transparencies were analyzed "\Vith Imagenet (Topcon, Tokyo) 
and ophthalmoscopy.11 Visual fields were screened with the Humphrey Field 
Analyzer (Dublin, California) and defects were confirmed by Goldmann 
perimetry.lO 
Although pseudoexfoliative glaucoma was not excluded at baseline, we refer to 
the disease status as POAG, because pseudoexfoliation was not observed at follow 
up. POAG was classified into definite, probable, and possible10 According to the 
presence of an elevated lOP, defined as an IOP > 21 mm Hg or the use of IOP-
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lowering treatment, POAG was stratified in high-tension POAG (htPOAG) and 
normal-tension POAG (ntPOAG). 
BP was measured with a random-zero sphygmo1nanometer.12 Pulse pressure 
was defined as the difference bet\veen systolic and diastolic BP; perfusion pressure 
as the difference between BP and lOP. Systemic hypertension was defined as a 
systolic BP ::0: 160 mm Hg, diastolic BP ::0: 100 mm Hg, or use of antihypertensive 
medication. 
Information on medical history, alcohol, smoking, and education \vas obtained 
during the interview. A positive history of myocardial infarction or stroke was 
confirmed by revie\ving medical records or by ECG. Diabetes was defined as a 
non-fasting serum glucose ~ 11.1 mmol/1 or the use of antidiabetic medication. 
Non-fasting total and high-density lipoprotein (HDL) cholesterol were determined 
using an automatic enzymatic procedure. 
Arterial stiffness was assessed during the third examination phase by measuring 
pulse wave velocity with tonometry and common carotid artery distensibility by 
measuring the vessel \vall motion with a Duplex scanner.n 
Statistical analysis 
Risk factors \vere investigated with logistic regression analysis, with definite and 
probable POAG cases as the case group and subjects without POAG as the 
reference group, repeated for htPOAG and ntPOi\G separately. Odds ratios were 
computed as measures of relative risks (RR's). 
Systolic, diastolic BP and pulse pressure were examined per 10 mm Hg and in 
four categories, using predefined cut-off points. For diastolic BP, we expected a]-
shaped relation.U·14 After inspection of the results, we chose the second category 
(65-74 mm Hg) as reference group. As we expected an inverse relationship for 
diastolic perfusion pressure, we chose the highest category P- 65 mm Hg) as 
reference group. Indicators of arterial stiffness were stratified in tertiles. As 
confounders were included: age; gender; smoking (categorized as never, former or 
current smoking); education (dichotomised in ::::; versus > primary education); and 
body mass index (weight/height2). 
55 
Chapter 2.3 
Study population 
Since the ophthalmic part of the Rotterdam Study started later than the other 
groups, 6,872 subjects participated and 6,756 (98.3%) had ophthalmic data for the 
diagnosis of POAG. Of these, 6,624 subjects \Vere available for analyses, since 132 
subjects had no data on BP. Data on pulse wave velocity were available for 3,364 
subjects and data on common carotid distensibility for 2,996 subjects. 
Results 
Baseline characteristics are given for definite (n = 50) and probable POAG cases (n 
= 176) and for subjects without POAG (n = 5,516) in Table 1. Subjects with possi-
ble POAG (n = 1 014) were excluded from all analyses. Definite POAG cases were 
older, and had more men, a higher lOP, and a higher pulse \vave velocity than 
subjects without POAG. 
Table 1 
Characteristics of the Study Population by Primary Open-angle Glaucoma Status 
Characteristic ;\Jo POAG Probable Definite 
POAG POAG 
No. 5,516 176 so 
Age, y 69.0 ± 9.0 73.0 ± 9.6 73.5 ± 7.3 
\X·' omen, 0/o 60 61 44 
Intraocular pressure, mm Hg 16.0 ± 3.4 16.9 ± 5.9t 18.0 ± 4.5t 
Systolic blood pressure, mm Hg 139.2 ± 22.4 144.0 ± 24.4 144.6 ± 21.6 
Diastolic blood pressure, mm Hg 73.6 ± 11.6 74.7 ± 12.3 71.7 ± 12.1 
Hypertension*,% 34 42 44 
Antihypertensive treatment, (Yo 32 40 40 
Body mass index, kg/ m2 26.3 ± 3.7 26.3 ± 3.2 25.8 ± 3.2 
Current smoker, % 24 20 22 
Former smoker, % 41 38 40 
Higher than primary education, 0/{J 62 58 62 
Pulse wave velocity*, m/s 13.5 ± 3.0 13.9 ± 2.7 16.1 ± 5.0 
Distensibility coefficient*, 10-3 /kPa 10.6 + 4.4 9.4 + 4.0 8.7 + 5.7 
Values are given as proportion or as mean± SD. POAG indicates primary open-angle glaucoma 
* see methods section for definitions 
t different from subjects with no POAG, p < 0.05, adjusted for age and gender 
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Table 2 
Association between blood pressure, pulse pressure per 10 mm Hg and primary 
open-angle glaucoma in subjects without blood pressure-lowering treatment 
Blood pressure Total Intraocular pressure 
PerlOmmHg :::;21mmHg >21mmHg 
Controls/POAG cases 3,600/139 3,600/101 3,600/38 
RR (95':;,, CI) RR (95% Cl) 
Svstolic BP 1.06 (0.98-1.15) 1.05 (0. 96-1.15) 
Diastolic BP 1.04 (0.90-1.21) 1.08 (0.91-1.29) 
Pulse pressure 1.06 (0.98-1.14) 1.04 (0.92-1.17) 
Both definite and probable POAG cases were included in case group. 
RR (95% Cl) 
1.16 (1.01-1.34) 
1.01 (0.78-1.33) 
1.25 (1.05-1.50) 
Relative risks are adjusted for age, gender, smoking, body mass index, and education. 
POAG indicates primary open-angle glaucoma; BP, blood pressure; RR, relative risk; CI, confidence 
interval 
Associations with POAG for systolic and diastolic BP and pulse pressure are 
given in Table 2 and Table 3. In these two tables, results are only shown for subjects 
without treatment for systemic hypertension, because of the difficulty in discrimi-
nating the effect of systemic BP on POAG from the effect of BP lowering treat-
ment on POAG. Increases of 10 mm Hg in systolic BP and pulse pressure were 
associated with an increased risk of htPOAG (RR 1.16, 95'Yc CI 1.01-1.34 and RR 
1.25, 95% CI 1.05-1.50, respectively) (Table 2). For diastolic BP, no association was 
found with htPOAG and a statistically non-significant positive association was 
found with ntPOr\G (RR 1.08, 95% CI 0.91-1.29). When only definite POAG cases 
were included in the case group, the RR's of htPOAG for systolic BP and for pulse 
pressure increased additionally (RR 1.23, 95% CI 1.01~1.51, and RR 1.30, 95% Cl 
1.00~ 1.68, respectively). 
Results of BP parameters examined in four categories are shown in Table 3; we 
found increasing risks of htPOAG for higher levels of systolic BP and higher levels 
of pulse pressure (Table 3). Subjects in the highest category of BP (> 160 mm Hg) 
had an RR of 2.9 (95'% CI 1.1-7.6) of htPOAG, compared to the reference group. 
Subjects in the highest category of pulse pressure (> 80 mm Hg) had an RR of 4.5 
(95'% CI 1.6~12.8) of htPOAG, compared to those with pulse pressure < 55 mm 
Hg. No association was found with ntPOAG for systolic BP, diastolic BP or pulse 
pressure. Since analyses bet\veen systolic perfusion pressure and POAG yielded 
results similar to those between systolic blood pressure and POAG, results of the 
former analyses "\vere not shown. 
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Table 3 
Association between blood pressure, perfusion pressure in four categories 
and primary open-angle glaucoma in subjects without blood pressure-
lowerin()' treatment 
Blood pressure 
Controls/POAG cases 
Systolic BP, mm Hg 
< 130 
130-144 
145-160 
> 160 
Diastolic BP, mm Hg 
< 65 
65-74 
75-85 
> 85 
Pulse pressure, mm Hg 
<55 
55-64 
65-80 
>so 
Intraocular pressure 
:::; 21 mm Hg > 21 mm Hg 
3600/101 3600/38 
RR (95% CI) RR (95% Cl) 
Reference Reference 
1.3 (0.8-2.2) 1.5 (0.5-4.1) 
0.8 (0.4-1.5) 2.5 (1.0-6.5) 
1.2 (0. 7 -2.2) 2.9 (1.1-7.6) 
1.0 (0.6-1.8) 1.1 (0.5-2.5) 
Reference Reference 
1.0 (0.6-1.7) 0.7 (0.3-1.6) 
1.3 (0.7-2.4) 1.1 (0.4-2.8) 
Reference Reference 
1.4 (0.8-2.5) 1.0 (0.3-3.6) 
1.3 ((1.7 -2.3) 2.0 (0.7-6.0) 
1.3 (0. 7 -2.5) 4.5 (1.6-12.8) 
Both definite and probable POAG cases '\vere included in case group. 
Relative risks are adjusted for age, gender, smoking, body mass index and education 
POAG indicates primary open-angle glaucoma; BP, blood pressure; RR, relative risk; CI, 
confidence interval 
Since we expected a perfusion problem in particular for low diastolic BP, we 
separately examined the association bet\veen diastolic BP and POAG. As any effect 
of low diastolic BP could particularly be obsen.red in subjects treated for systemic 
hypertension, "\Ve examined the relation between diastolic BP, diastolic perfusion 
pressure, and POAG in the treated group (Table 4). The risk of htPOAG increased 
when the diastolic BP decreased, with an RR of 3.0 (95% CI 1.1-8.2) for a diastolic 
BP < 65 mm Hg, compared to those with diastolic BP between 65 and 75 mm Hg. 
No significant association was found bet\veen diastolic BP and ntPOAG (data not 
shown). Subjects with a diastolic perfusion pressure < 50 mm Hg had an RR of 4.8 
(95% CI 1.3-17.6), compared to those with diastolic perfusion pressure 2: 65 mm 
Hg. 
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Table 4 
Association between diastolic blood pressure, diastolic perfusion 
pressure and primary open-angle glaucoma in subjects taking blood 
pressure-lowering treatment 
Characteristic RR (95 1% Cl) 
Diastolic blood pressure, mm Hg 
< 65 
65-75 
75-85 
eo 85 
Diastolic perfusion pressure, mm Hg 
<50 
50-57.5 
57.5-65 
:2:: 65 
3.0 (1.1-8.2) 
Reference 
1.4 (0.5-4.3) 
1.0 (0.2-3.9) 
4.8 (1.3-17.6) 
2.1 (0.5-9.1) 
1.8 (0.4-7.6) 
Reference 
Both definite and probable POAG cases "\Vere included in case group. 
RR indicates relative risk; CI, confidence interval 
Table 5 
Association between arterial stiffness and primary open-angle glaucoma 
Indicators of arterial stiffness Total Intraocular pressure 
< 21 mm Hg > 21 mm Hg 
Pulse wave velocity, m/s 
RR (95% Cl) RR (95% CI) RR (95% CI) 
Controls/POAG cases 2,735/91 2,735/58 2,735/33 
< 13.2 Reference Reference Reference 
13.2-153 1.7 (1.0-2.8) 1.8 (1.0-3.4) I. 7 (0.6-4.6) 
eo 15.3 1.2 (0.7 -2.0) 0.7 (0.3-1.7) 2.2 (0.9-5.5) 
Distensibility, J0~3/kPa 
RR (95% CI) RR (95% CI) RR (95% CI) 
Controls/POAG cases 2,417/79 2,417/52 2,417/27 
< 7.4 1.9 (1.0-3.4) 1.4 (0. 7-3.1) 2. 7 (1.0-7.4) 
7.4-9.9 1.3 (0.7 -2.4) 1.7 (0.9-3.3) 0.6 (0.1-2.3) 
> 9.9 Reference Reference Reference 
Both definite and probable POAG cases were included in case t:,JToup. 
RR indicates relative risk; POAG, primary open-angle glaucoma; CI, confidence interval 
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The presence of systemic hypertension was associated with a weakly increased risk 
of definite or probable POAG (RR 1.3, 95% CI 1.0-1.7). In those without 
antihypertensive treatment, the risk of htPOAG increased, but both estimates were 
not significant (RR 1.5, 95% CI 0.7-3.0). No association was observed between 
systemic hypertension and ntPOAG. 
An increased pulse \vave velocity and a low distensibility coefficient, both 
indicative for a high arterial stiffness, \Vere associated with an increased risk of 
htPOAG in a dose-response relationship (Table 5). The lowest category of disten-
sibility (< 7.4 10-3/kPa) reached statistical significance (RR 2.7, 95% CI 1.0-7.4, 
compared to distensibility ;o. 9.9 10·3/kPa). 
Discussion 
In this population-based study, we found that an increased systolic BP and an 
increased pulse pressure were associated with a higher risk of htPOAG in subjects 
who were not treated for systemic hypertension, while no association was found for 
diastolic BP. A low diastolic BP and a low diastolic perfusion pressure were 
associated with an increased risk of htPOAG in subjects with treatment for 
systemic hypertension. Furthermore, indicators of arterial stiffness were associated 
with htPOAG. \Xle found no significant association between ntPOAG and systolic 
BP, diastolic BP, pulse pressure or arterial stiffness. 
The present study has a cross-sectional design, which limits the causal interpre-
tation of our findings. V/ e have no evidence that the examined risk factors were 
present before POAG occurred. Ho\.vever, it is very unlikely that our results are 
caused by an effect of POAG on systemic BP or arterial stiffness. Therefore, the 
determinants can be interpreted as risk factors of POAG. Furthermore, \.VC 
consider it unlikely that the association between low diastolic BP, diastolic perfu-
sion pressure, and htPOAG in subjects treated for systemic hypertension is caused 
by the selective systemic antihypertensive treatment of POAG patients. 
For the definition of POAG, we used the criteria described before. 111 All partici-
pants underwent a standardised ophthalmological examination where features of 
POAG were assessed separately in a masked fashion to ensure an unbiased 
diagnosis. The level of lOP \.vas not included in these criteria, which enabled us to 
investigate risk factors separately in cases with ntPOAG and those with ntPOAG. 
The distinction between lOP > 21 and :<:; 21 mm Hg is artificial for a 
continuous measure such as lOP. However, the cut-off point of 21 mm Hg 
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represents the 97.5 cencile in our populationlO and is a commonly used cut-off 
point for elevated lOP. It is generally acknowledged, that POAG is considered a 
multifactorial disease, where it is likely that different combinations of factors are 
responsible for the different phenotypes of the disease-'S In POs\G accompanied 
by a normal lOP, other factors may be of importance than in POs\G accompanied 
by a high lOP. Therefore, risk factors that are involved in a subset of the heteroge-
neous group of POAG may better be identified when analysing these subsets, 
instead of analysing the total group. Ophthalmological data were collected during 
the baseline phase of the study, while arterial stiffness was assessed in the third 
phase. As PO£\G is not related to survival (PH Borger et al, unpublished data, 
2001),16 it is unlikely that the different moments of measurements have biased our 
results. Arterial stiffness may be associated with an increased risk of cardiovascular 
diseaseJ,S As a consequence, subjects \vith a high level of arterial stiffness may have 
died before the third phase of the Rotterdam Study, which may have led to an 
underestimation of the association between arterial stiffness and POAG. 
Several population-based studies have investigated the relation bet\veen BP and 
POAG. 1•2·4•17 Our findings of an association between high systolic BP, low diastolic 
perfusion pressure and htPOAG were also observed in the Egna-Neumarkt Study,' 
but in that study, the association bertveen systolic BP and htPOAG was weak. In 
the Baltimore Eye Survey1 and the Barbados Eye Study,n htPOAG was not 
separately examined, \Vhich complicates exact comparison with our findings. A 
modest positive association bet\veen systolic BP and the total group of POAG 
cases was found in the Baltimore Eye Survey1 The Barbados Eye Study17 found no 
association with systolic BP, but reported low systolic BP /lOP ratios to be 
associated with POAG. Both studies found a strongly increased risk of POAG with 
low diastolic perfusion pressures, which is partly in agreement with our finding, 
because we found this association specifically in htPOAG and in subjects with 
treatment for systemic hypertension. No reports exist on the association between 
pulse pressure and POAG. 
Although vascular factors often have been proposed as important risk factors of 
ntPOAG, we found no relation between ntPOAG and systolic BP, diastolic BP, 
pulse pressure or arterial stiffness. Our findings contradict several clinic-based case-
control studies, which report that low systolic or diastolic BP are associated with 
ntPOAG,18-2 1. One explanation for the absence of an association in our study, while 
clinic-based studies did find an association, could be the absence of extremer levels 
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of BP in clinic-based studies. Ho\.veycr, clinic-based studies are also more prone to 
selection-bias, which may be another explanation for the differences bet\veen our 
population-based study and clinic-based studies. Our results are in agreement with 
the only population-based study that examined ntPOAG apart from htPOAG,2 and 
that found, like our study, no significant association bertveen systolic or diastolic 
perfusion pressure and ntPOAG. The absence of an association with ntPOAG may 
be expected from the positive association between systolic BP and lOP: in contrast, 
in subjects \.Vith a nonnal IOP no increased systolic BP is present. i-\lthough our 
findings of ntPOAG need to be confirmed in other population-based studies, \Vt 
may conclude that the mechanisms involved in the etiology of htPOAG may, at 
least partly, be different from those of ntPOAG. 
TYvo mechanisms could be responsible for our finding of a higher risk of 
htPOAG with increased systolic BP, pulse pressure, and arterial stiffness. Firstly, in 
elderly subjects, an isolated systolic hypertension with normal or even low diastolic 
BP levels is often observed, resulting in a high pulse pressure and accompanying 
arterial stiffness. A perfusion pressure above or below a critical range may disturb 
the autoregulation. 14 ~re hypothesize that a high pulse pressure and arterial stiffness 
may lead to disruption of autoregulation. A disturbed autoregulation is observed in 
POAG patients.22·23 \'Vben in subjects with a defective autoregulation the lOP 
increases, vessels may· not be able to respond to changes in BP to maintain perfu-
sion. This may lead to ischemia and optic nerve damage. Ischemia has been 
proposed byr many investigators as a cause of POAG, as in these patients, the blood 
flow in the optic nerve head, retina, and choroids is reduced.24-2G 
A second explanation for the association between high systolic BP, pulse 
pressure, arterial stiffness, and htPOAG, may be a direct effect on the optic nerve 
head. The axons of the ganglion cells enter the optic nerve head embedded in a 
structure called the cribriform plate. Assuming that a high systemic pulse pressure 
produces a high pulse pressure in the eye, this may lead to more shearing forces in 
the cribriform plate and degeneration of the axons and the retinal ganglion cells. 
The finding of an association between low diastolic BP and lo-w diastolic perfu-
sion pressure and htPOAG in subjects treated for systemic hypertension may be 
explained by a low perfusion of the optic nerve. A level of lo\v perfusion may in 
particular be reached in case of an elevated lOP. It is known that if the diastolic BP 
drops below a critical level, cardiovascular mortality and morbidity increases, which 
has been called "a ]-shape phenomenon" Y This would occur especially under 
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antihypertensive treatment, demonstrating a harmful effect of artificially decreasing 
BP. Visual field progression in POAG patients has been found to be associated 
with nocturnal dips in systemic BP,192S in particular \Vhen receiving systemic anti-
hypertensive therapy29or in combination with a high nocturnal IOP.3° Our findings 
confirm that (over) treatment of systemic hypertension may be a risk factor for 
htPOAG. 
In the present study, \Ve found a \.veaker association bet\veen systemic 
hypertension and POAG than in our previous study31 This is probably explained 
by the use of ne\.v criteria for both parameters. There is a discrepancy bet\veen the 
weak association bet\veen systemic hypertension and POAG, and the associations 
between systolic and diastolic BP and PO£\G. The different directions of the 
effects of systolic and diastolic BP on POAG may cause this discrepancy. A high 
level of systolic and a lo\V level of diastolic BP were associated with an increased 
risk of htPOAG, while hypertension was defined as high levels of either systolic or 
diastolic BP. 
It has been suggested, that the increased risk of systolic BP and pulse pressure 
for POAG is explained through an association with IOP,r:: as a significant associa-
tion benveen systolic BP and lOP is well established. 1,2JJ,32 Although the 
association between systolic BP, pulse pressure and POAG may partly be explained 
through lOP, \Ve consider the increase in lOP too small (0.23 mm Hg increase in 
lOP per 10 mm Hg increase in systolic BP)31 to contribute largely to the risk of 
POAG. 
We showed a strong positive relation between htPOJ\G and systolic BP and 
pulse pressure in subjects not treated for systemic BP, an inverse relation \Vith 
diastolic BP in subjects treated for systemic BP, and a relation bet\veen bet\veen 
htPOAG and arterial stiffness. Our results confirm the findings of other studies, 
and support the role of these risk factors and their consequences in the etiology of 
POJ\G. 
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Myocilin mutations in a population-based sample of 
cases with primary open-angle glaucoma 
Abstract 
AIMS/BACKGROCND- To investigate the prevalence of myocilin (MYOC) 
mutations in a population-based sample of primary open-angle glaucoma 
(POAG) cases and to describe a family with both juvenile and adult onset 
POAG caused by a mutation in ""IYOC. 
iv1ETHODS- The ~fYOC gene was screened in cases derived from the 
Rotterdam Study in the :--Jetherlands. Definite POAG was defined as a 
glaucomatous optic neuropathy together \Vith a glauc01natous visual field 
defect. Upon the identification of the Asn480Lys mutation in one case, 
seven additional family members were studied. To test for a founder effect 
with earlier reported families \Vith this mutation, the haplotypes of the 
MYOC flanking markers D1S2851, D1S242, D1S218, and D1S1165 were 
compared. 
RESULTS- Seven sequence alterations in iviYOC were found in 14 of 47 
POAG cases; six of these \vere also found in controls. In one case, an 
Asn480Lys mutation was found. In the family members of the latter patient, 
the phenotype ranged from a glaucomatous optic neuropathy without visual 
field defect in a 70-year old patient to severely affected optic discs and a 
remaining peripheral island in a 34-year old patient; those ·without the muta-
tion had no signs of POAG. Haplotype analysis suggested a different origin 
of the mutation. 
COJ>;CLCSIONS- The prevalence of ;vrYOC mutations (2.2%) among POAG 
patients was similar to that found in hospital-based studies. Although muta-
tions in 1J'{0C are rare, relatives carrying this mutation run a high risk of 
developing the disease. Instead of submitting all members of a family \.vith 
the Asn480Lys mutation to frequent follov.r up, medical care can be 
restricted to those carrying the mutation. 
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Introduction 
Primary open-angle glaucoma (PO A G) is clinically characterised by a glaucomatous 
optic neuropathy (GON) and a glaucomatous visual field defect (GVFD) in eyes 
with open chamber angles and no history or signs of secondary glaucoma. Its 
prevalence increases from 0.1 ryo in subjects aged 55, to 2.0°/o in subjects aged 80 or 
over. 1 In adclition to age, risk factors include a high intraocular pressure (lOP), 
ethnic origin and myopia.2-4 A major risk factor is a positive family history.5·7 It is 
now generally accepted that POAG is a complex disease, \vhich is a result of 
multiple and interactive genetic and environmental effects. Although six chromo-
somal loci8- 13 and five possibly involved genomic regions 14 for POAG have been 
described, the only causative gene known at present is myocilin15 (lvfYOC) which 
codes for the lviYOC protein16,I7 
The normal function of _i\f'{OC is largely unknown. IviYOC is expressed in 
multiple eye tissues, including the trabecular meshwork,16 ciliary body and sclera, 1S 
axons of ganglion cells and several parts of the optic nenre head, 19,2U as \\rell as in 
nonocular tissues. 18 It is not clear how mutations in JYfYOC cause glaucoma. Since 
the lviYOC-related phenotype is characterised by an elevated IOP, the outflow of 
aqueous humour may be obstructed.2 1 The mutated protein may either disturb the 
normal cytoskeletal function, 22 or contribute to extracellular matrix affecting the 
outflow. 1' Increased J\.IYOC expression in trabecular meshwork was found in 
POAG and pseudoexfoliative glaucoma.23 Since expression of J\.IYOC in the optic 
nerve head was sho"\vn, Karali et al. suggested that the protein might be involved in 
glaucomatous damage in this tissue.19 
\\i'hile myocilin has been implicated in families with autosomal dominant juve-
nile glaucoma, mutations have also been described in sporadic patients with adult 
onset POAG, Among patients with a family history of POAG, the prevalence of 
!vfitOC mutations was 4.4°/o, and among sporadic POAG patients 2.6-4.6°/o.15•24·25 
In total, more than 30 different disease-causing mutations have been identified in 
large samples of patients from different ethnic backgrounds.25 The age of onset, the 
penctrance and the severity of the disease vary considerably among subjects with 
mutations in 1fYOC. 
So far, all mutation analyses have been carried out in samples of POAG patients 
from hospital-based studies, which are not representative of POAG in the general 
population. To know the prevalence of J\1YOC mutations in POAG in the general 
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population, it is necessary to screen a sample of POAG cases that is drawn from a 
population-based study, not selected by level of lOP, age at diagnosis or family 
history. 
We investigated the prevalence of i\IYOC mutations in POAG cases from the 
population-based Rotterdam Study in the Netherlands. We also described a family 
derived from our current study with both juvenile and adult onset POAG caused 
by a mutation in 1-lYOC and investigated whether this mutation was based on a 
European founder effect. 
Material and methods 
Cases 
Cases were derived from the Rotterdam Study, a follow-up study of determinants 
and prognosis of chronic diseases in the elderly.26 All residents, aged 55 years and 
older, living in one suburb of Rotterdam, the Netherlands, were invited to partici-
pate. The present study was performed in baseline data, which were collected from 
1990 to mid 1993. The study has heen approved by the Medical Ethics Committee 
of Erasmus "Cniversity (Rotterdam) and \.Vritten informed consent was obtained 
from all participants. 
Although pseudoexfoliative glaucoma was not specifically excluded in the base-
line phase of the study, we refer to the disease status as POAG, because at follow 
up no cases \Vith pseudoexfoliative glaucoma were found. 
The complete eye examination included testing of best-corrected visual acuity, 
measurement of lOP, slitlamp examination, direct and indirect ophthalmoscopy, 
fundus photography, and simultaneous stereo photography of the optic discs on 
colour transparencies.l Optic disc parameters were assessed with the Topcon image 
analyser Imagenet. Visual fields were screened with a modified 52-point 
suprathreshold test (Humphrey VFA) and confirmed with kinetic Goldmann 
perimetry (Haag Streit, Bern Switzerland) 1 
POAG was classified into three categories: definite, probable and possible. 
Definitions and cut-off points have been described before.1 In short, definite 
POAG was defined as a possible or probable GON together with the presence of a 
GVFD. Probable POAG was defined as the presence of a probable GON without 
a GVFD or the presence of a GVFD without a possible GON. 
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To perform the present mutation analysis in the sample of cases derived from 
the Rotterdam Study, only cases with definite POAG were included. The age of 
onset of the disease was not determined. An elevated lOP was considered present 
\-vhen either the lOP was over 21 mm Hg during our examination or lOP-lowering 
treatment had been used, including medical, laser or surgical therapy. Unaffected 
relatives and spouses from families who participated in prior linkage studies were 
included as controls.27 Sequence changes, which were supposed to be disease 
causing, \Vere tested among 100 controls; those that were previously described as 
polymorphisms were tested in at least 50 controls. 
After detection of the Asn480Lys mutation in one POAG case, \vho was 
deceased in the meantime of the study, relatives "\vere contacted through another 
member of the family. Since the history of glaucoma was known in the family, most 
relatives had been attending an ophthalmologist. For most participating relatives 
and for relatives who were deceased at the time of the investigation, data were 
retrieved from medical charts. 
DNA analysis 
Genomic DNA was isolated from the peripheral blood lymphocytes. The three 
exons of the fv1YOC gene, the flanking splice sites, and the promoter regions that 
were proven to be functionally important28 were screened by single strand 
conformational polymorphism (SSCP) analysis on a 6°;;, acrylamide gel with 0 and 
5% glycerol. For the first and the third exon, three pairs of primers and for the 
second exon one pair of primers were used. Except for one pair of primers of the 
first exon (F: ccaagcctctgcaatgaggt) and one of the second exon (F: 
ctggccggcagcctatttaa), primers were described before. 18 Niicrosatellite markers were 
PCR amplified using standard procedures.29 Nucleotide sequences were determined 
by direct sequencing of both strands of the PCR product. 
For seven family members of the POAG case carrying the Asn480Lys mutation, 
DNA was obtained. These persons were screened for the presence or absence of 
the mutation by direct sequencing. To investigate the possibility of a founder effect 
with the patients described by Brezin30 the alleles of four markers in the region of 
the disease gene were compared between these patients and the patients of our 
family. The markers D1S2851, D1S242, D1S218, and D1S1165 were tested. 
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Results 
Cases 
Definite POAG was present in 50 subjects of those who were ophthalmologicaly 
examined (n = 6,756). DNA was available of 47 of them. cvlean age of these 47 
cases was 73.3 years, ranging from 58.7 to 88.5 years and 26 (55°/o) were male. A 
positive family history of first-degree relatives was reported by 14 (30'Yo) patients. 
Of the 47 cases, 23 were previously known to have POAG and received lOP-
lowering treatment. Of the remaining 24 newly identified cases, six had an lOP > 
21 mm Hg. 
lvfutation screening 
In the 47 cases from the Rotterdam Study, seven sequence alterations in .i\ITOC 
were found (Table 1). One case had a previously reported heterozygous Asn480Lys 
mutation in the third exon, which could not be found among control persons 
(n = 100). The Arg76Lys change in the first exon was found in 10 cases and in 30 
Table 1 
Sequence changes in myocilin found in 47 primary open-angle glaucoma patients 
from the Rotterdam study (1990-1993) and in unrelated controls 
Sequence Location Fraction of Fraction of Fraction of 
change patients of unrelated controls with 
Rotterdam Study controls with variant from 
with varianta varianta other reports 
Bp -127 (T-+C) promoter 2/40 6/94 not applicable 
Bp -83 promoter 8/40 30/94 112/68624.25 
(G-+A) 
Arg76Lys exon 1 10/46 30/103 18/28824·25 
23/13221 
Tyr122Tyr exon 1 1/46 2/86 2/79324 
Tyr347Tyr exon 3 2/45 1/51 34/79324 
Lys398Arg exon 3 1/45 3/111 I I 6QlB 
7 /793 24·25 
Asn480Lys exon 3 1/45 0/100 not applicable 
"The number of patients differs among parts of exons, because only results that have been confirmed 
in our laboratory nvice are reported. The samples \Vitbout unambiguous results of cases or controls 
have been omitted from the table. 
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controls. In at least eight cases with this change, an additional bp -83 (G->A) 
change in the promoter region was detected, \.Vhich was also found in the same 30 
controls. 
Another sequence change in the promoter region (bp -127 T ~C) as well as a 
Lys398Arg change in the third exon was found both in cases and controls. Two 
other variations resulted m synonymous codon changes (Tyr122Tyr and 
Tyr347Tyr). 
Myocilin Asn480Lys: Clinical investigation and genetic analysis 
Upon the identification of the Asn480Lys mutation in one female case, "\Ve initiated 
the investigation of additional family members. A pedigree was constructed (Figure 
1) including one additional case with definite POAG and one case with probable 
POAG (Table 2). 
II 
Ill 
IV 
v 
Figure 1 
Square = male; circle = female; solid symbol = definite POAG; hatched symbol = probable POAG; 
open symbols = disease status unkno-wn; symbol with N ""' unaffected individual; + sign :::: Asn480Lys 
mutation present; - sib:rn :::: Asn480Lys mutation absent; diagonal line through symbol :::: individual is 
deceased. 
Subjects from generation I and II and subjects '-Vho "\Vere deceased at the time of the investigation (III-
1, III-6, IV-1) have not been examined. The definition ofPOAG in these subjects is based on history 
from relatives or on data from medical charts. 
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The female proband (III:5) had a history of POAG being present around age 
40. Despite medical therapy and surgery, visual field loss deteriorated. \Xrhen she 
came to our attention through participating in the Rotterdam study, she was 88 
years old and "\vas using medical therapy to lower the lOP. She had lost sight in her 
left eye due to a haemorrhage during glaucoma surgery. The other eye showed a 
GVFD of a large part of the upper hemisphere. 
Patient IV:7 was diagnosed with definite POAG. When she visited an ophthal-
mologist for the first time at age 34, she had severely excavated discs in both eyes, 
with a glaucomatous quadrant anopia in the right eye, an lOP of 31 mm Hg in the 
right eye, and 21 in the left eye. Also in this patient, visual fields and optic discs 
deteriorated, despite medical therapy and surgery. At the time of our study, visual 
field testing showed a remaining temporal island of the right eye and an arcuate 
defect of the left eye. Probable GON was present in both eyes, existing of a total 
excavation in the right eye and an excavation locally extending to the disc margin in 
the left eye. 
Table 2 
Clinical features of affected relatives of pedigree with Asn480Lys mutation in 
myocilin 
Subject Diagnosis Age at GO~ GVFD Maximum Therapy 
diagnosis introcular 
res sure 
IIU POAG ± 30 + + 52 medical, laser, 
surgery 
Ili:S definite POAG 40 + + 30 medical, surgery 
Ill:6 POAG "middle age" + + unkno'\vn C'nknmvn 
lV:l POAG "middle age" + + 30 medical, laser 
1V:3 probable POAG 40 + 52 laser, medical, 
surgery 
1V:7 definite POAG 34 + + 31 medical, laser, 
surg-erv 
GO!'-: =Glaucomatous oprjc neuropathy, detlned as a vertical cup-to-disc ratio~ 0.7 or an asymmetry 
bet\-veen vertical cup-to-disc ratios of both eyes ;:;;: 0.2 
GVFD ::: Glaucomatous Yisual field defect 
POAG :::Primary open-angle glaucoma; definite POAG is defined as a GON plus a GVFD; probable 
POAG is defined as a GON '\vithout a GVFD or a GVFD \vithout a GON 
+ = Present; - absent 
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Patient (IV:3) showed a less severe phenotype. Since age 30 he had been treated 
for a high lOP, with medical, laser and surgical therapy. At the time of our investi-
gation, he had a probable GON with normal visual fields at age 70. 
Medical records of subjects III-1, III-6 and IV-1 showed strong evidence for 
definite POAG. In the ophthalmic records, a probable or possible GON was 
described and a GVFD was present. Since these persons were deceased at the time 
of our investigation, DNA for analyses was not available and it was not possible to 
screen for the presence of the mutation. An additional number of three persons, 
deceased at the time of investigation, had a history of POAG according to relatives 
(1:2, II:l, and II:3), but no medical records were available to verify the diagnosis. 
Molecular analysis of the DNA of the definite and probable POAG patients of 
this pedigree revealed cosegregation of the Asn480Lys mutation and gene-flanking 
markers with the disease phenotype (Figure 1). The haplotypes of four gene-
flanking markers in the l'viYOC region differed between our patients and the six 
POAG patients with the Asn480Lys mutation from Northern France. 
Discussion 
In a sample of 47 POAG cases of a population-based study one definite disease-
causing mutation in the 1v1YOC gene (Asn480Lvs) has been identified. Six 
additional sequence changes were considered to be polymorphisms, because they 
were found in both cases and controls. All sequence changes were obsen.red before 
by other research groups, except for the putative promoter polymorphism bp -127 
(T ----1-C). The latter is, however, apparently not located in a regulatory element of the 
promoter. 17,28 
The Arg76Lys change in 10 of our cases was reported before to be a polymor-
phism. In one study, the Arg76Lys segregated with a non-disease associated 
haplotype in a POAG family3 1 and in other studies it was found in controls as 
well.24,2j In eight of the cases carrying Arg76Lys also the bp -83 (G~A) change was 
found. This co-occurrence of the bp -83 (G-+ A) and Arg 7 6Lys polymorphisms in 
the same subjects has been reported in a Chinese population,21 where these changes 
always occurred together. It was not reported in Caucasians before. A potential 
functional effect of the latter phenomenon on the glaucoma phenotype remains to 
be elucidated. 
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As most POAG-causing 1\fYOC mutations, the Asn480Lys mutation is located 
m the third exon of the J\.{'{0( gene. This is a domain homologous to 
olfactomedin, a protein secreted by nasal epithelium.lS The Asn480Lys mutation is 
situated near a casein lcinase II site and causes a change in charge in the local 
residue and a gain of a-helix in the structural conformation of the 1f'i(()( 
protein.32 A POAG pecligree segregating this mutation was previously described by 
Adam et al. 18•30 
Upon examination of seven relatives of our case carrying the Asn480Lys muta-
tion, we identified two additional affected subjects. The phenotypes of the patients 
varied, ranging from GON but no visual field damage in a 70-year old patient to a 
severely affected optic disc and a remaining temporal rest in a 34-year old patient. 
The four subjects without the mutation had no GON, GVFD or elevated lOP. 
These findings are consistent with observations reported by Brezin et al,3D "\vho 
found variable expressivity among carriers with the same mutation, ranging from an 
unaffected carrier at age 60 to severe POAG at age 23. Obviously, other genetic or 
environmental factors must be responsible for these differences in phenotypes. 
11utations in different families may have an independent origin, or may be 
inherited from the same founder, many generations ago. Haplotypes corresponding 
to the iVIYOC locus were different between our family and a family from Northern 
France carrying the Asn480Lys mutation.3° From these data it can be concluded 
that the mutation in our family is most likely a recurrent one. 
A difficulty in glaucoma studies has been the lack of a gold clinical standard to 
define POAG. J\ world-wide-accepted definition would facilitate comparison of 
different studies. The classification of POAG we used was proposed in the World-
wide Glaucoma meeting, Hopkins, Baltimore 2000. A strength of our study is the 
assessment of all characteristics in a masked way and the use of objective criteria to 
define POAG, independent of any previous glaucoma diagnosis, treatment or IOP.l 
A world-wide conclusive classification based on objecti\Te criteria is necessary to 
unravel the factors involved in the heterogeneous group of diseases named POAG. 
\'V'hen investigating the contribution of a gene to a disease phenotype in the 
general population, a population-based approach has an advantage over hospital-
based studies. Since, in hospital-based studies, most patients are probably identified 
by the occurrence of an elevated lOP, samples of these patients tend to be biased 
towards the type of POAG with a high lOP. In our study, the proportion of cases 
with an lOP \vithin normal limits was 38°/o, which is similar to other population-
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based studies. 1,33,34 Using a population~based approach selection bias towards a 
specific type of POAG is minimised. 
Our approach also involves a difficulty, because the number of cases is limited 
by the prevalence of the disease and our strict clinical definition. Since the 
prevalence of definite PO.i\G cases in our study \Vas 0.8°/o, which is comparable to 
other population-based studies,4,33,33-37 the total number of cases in our sample was 
relatively low. 
From this study, it can be concluded that the prevalence of lvfYOC mutations 
within the population-based sample of the Rotterdam study (2.2%) is approximately 
equal to that found in hospital-based studies. 15,l1,24,2S Although mutations in the 
lvfYOC gene are only responsible for a minority of POAG patients, it is important 
to realise that in a family with POAG caused by a i'vfYOC mutation, relatives 
carrying this mutation run a high risk of developing the disease and need frequent 
follow up. At the same time, relatives not carrying the mutation have a risk not 
higher than that in the general population and need less follow up. 
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FAMILY STUDY 

4 
Family score as indicator of genetic risk of 
primary open-angle glaucoma 
Abstract 
OBJECTIVES- To assess the genetic risk of primary open-angle glaucoma 
(POAG) in individuals by calculating a family score (FS), which summarizes 
the information about all relatives including their disease status, age, gender 
and degree of kinship. Furthermore, to examine the contribution of genetic 
factors to the occurrence of POAG with and without an increased 
intraocular pressure (lOP). 
METHODS- Case and control probands, derived from the Rotterdam Study, 
undenvent the same eye examination as their relatives. FS's were calculated 
by summing the differences bet\veen observed and expected values for each 
relative, corrected for the degree of kinship. The expected values were based 
on age- and gender-specific prevalences of POAG in the Rotterdam popula-
tion. The risk of POAG for FS was calculated by comparing FS's in case and 
control probands using logistic regression analysis, with adjustments for 
lOP. 
RESULTS- Of 37 case probands 42 siblings, 2 half-siblings, and 86 children 
were available for analyses, and of 83 control probands there were 95 sib-
lings, 2 half-siblings, and 155 children. FS's ranged from -0.44 to 7.08 in case 
families and from -0.98 to 2.46 in control families. An increase of one unit 
FS was significantly associated with a higher risk of POAG (odds ratio 1.59, 
95% confidence interval 1.14, 2.23, adjusted for age and gender). Adjust-
ments for lOP did not significantly change the odds ratio. 
CONCLUSIO"S- These data show that the FS strongly predicts POAG, 
independent of the lOP. Therefore, the FS is useful to identify individuals 
with a high genetic risk. 
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Introduction 
Primary open-angle glaucoma (POAG) could be described as a degenerative 
process of the ganglion cells in the retina. This neurodegeneration is clinically 
characterised by a glaucomatous optic neuropathy (GO:::-.J) with a glaucomatous 
visual field defect (GVFD) and open chamber angles. The prevalence of POAG 
varies around 1 °/o in individuals 55 years and older in the western world,1-4 and a 
positive family history as well as an elevated intraocular pressure (IOP) have 
consistently been shown to be major risk factors. 5-7 It is generally recognised that 
genetic factors play an important role. Linkage with several genomic regions has 
been found in different selected families, where the disease segregates as an 
autosomal dominant trait.S- 13 Recently, the myocilin gene has been identified, 
accounting for 3-5% of adult onset POAG. 14 Apart from this small subset of 
families, the majority of POAG families do not follow a clear-cut Mendelian 
inheritance pattern. Instead, POAG is considered to be a heterogeneous, multifac-
torial disease, in which probably multiple genetic and non-genetic factors are 
involved.15-l8 To quantify the effects of these factors and interaction bet\veen them 
on the aetiology of POAG, family studies are carried out. 
A familial aggregation study has recently been performed in siblings, half-sib-
lings and children of POAG cases and controls, drawn from the population-based 
Rotterdam study10 The lifetime risk of POAG in relatives of cases was 9.2 
compared to relatives of controls. 
Here we use a new approach, which integrates all information from a family to 
calculate a family score (FS). Houwing-Duistermaat et al.2° derived that an FS 
defined as the sum of the weighted difference between the observed and expected 
value of each relative for a certain disease performs well under various genetic 
mechanisms. The expected value for each relative is based on the age- and gender-
adjusted prevalence in the population where the families are drawn from. The 
\-Veights are proportional to the degree of kinship between the relative and the 
proband. This method summarizes the information about all relatives including 
their disease status, age, gender and degree of kinship. 
The first aim of this study was to apply this novel method to our family data of 
POAG in the Rotterdam Study and to check whether an association exists between 
the family-derived FS and POAG in the pro bands. The second aim of the study 
was to address the issue of clinical heterogeneity in POAG. \Xle examined whether 
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there \.Vas evidence for a difference in contribution of genetic factors to the occur-
rence of POAG with and without an increased lOP. 
Materials and methods 
Study population 
Design and methods of the familial aggregation study have been described before. 19 
Case and control individuals, here to be called case and control probands to discern 
them from their relatives, were recruited from the baseline phase of the Rotterdam 
Study. This is a population-based cohort study that aims to assess the occurrence of 
and the risk factors for chronic diseases in subjects aged 55 years and older.4•21 The 
study was performed according to the Declaration of Helsinki and was approved by 
the 1fedical Ethics Committee of the Erasmus University. Informed consent was 
obtained from all participants. 
In the present analysis, the group of case pro bands differed from the group in 
the original aggregation study, because we recently changed our definitions of 
POAG.4 Of the 48 case pro bands from the original familial aggregation study,19 37 
probands fulfilled the ne"\v POAG criteria. Together with 13 new case probands, a 
total of 50 case pro bands had definite POi\ G. Three of them were deceased at the 
time of the family study, resulting in 47 eligible case pro bands for the present study. 
Of the 135 (87%) control probands who consented to participate in the original 
familial aggregation study, 23 were excluded, because after resetting the definition 
of POAG, they met the criteria for possible or probable POAG. Thus, 112 control 
pro bands were eligible for the present study. Although pseudoexfoliative glaucoma 
was not specifically excluded in the baseline phase of the study, we refer to the 
disease status as POAG, because at follow up no cases with pseudoexfoliative 
glaucoma were found. 
Measurements and diagnosis of POAG 
Relatives of case and control probands underwent a standardised eye examina-
tion.4·7 In short, the ophthalmological examination included measurement of lOP, 
direct and indirect ophthalmoscopy, stereo fundus photography, and simultaneous 
stereo disc photography. Optic disc characteristics were measured with a digital 
1mage analyzer (Imagenet system, Topcon Optical Co, Tokyo, Japan) and 
85 
Chapter4 
ophthalmoscopy.22 Visual fields were tested with the Humphrey perimeter 
(Humphrey Visual Field Analyzer II, model 750, Dublin, California). 
POAG cases were classified in three categories according to our new definirion:4 
definite, probable, or possible POAG. Definite POAG cases had a probable or 
possible GON in combination with a GVFD. Probable POAG was defined as 
either a probable GON without a GVFD, or a GVFD without GON. Possible 
POAG cases had a possible GON without a GVFD. Only definite POAG cases 
were included as case probands. Control probands were included when they had 
neither GON nor GVFD, nor age-related maculopathy. The lOP was defined as 
elevated if it "\Vas > 21 mm Hg during our examination or if treatment to lower the 
lOP had been used. To investigate whether hypertension or diabetes mellitus could 
account for the familial risk, either directly, or through their relation with lOP, 
these disorders were included in the analyses. Hypertension was defined as either a 
systolic blood pressure?:: 160 mm Hg, or a diastolic blood pressure?:: 95 mm Hg, or 
the use of antihypertensive treatment. Diabetes mellitus was considered present if 
the non-fasting serum glucose was ?:: 11.1 mmol/1 or if antidiabetic medication was 
used. 
Statistical analysis 
Baseline characteristics of case and control probands \\rere compared using 
Students' t-test. For each family an FS was computed, based on the disease status, 
number, age, and gender of all relatives available for analyses. As a few half-siblings 
were included, a correction was made for the degree of kinship. The FS was calcu-
lated according to the formula described by Houwing-Duistermaat20 
where the sum (2.) is taken over the values of all relatives j of a proband, lJ.j· is the 
kinship coefficient between each relative; and the proband (0.25 for siblings and 
children of the proband, and 0.125 for half-siblings), 01 is the observed disease 
status (1 affected, 0 otherwise) and E1 is the expected value for each relative j. 
Expected values were based on age- and gender-specific prevalences of POAG in 
the Rotterdam Study, based on Imagenet data combined with ophthalmoscopic 
data (Table 1);4 for relatives younger than 55 years a prevalence of 0% \Vas 
assumed. For the purpose of presentation, we multiplied the sum of all individual 
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scores by ten. As an example, for a family that consists of relatives a) b and c, the 
formula can be written as: 
FS = 10 ~,(0,- E) + IJl;,(Or,- E 1) + <Jf,. (0,- EJ) 
Logistic regression analysis was perfonned to estimate the risk of POAG in 
probands given the FS. First, analyses were performed after calculating FS's 
assigning both relatives with definite POAG and relatives with probable POAG as 
affected (FSdp): definitely and probably affected relatives were included as observed 
cases; expected values were derived from prevalences of definite and probable 
POAG (Table 1). 
Next, the analyses were repeated after calculation of the FS's assigning only 
definitely affected relatives as observed cases and excluding relatives with probable 
POAG (FSd). Expected values were derived from prevalences of definite POAG. 
Relatives with possible POAG and without POAG were assigned as unaffected. 
Table 1 
Prevalences of primary open-angle glaucoma in independently living 
subjects of a population-based cohort (n = 6281), aged 55 years and over. 
Imagenet data combined with ophthalmoscopic data, the Rotterdam 
Study (1990-1993)4 
Age (years) Detl.nite* 
Alen 
55-59 0.002 0.017 0.019 
60-64 0.006 0.018 0.024 
65-69 0.008 0.020 0.028 
70-74 0.013 0.027 0.040 
75-79 0.019 0.041 0.060 
80+ 0.036 0.054 0.090 
TV omen 
55-59 0 O.G15 O.G15 
60-64 0.001 0.017 O.Q18 
65-69 0.009 0.026 0.035 
70-74 0.011 O.G18 0.029 
75-79 0.006 0.042 0.048 
80+ 0.013 0.038 0.051 
* Prevalences used in calculation of the family score, with only de:Hnitely affected relatives 
t Prevalences used in calculation of the family score, with both definitely and probably 
affected relatives 
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Analyses were adjusted for age, gender, diabetes mellitus and hypertension status 
of the proband. To examine whether an elevated lOP had effect on the relation 
between FS and POAG, additional adjustments were made for lOP and lOP-
lowering treatment. \Vre tested whether the relation between FS and POAG "\Vas 
different for POAG with and without an lOP > 21 mm Hg, by adding an interac-
tion term between FS and lOP (1 elevated, 0 normal). 
Results 
Response rates and baseline characteristics 
Of the 47 eligible case pro bands, 43 (91 %) consented to participate, and of six no 
relatives \.vere available for analyses. Among the relatives of case probands, 48 
(80%) (half) siblings and 87 (95%) children responded, of whom 42 siblings, 2 half-
siblings, and 86 children had complete data to diagnose or exclude POAG. Of 112 
control pro bands, 101 (90%) participated, and 110 (81 %) (half) siblings and 158 
(81 %) children responded. Complete data on POAG status were available for 95 
siblings, 2 half-siblings, and 155 children. For 18 control probands, no relatives 
were available for analyses. This resulted in 37 case and 83 control probands \.Vith 
families available for analyses (Table 2A). 
Their maximum lOP before or during treatment often "\vas not known. In three 
of the remaining 18 cases an lOP > 21 mm Hg was measured during our examina-
tion. Of control probands five (6%) had lOP-lowering treatment and in seven of 
the remaining controls, we measured an lOP> 21 mm Hg. 
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Characteristics of case pro bands with definite primary open-angle 
glaucoma and control pro bands 
Characteristic 
:0Jean age ± SD* 
%\\?omen 
!Yiean intraocular pressure, mm Hg 
%intraocular pressure-lowering 
treatment 
% EleYated intraocular pressuret 
*SD: standard deviation 
Case probands 
(n = 37) 
73.2 ± 7.3 
37.8 
17.3 ± 3.6 
51.4 
59.5 
Control 
pro bands 
(n = 83) 
75.5 ± 8.3 
55.4 
16.3 ± 3.1 
6.1 
14.5 
t Elevated lOP "\vas defined as an lOP > 21 mm Hg or the use of IOP-lo,vering 
treatment 
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Table ZB 
Characteristics of relatives of case pro bands and of control pro bands 
Characteristic 
Siblings 
1"\'"umber 
Mean age ± SD* 
0/o \X-' omen 
fvlcan intraocular pressure, mm Hg 
0/o Intraocular pressure-lmvering treatment 
Primary open-angle glaucoma:j: 
Definite 
Probable 
Possible 
Child1?n 
Number 
J\fean age ± SDx 
%\\/omen 
t.Jean intraocular pressure, mm Hg 
% intraocular pressure-lowering treatment 
Primary open-angle Glaucoma+ Definite 
*SD: standard deviation 
Probable 
Possible 
Case pro bands Control probands 
(n = 37) (n = 83) 
44t 
73.8 ± 7.2 
57 
17.7±11.2 
11.4 
7 (15.9) 
7 (15.9) 
12 (27.3) 
86 
46.1 ± 8.7 
47 
15.2 ± 3.2 
0.02 
1 (1.2) 
2 (2.3) 
IS (20.9) 
97t 
74.3 ± 9.3 
66 
13.8 ± 3.0 
2.2 
1 (1.0) 
10 (10.3) 
5 (5.2) 
155 
48.5 ± 8.9 
41 
14.0 ± 2.7 
O.Gl 
0 
2 (1.2) 
16 (10.3) 
t Two half-siblings are present among siblings of case pro bands and ruco among siblings of control 
pro bands 
:j: Values in parentheses are percentages 
The number of examined relatives varied from one to nine among case 
probands and from one to 11 among control probands and did not differ signifi-
cantly (p = 0.29) (Table 2B). The number, mean age and proportion of women 
were similar in (half) siblings of cases and controls. These characteristics were also 
similar in their children, except for age: children of cases were on average 2.4 years 
younger than children of controls (46.1 versus 48.5 years). 
Relatives of cases had a higher mean lOP than relatives of controls, especially 
siblings (17.7 versus 13.8 mm Hg). (Half) siblings of cases also had lOP-lowering 
treatment more often than those of controls (11 °/o versus 2°/o). The distribution of 
case and control families with different numbers of affected relatives is shown in 
Table 3. 
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Table 3A 
Number (percentage) of families of case and control probands 
including 0, 1, 2 or 3 relatives with definite or probable open-angle 
laucoma 
:-Jumber of affected relatives 
0 
2 
3 
Values in parentheses are percentages 
Table 3B 
Case families 
(n = 37 
24 (65) 
10 (27) 
2 (5) 
1 (3) 
Control families 
(n = 83) 
70 (84) 
13 (16) 
Number (percentage) of families of case and control pro bands 
including 0, 1, 2 or 3 relatives with definite open-angle glaucoma 
::-Jumber of affected relatives Case families Control families 
0 
2 
3 
Values in parentheses are percentages 
(n = 37) 
30 (81) 
6 (16) 
1 (3) 
n = 83) 
82 (99) 
1 (1) 
Famzly scores 
First, FSdr's were calculated (Figure 1). In families of POAG case probands, the 
FSdp ranged from ~0.44 to 7.08, with a mean FSdp of 0.98. In families of control 
pro bands, FSdp's Yvere lower, ranging from -0.98 to 2.46, with a mean FSJp of 0.24. 
Logistic regression analysis showed that an increase of 1 unit in FSdp was associated 
with a significantly increased risk of POAG in the pro bands (odds ratio (OR) 1.59, 
95% confidence interval (CI): 1.14, 2.23), adjusted for age and gender (Table 4). 
\Xlith the inclusion of IOP as a continuous variable, and IOP~lmvering treatment, 
diabetes mellitus and hypertension of the proband as covariates, the risk of POAG 
\.Vas even more increased per unit of FSJp and still significant (OR 1.76, 95% CI 
1.15, 2.70). After additional inclusion of the interaction term bet\veen FSdp and an 
elevated lOP as covariate, this term was not associated \.Vith POAG (OR 1.10; 95% 
CI 0.41, 2.94), while FSdp alone was still significantly associated with POAG (OR 
1.67, 95% CI 1.05, 2.65). 
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5 6 7 
Distribution of family score (FS) in case (n = 37) and control (n = 83) probands. Affected relatives 
had definite or probable primary open-angle glaucoma. Numbers of FS are midvalues of categories. 
Range of categories: -0.25 + value, Yalue + 0.25. Black bars represent case pro bands, '\Vhite bars 
represent control pro bands. 
The FSd in families of case probands ranged from -0.14 to 4.89, with a mean 
FSd of 0.48, and in families of control pro bands ranged from -0.29 to 2.41, with a 
mean FSJ of -0.01. An increase of 1 unit of FSd was associated \Vith a higher risk of 
POAG in the proband than the former FSdp (OR 3.32, 95% CI 1.25, 8.82). 
Adjusted for all risk factors mentioned above, and after the additional adjustments 
of lOP and lOP-lowering treatment, the OR did not change and was still statisti-
cally significant. Finally the interaction term bet\:veen FSac:t and an elevated lOP was 
not significantly associated with POAG in the proband (p = 0.67), while FSdcf alone 
was still significantly associated with POAG. 
To illustrate the FS method, we describe three families with different FSdp's. The 
family with the highest FSdp (7.08) included eight siblings, of whom three were 
affected. Two sisters, aged 71 and 72, had definite POAG and one sister, aged 73, 
had probable POAG. The age- and gender- adjusted prevalence for each of them 
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Table 4 
Odds ratios of primary open-angle glaucoma in the proband by family score 
Relatives have definite or probable fm!nat) 1 open-anj!,le f!,laucoma 
Odds ratio* (95% CI) 
Family score :j: 1.59 (1.14-2.23) 
Intraocular pressure, mm Hg 
Diabetes mellitus 
Hy ertension 
Relatives have definite open-an:f!,le glaucoma 
Odds ratio* (95% CI) 
Family score § 3.32 (1.25-8.82) 
Intraocular pressure, mm Hg 
Diabetes mellitus 
Hv ertcnsion 
* Adjusted for age and gender of the proband 
Odds ratiot (95% CI) 
1.76 (1.15-2.70) 
1.13 (0.96-1.33) 
4.36 (0.76-24.88) 
1.30 (0.48-3.53) 
Odds ratiot (95% CI) 
3.33 (1.15-9.62) 
1.15 (0.98-1.36) 
3.18 (0.58-17.40) 
1.77 (0.64-4.85) 
t Adjusted for age, gender, presence of diabetes mellitus, hypertension, intraocular pressure and 
intraocular pressure-lo\vering treatment in the proband 
+Based on probable and definite open-angle glaucoma in relatives 
§. Based on only definite open-angle glaucoma in relatives 
was 0.029 (Table 1). Subtracting the expected (0.029) from the observed value (= 1) 
and weighting with 'lj (= 0.25) resulted in an individual score of (1 - 0.029) x 0.25 
= 0.24275 each. Three unaffected sisters aged 63, 65 and 74 had expected values of 
0.018, 0.035, and 0.029 respectively, resulting in individual scores of -0.0045, -
0.00875, and -0.00725 after weighting. Two unaffected sons, aged 44 and 41, had 
an expected value of 0, resulting in an individual score of 0. The sum of these indi~ 
vidual scores of all relatives was an FSdp of (0.24275 + 0.24275 + 0.24275- 0.0045 
-0.00875-0.00725 + 0 + 0 =) 0.708. Multiplying by 10 resulted in an FSdp of7.08. 
In a second family, no POAG was obsen.red among all eight siblings, aged 
between 67 and 80, and two children, aged 48 and 57. Subtracting the expected 
values from these obsetv'ed values of 0 resulted in negative individual scores. After 
weighting with lJlj, these individual scores \Vere added up to an FSdr of -0.098 and 
multiplied by ten to -0.98. 
92 
ramdy Score and POAG 
A third family included seven unaffected children. Since they were relati,·ely 
young (aged 35 to 52), expected values \vere 0, resulting in individual scores of 0, 
and, subsequently, an FSdp of 0. This example demonstrates that a family with FSdp 
::;;:;: 0 does not contain much information about the genetic risk of that family. 
Discussion 
In this studv, we applied a new statistical method to estimate the risk of POAG for 
a individual, given the disease distribution in relatives. The presence of POAG in 
siblings and children was quantified by an FS, which took the disease status, 
number, age, gender, and kinship coefficient of the relatives into account. The FS, 
which can be interpreted as the generic risk for that particular individual, was 
heterogeneous among case probands. \X/e found that an increase in FS was signifi-
cantlv associated with an increased risk of POAG. This association "\vas 
independent of the presence of an elevated lOP. 
FS's are distributed around zero. A positive FS indicates that in a family, more 
cases are observed than expected and therefore points to genetic risk in that family, 
and vice versa. The magnitude of the FS depends on the size and age distribution in 
the family. Small and/ or young families do not contain much information about the 
genetic risk of the proband. This is reflected in the model by the fact that small 
families produce an FS zero or close to zero. As long as candidate genes are not 
identified, the risk estimation of POi\G for the individuals with these FS's should 
not be based on the occurrence of POAG in the family, but on other risk factors. 
Since the sizes and age distributions of the case families \Vere similar to those of the 
control families confounding by family size was unlikely. 
A strength of the study is the fact that all case and control pro bands and their 
relatives underwent a standardised ophthalmological examination. Features of 
POAG \vere assessed separately in a masked fashion to ensure an unbiased 
diagnosis. Examining relatives instead of taking a family history from the probands 
reduces misclassification of disease status due to the insidious course of the disease, 
lack of knowledge of the disease status in proband or relative, and different and 
changing definitions of POAG.7 By recruiting pro bands from the population-based 
Rotterdam study, ascertainment bias due to family size and selection bias towards a 
specific type of POAG was reduced. 
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Our findings indicate that the contribution of genetic factors to the occurrence 
of POAG is independent of lOP. Both low and high FS's were observed in case 
pro bands with and without an elevated lOP (data not shown). Adjustment for lOP 
did not change the effect of FS on the risk of POAG; the OR of POAG remained 
significantly increased. Finally, the interaction term between FS and lOP was not 
significant, and did not change the effect of FS. Thus, FS had an effect on POAG 
with and without an elevated lOP, and the effect of FS on POAG was not statisti-
cally different within these nvo subgroups. Our findings match the observation in 
literature where the occurrence within families of POAG cases with high 
IOP,I0,11,13J4 low IOP,l2,23 and both9,24 are reported. Hm,vever, the design of many 
studies complicates distinguishing between the genetic influence leading directly to 
POAG and that leading to POAG through lOP. Genetic factors are involved in 
TOP, 25-27 \.vhile lOP is considered an important risk factor for POAG. In our study, 
we were able to investigate the effect of lOP apart from POAG because the level 
of lOP was not included in the definition of POAG and because an eleYated lOP 
was defined independently from the POAG diagnosis. 
It is generally accepted that POAG is a multifactorial disease,15·1S caused by 
actions of many genes and effects from the environment. Ho\vever, it is difficult to 
discriminate \Vhether familial occurrence of a multifactorial disease is the result of 
shared genetic or environmental factors. 28 It seems unlikely that shared environ-
mental factors early in life contribute to the occurrence of POAG at middle age. 
Indeed, no environmental factor has consistently been associated \Vith the risk of 
POAG, neither in clinic-based case-control studies,1 8 nor in population-based 
studies.29-3J Also, a recent t\vin study sho\ved concordance of POAG in t\vins but 
not in spouses, suggesting the involvement of genetic rather than environmental 
factors_27 To identify possible environmental risk factors, further research in cohort 
studies is necessary. To separate the effects of genetic and environmental factors, 
and the interactions beru.reen these, genetic epidemiological studies in POAG 
families should be carried out, preferably encompassing more generations.32 In such 
studies, the FS can be used to represent the familial risk of an individual. Further-
more, the FS is valuable to select individuals for clinical follo\V up and for further 
genetic analysis. Research into genotype-phenotype relations in families will remain 
necessary, also after identification of a disease-causing genetic defect, to study 
possible modifier genes or environmental factors influencing its expression. 
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5 
GENETICALLY ISOLATED 
POPULATION 

5.1 
Exclusion of candidate gene loci for 
adult onset primary open-angle glaucoma using a 
combined linkage-linkage disequilibrium analysis 
Abstract 
Primary open-angle glaucoma (POAG) is a genetically heterogeneous eye 
disorder. In order to localize ne"\v genes implicated in POAG, we clinically 
investigated a sample of patients in a genetically isolated population. 
Furthermore, we studied "\vhether sharing of any of the known glaucoma 
candidate chromosomal regions was present among the patients identified. 
For the current exclusion analysis, only definite POAG patients \Vete 
included, defined as a glaucomatous optic neuropathy together with a 
glaucomatous visual field defect. In total, t\venty-seven markers were used to 
screen the myocilin (.MYOC) gene, five candidate POAG loci (GLC1B to F) 
and five other, potentially involved, genomic regions. A combined likelihood 
ratio test for linkage and linkage disequilibrium was carried OUt, \Vith e 
representing the recombination fraction, and A the proportion of disease 
chromosomes \vith the associated allele. 
A sample of 11 definitely and 15 probably affected individuals were identi-
fied. Only the definite POAG patients were included for the current exclu-
sion analysis. Negative lodscores \Vere obtained for all markers; maximizing 
A resulted in null values. 
It can be concluded that neither the fvlYOC gene nor other known candidate 
regions are implicated in POAG in our sample of patients. Based on the 
population structure and the previous genetic studies in this isolate, we 
expect this sample to be suitable for a subsequent whole genome scan to 
identify yet unknown genes for POAG. 
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Introduction 
Primary open-angle glaucoma (POAG) is clinically characterized by an atrophic 
excavation of the optic nen.re, referred to as glaucomatous optic neuropathy 
(GO~), a typical glaucomatous visual field loss (GVFL), and an open anterior 
chamber angle. Its prevalence is 1 r;~o in subjects 55 years and over in the \\lestern 
world. 1 It is generally recognized that genetic factors are an important component 
in the etiology of PO A. G. 
lvfany POAG families do not reveal a clear-cut !viendelian inheritance pattern. 
Linkage analysis in families implicated the involvement of several chromosomal 
regions: 1q21-q31,2 2cen-ql3,3 3q21-q24,4 8q23,5 10p15-p14,G 7q35,' and possibly 
2p12, 14pll, 17p13, 17q24 and 19q138 The only !mown causative gene is the 
Myocilin (MYOC) gene (GLC1A.) on chromosome lq9 
The problems that arise when investigating the etiology of POAG include the 
late age of onset, the lack of internationally accepted diagnostic criteria, genetic 
heterogeneity and possible presence of phenocopies. To address these problems, 
we identified a sample of POAG patients from a genetically isolated population, 
and investigated whether sharing of any of the known glaucoma candidate chromo-
somal regions was present among the definite POAG patients. 
Materials and Methods 
Patients 
The current study "\vas carried out within the same community in "\vhich the gene 
for retinitis pigrnentosa type 12,10 and the gene for pseudoxanthoma elasticum11 
were identified. The existence of this community has been reported for the first 
time in 1462. The number of inhabitants increased steadily from five in that year to 
1,000 in 1830. From that moment on, a rapid growth took place to 20,029 inhabi-
tants in the year 2000. During these centuries, the community was isolated for 
cultural/ religious reasons. 
The study was approved by the medical ethical committee of the Academic 
.;\fedical Center in Amsterdam. lill participants gave written informed consent. 
Individuals were ascertained through registers of ophthalmologists and general 
practitioners. Ophthalmologic examination included IOP measurement, goruo-
scopy, ophthalmoscopy, and optic disc photography (35° field, RC-2 fundus 
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camera, Ko\va Corporation, Japan). Visual field tests were retrieved from medical 
records; if patients with normal fields had not been tested within the last year, a 
Humphrey 24-2 test was performed (Zeiss Instruments, Oherkocken, Germany). 
Both definite and probable POAG patients were identified1 Only definite 
patients ·were included in the current analyses. Our criteria for GON \vere slightly 
adapted for the use of optic disc morphometry. Subjects with visual field loss plus a 
normal optic disc were excluded. Spouses (n = 6) of the patients and individuals (n 
= 12) from the same population were included as controls. 
DNA analysis 
DN.A analysis was carried out as described before. 12 IvfYOC was screened for muta-
tions in the promoter region 13 and all three exons including the flanking splice sites. 
Primers \vere used as described before,14 except for the first (F: ccaagcctctgcaat-
gaggt) and second exon (F: ctggccggcagcctatttaa). 
S tatirtical Analysis 
A combined test for linkage and linkage disequilibrium was carried out. 15 This test, 
a modification of the procedure described by Tenvilliger,16 examines the likelihood 
that a marker allele is over-represented on disease chromosomes compared with 
control chromosomes. Genot~ypes of control individuals and spouses or, in their 
absence, children were used for estimation of the control population-frequencies of 
marker alleles as nuisance parameters in the likelihood calculationsY 
The logarithm of the likelihood ratio Qod score) was calculated using a modified 
version of ILINK: 15 LOGw(L, .. e/Lo), where 8 represents the recombination 
fraction, and ),_ the proportion of disease chromosomes with the associated allele. 15 
An autosomal dominant mode of transmission of the disease was modelled with 
50°/o penetrance and a gene frequency of 0.01. Definite POAG patients were desig-
nated affected; the disease status of all other individuals was set to unknown. 
Likelihood's were maximized for A, and also calculated for fixed values of A (0.8 
and 0.9), all for e fixed at 0 (association and linkage present), and compared with 
the likelihood ohrained for A = 0 and 8 = o.s (no association or linkage). 
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Definite (solid ~ymboh, n = 11) and probable primary open-angle glaucoma patients (hatched, n = 15) were related. Open symbols: disease status unknown. 
All individuals in the generations prior to the ones with primary open-angle glaucoma paLicnts wc.:rc deceased before the investigation started. Their DNA was 
not available. Only definite patients were included in the current exclusion analysis. 
Exclusion cfPOAG candidate loci in a genetic isolate 
Results 
We identified 11 definite and 15 probable POAG patients. Mean age at diagnosis in 
the definite patients was 68.5 years, ranging from 49 to 82 years. The maximum 
lOP ranged from 21 to 40 m1n Hg . .All definite patients received lOP-lowering 
medication and t\vo had also undergone laser or surgical treatment. 
After construction of the pedigree (Fig. 1), we computed what proportion of 
patients would be expected to share a marker allele in the immediate vicinity of a 
shared disease gene. Assuming an average distance of 12 generations between the 
patients and their presumed ancestor and a distance bet\veen marker locus and 
disease gene of at most 2.3 eM (the largest distance bet\veen locus boundary and 
closest flanking marker), )_ should exceed 0.8 with a probability of 75%, and it 
should be greater than 0.5 witb a probability of 99.8%. lvlarker analysis with at least 
three markers revealed negative lodscores for), fixed at 0.8 or 0.9 for all candidate 
POAG regions (Table 1). The maximized value of A was 0 for all markers except 
D8S85, which yielded a A of 0.39 with a lod score of 0.19. Five definite POAG 
patients were screened for mutations in MYOC. No non-synonymous nucleotide 
changes were found compared with the wild type sequence. 
Discussion 
Research into the genetics of POAG has been hampered by the acceptance of an 
unambiguous clinical definition of POAG. Recently, we proposed a strict defini-
tion1 at the Worldwide Glaucoma Meeting (Hopkins, Baltimore May 2000) which 
v.ras also used in the current study. Unlike most genetic glaucoma studies, but in 
agreement with many epidemiological studies,19-21 our system considers an elevated 
lOP an important risk factor, but not a criterion for POAG. Our system also 
differs from the "pedigree probability" score developed by the Glaucoma Inheri-
tance Study of Tasmania,22 by using objective clinical criteria instead of genetic or 
clinical information on relatives. 
Given the pedigree structure and the young history of our population, it is plau-
sible that many patients will share a POAG risk-allele from a single common 
ancestor, surrounded by a shared DNA segment.10 Consequently, a test combining 
association and linkage can be carried out, which has been successfully used before 
in genetically isolated populations to exclude loci or map genes of complex 
disorders. 15,1 7 
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Table 1 
Lodscores of markers tested in each candidate region for 
primary open-angle glaucoma 
Locus Lodrcore Lodscore 
AL4RKLRI" (.1 = 0.8) (.1 = 0.9) 
GLC1A D1S2844 -1.64 -2.87 
D1S445 -0.86 
-1.39 
D1S212 -1.07 -2.53 
D1S191 -1.12 -1.75 
GLCJB D2S139 -1.66 -2.33 
D2S2161 -0.70 -1.17 
D2S2175 -1.88 -2.94 
D2S1897 -2.38 -4.36 
GLC1C D3S3637 -3.77 -5.18 
D3S1569 -2.84 -3.20 
D3S1555 -0.39 -1.13 
D3S1279 -1.74 -2.95 
GLCJD D8S167 -4.16 -5.42 
D8S85 -1.20 -2.20 
D8S19S -1.88 -3.15 
GLC1E D10S1745 -2.40 -3.89 
D10S1779 -2.85 -4.44 
D10S1216 -2.61 -3.41 
D10S191 -2.69 -3.53 
GLC1F D7S688 -3.84 -4.98 
D7S2439 -2.80 -3.10 
D7S2S46 -3.76 -4.87 
:VIarkersa D2S441 -1.06 -1.81 
D14S742 -1.11 -1.79 
D17S926 -3.16 -5.34 
D17S801 -4.03 -5.70 
D19S408 -1.20 -4.13 
~ _0..hrkers used in the recently published primary open-angle glaucoma 
genome scan.cl 
For every candidate region (GLC1J\ to GLC1F), at least one marker 
within the locus ·was tested and at least one marker flanking the locus. 
Negative lodscores \.vere achieved for each candidate locus, under both 
the assumption for), (the proportion of disease chromosomes '\Vith the 
associated allele) = 0.8 and A = 0.9. The data sug_£Sest that these loci are 
not involved in the development of primary open-angle glaucoma in our 
sample. 
Exclusion if POAG candidate loci in a genetic isolate 
The structure of our population enabled us to collect a large number of 
individual patients, who were distantly related. \Xle chose control persons from the 
same population to determine the normal allele distribution within the population. 
Obviously, the latter may be quite different from outbred populations. 
Due to our strict clinical criteria the number of definite patients was small, which 
reduces power and explains the absence of significance in exclusion of some 
markers. However, simulation calculations indicate that our analyses should 
virtually ahvays (99.8°/o) yield positive evidence with A > 0.5 around a true 
glaucoma risk gene. The fact that none of the analyzed regions gave a A > 0.4 
strongly argues against involvement of any of these loci. In calculations \Vith fixed 
),, values of A were chosen to be 0.8 and 0.9 to allow for 10 to 20% of pheno-
copies. Based on the structure of this isolate and the previous genetic studies in this 
population,HU 1 we expect this sample to be suitable for a subsequent whole genome 
scan to identify yet unknown genes for POAG. 
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Genome wide search for primary open-angle glaucoma 
in a genetically isolated population indicates potential 
susceptibility loci on chromosomes 2p14 and 12q24 
Abstract 
Primary open-angle glaucoma (PO A G) is a complex eye disease. To identify 
POAG susceptibility genes, we performed a complete genome scan of a 
sample of POAG patients from a genetically isolated population in the 
Netherlands. 
The clinical definition of definite POAG \.vas based on a glaucomatous optic 
neuropathy and a glaucomatous visual field defect. Eleven definitely and 15 
probably affected POAG patients were identified, as well as 23 individuals 
with ocular hypertension. The POAG patients were tested with 347 markers 
distributed over the total genome. A likelihood ratio statistic was carried out 
\Vith a combined test for linkage and linkage disequilibrium both in the 
definite patients only and in the total sample of patients. \X7e found lodscores 
> 1.5 with marker D2S123 on chromosome 2p14 and with marker D12S97 
on chromosome 12q24. Additional markers in the regions around D2S123 
and D12S97 were tested and haplotype sharing of adjacent markers in 
affected individuals was observed. These findings potentially suggest the 
presence of at least two novel POAG loci on chromosome 2p14 and on 
chromosome 12q24. 
Introduction 
Primary open~angle glaucoma (POAG) is an etiologically diverse eye disease. 
POAG is clinically characterized by a glaucomatous optic neuropathy (GON) and a 
glaucomatous visual field defect (GVFD), together with open and normal anterior 
chamber angles. In the \\restern \Vorld, the prevalence of POAG increases with age 
from 0.1% in persons aged 55 to 2°/o in those over age 80. 1-4. In addition to age, 
major risk factors include an elevated intraocular pressure (lOP) and a positive 
family history.s-s 
107 
Chapter 5.2 
It is generally accepted that genetic factors are involved in POAG. During the 
last decades, several POAG families have been described and different inheritance 
patterns for the disease have been postulated. The first and, so far, only gene found 
for POAG is myocilin (MYOC, MI;\1 601652; GLClA) on chromosome lq. This 
gene was originally identified in a family with autosomal dominant juvenile onset 
POAG,9 but mutations also appeared to be present in a small subset (3-5%) of 
patients with adult onset PO AGIO 
Five additional chromosomal regions have been identified using linkage analysis 
in unrelated POAG families: 2cen-q13 (GLC1B),1 1 3q21-q24 (GLC!C),l2 8q23 
(GLC1D),13 10p15-p14 (GLC!E), 14 and 7q35 (GLC!F). 15 Of these loci, GLC1A, 
B,16 and C17 were confirmed with data from independent POAG family studies. So 
far, the loci GLC1D, E, and F have not been confirmed. A genome-wide scan in a 
larger sample of unrelated POAG families and sib pairs showed five additional 
genomic regions on chromosomes 2p, 14p, 17p, 17q, and 19q to be potentially 
involved in POAG.JS 
The regions thus far identified in linkage studies were found in a subset of 
POAG families where the disease segregates as an autosomal dominant trait. 
However, in the majority of POAG families, the disease does not follow a clear-cut 
lviendelian inheritance pattern. Instead, POAG is considered to be a complex 
disease,t9-22 with many genetic and non-genetic factors involved.23 \'\lhen searching 
for genes in a complex disease such as POAG, problems are encountered such as 
its genetic heterogeneous character, possible presence of phenocopies, unknown 
mode of transmission and late age of onset of the disease. 
Because of these difficulties, we chose a different study design to aid the search 
of additional genes for POAG.24 Evaluation of linkage disequilibrium (LD) in 
genetically isolated populations has proved to be useful to map genes for 
monogenic diseases.25-28 In the current study, we attempt to identify susceptibility 
loci for POAG in a genetically isolated population, because it is expected that these 
populations are genetically more homogeneous, and that they have larger regions of 
LD than mixed populations. 
ivforeover, the genetic isolate enabled us to ascertain individual patients, 
independent of the disease status of their relatives. Consequently, we could collect a 
relatively large number of patients who were distantly related.29 \Xle examined 11 
definite and 15 probable POAG patients from a recently genetically isolated popu-
lation. In a former study (Hulsman et al, manuscript in press), we examined the 
108 
Genomic scan rifPOAG in a genetic isolate 
known candidate POAG gene loci GLC1A to F, and the five regions identified in a 
genome scan performed by \\liggs. 18 All loci were excluded in the definite patients 
with a combined test for linkage and association.30,31 
In the current paper, we present the results of a whole genome scan in a group 
of POAG patients from a genetically isolated population. Furthermore, we evaluate 
t\vo promising regions for haplotype sharing among patients, and propose potential 
candidate susceptibility genes for POAG within these regions. 
Materials and methods 
Study population 
The current study \Vas carried out in the same community in which the gene for 
retinitis pigmentosa type 12,25 and the gene for pseudoxanthoma elasticum28 were 
identified. The existence of this community has been reported since 1462. The 
number of inhabitants increased steadily from 25 in that year to 1,000 in 1830. 
From that moment on, a rapid growth took place to 20,029 inhabitants in the year 
2000. During these centuries, the community was isolated for cultural and religious 
reasons and immigration has been estimated to be only a few percent. The study 
was approved by the medical ethical committee of the Academic ~Iedical Center in 
Amsterdam and written informed consent was obtained from all participants. 
Patient recruitment and clinical measurements 
Individuals were ascertained through registers of ophthalmologists and general 
practitioners. Data on family and medical history were obtained from a question-
naire. The eye examination included applanation tonometry, gonioscopy, ophthal-
moscopy, and fundus photography of the optic disc and 35° macular field (RC-2 
fundus camera, Kowa Corporation LTD, Tokyo, Japan). Papillometry was used to 
measure the vertical cup-to-disc ratio and the width of the neuroretinal rim.32 \Xlhen 
available, visual field tests were retrieved from medical records of the ophthalmolo-
gists, who used a Humphrey or Octopus perimeter. If visual field tests had not 
been performed within the last year, patients were tested with the 24-2 program of 
the Humphrey Field Analyser (Humphrey Instruments, San Leandro, California). 
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For the definition of POAG, we used the criteria from the Rotterdam Study as 
described by Wolfs,4 adapted for the use of papillometry instead of Imagenet. In 
short, definite POAG was defined as a GVFD together with a possible (vertical 
cup-to-disc ratio:?: 0.7, asymmetry in vertical cup-to-disc ratio 2: 0.2, or neuroretinal 
rim< 0.1) or probable (0.8, 0.3, and 0.05, respectively) GON. Probable POAG was 
defined as a probable GON with a normal visual field. l.:nlike Wolfs' definition, we 
did not define a GVFD with a normal optic disc as probable POAG, because 
neurological causes of visual field defects could not be excluded as extensively as in 
the Rotterdam Study. Instead, we excluded those individuals from all analyses. Age 
at diagnosis was defined as the age of detection of a GVFD in the definite patients, 
and as the age of detection of a GON in probable patients. Ocular hypertension 
\Vas defined as a maximum lOP measured in a patient's history> 21 mm Hg or the 
use of lOP-lowering treatment, without any signs of a GON or a GVFD. 
Definite and probable POAG patients were included in the analyses of the 
present study. \Xle have chosen two phenotypes for genetic analyses; first, a broad 
category including definite and probable POAG patients, and second, a narrow 
category, only including definite POAG patients. Individuals from the same popu-
lation, who showed no signs of POAG, were included as population-matched 
controls. Likewise, spouses of the patients were included as controls. Spouses were 
asked for history of eye disease, in particular for the presence of POAG or elevated 
lOP, but they were not ophthalmologically examined. Blood samples were taken 
from all patients, their spouses and, if available, at least three children to construct 
phase~known haplotypes. 
DJ\TA analysis 
DNA was extracted from \Vhite blood cells following standard protocols. 
Genotyping was performed with an ABI rype 3 77 sequencer. A total of 34 7 
markers were tested covering the autosomal genome, with an average spacing of 10 
dvi and an average heterozygosity of 78°/o. The set of markers was obtained from 
http:/ /www.msz.mdc~berlin.de/markers.html. 
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Statistical analysis 
A combined test for linkage and LD was carried out.3°.31 In a genetically isolated 
population, a high proportion of patients are likely to share a chromosomal 
segment containing the disease gene, \vhich they inherited from a common 
ancestor.27,29,33,34 Therefore, if in a sample of patients, marker allele frequencies 
differ significantly from control individuals, the disease locus is most Jjkely located 
in the chromosomal region flanking that marker. This region is in LD with the 
marker allele. \\le used a modification of the procedure described by Terwilliger35 to 
examine the likelihood that a marker allele is over-represented on disease chromo-
somes compared with control chromosomes.3U,3J Genotypes of control individuals 
and spouses, or, in their absence, children were used for estimation of the control 
population-frequencies of marker alleles as nuisance parameters in the likelihood 
calculations. 
The logarithm of the likelihood ratio (lod score) was calculated using a modified 
version of ILINK"•: LOGw(L)_,e/Le), where 8 represents the recombination 
fraction, and f~ the proportion of disease chromosomes \Vith the associated allele. 
Since a priori it is not known which allele will be overrepresented, each allele is 
considered the potential founder allele. A total likelihood is obtained by summing 
the likelihoods for each potential founder allele, weighted for their population 
frequency. The gene frequency \Vas set at 0.01. An autosomal dominant inheritance 
WaS assumed, \Vith 50°/o penetrance. 
For each marker, likelihoods were first calculated under the hypothesis of no 
linkage (8 = 0.5) and no LD (A = OJ. Then, analyses were repeated with additional 
estimation of A, starting from 0.3, 0.6, and 0.9, all for 8 = 0. The analyses were 
performed under both the narrow and the broad phenotype. 
In our study, multiple markers \vith multiple alleles were tested, as beforehand, 
it was not known which allele of which marker \vould be in LD with the disease. 
This increases the chance of false-positive findings,24 requiring a higher level of 
significance for e\Tidence of linkage and association. Ho\vever, there is discussion 
about the exact threshold in whole genome scans to accept as conclusive evidence. 
Since our findings are used to give an initial indication for localization of the 
disease gene, we considered lod scores > 1 interesting for further exploration. 
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Fine mapping and haplotype analysis of t1JJo regions 
Two regions around the markers with the highest lod scores under both the narrow 
and the broader phenotype were further examined by testing extra markers in those 
regions. Around D2S123 on chromosome 2p14, the markers D2S119, D2S2298, 
D2S2378, D2S2156, D2S2251, and D2S378 were additionally genotyped. Further-
more, we developed a novel marker, which we denote as D2Sm1, 70 kb down-
stream from D2S123. 
Around marker D12S97 on chromosome 12q24, markers D12S1609, D12S367, 
and D12S343 were genotyped. PCR reactions \vere carried out as described 
before. 37 The additional markers were analysed with the same combined linkage 
and association method as described above.30) 1 The haplotypes of offspring were 
used to determine the phase of adjacent marker alleles in patients and spouses, who 
were included as controls, and, in the absence of a spouse, to reconstruct phase-
known haplotypes. 
Selection of candidate genes 
To evaluate the presence of candidate disease genes in the chromosomal region in 
linkage disequilibrium with the disease-associated allele, we used the databases of 
Map view (http:/ /www.ncbi.nlm.nih.gov:SO/cgi-bin/Entrez)) and UDB (http:// 
bioinformatics.weizmann.ac.il/udb). Of the positional candidate genes, the 
function, expression, and possible involYement in POAG were evaluated using the 
OMLVI (http:/ /W\\>-w3.ncbi.nlm.nih.gov /htbin-post/Omim) and Gene card data-
bases (http:/ /thr.cit.nih.gov:8081 /cards/index. html). 
Results 
Patients 
In total, 63 patients \vere ascertained. Of these, seven \Vere excluded because one of 
the parents was not born in the genetic isolate (n = 3), data to establish the 
presence of or exclude POAG were incomplete (n = 1), or because other causes of 
visual field loss were present (n == 3), such as a cerebrovascular accident, central 
retinal vein occlusion, or medication. Seven additional patients were excluded 
because they had other types of glaucoma, including angle closure glaucoma (n == 
5), nanophthalmos (n = 1) and glaucoma as part of a syndrome with early 
menopause and congenital deafness (n = 1), resulting in 11 patients "\Vith definite 
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POAG, 15 with probable POAG, and 23 with ocular hypertension. None of these 
had any signs of ocular pigment dispersion or pseudoexfoliation, and in all, the 
anterior chamber angle \Vas open and normal. The individuals with ocular hyper-
tension \vere not included for present analyses, but they were ascertained for future 
studies. Thus remained 11 definite and 15 probable POAG patients for the present 
genome scan (Table 1). 
As population-matched controls \Ve included: 14 spouses of patients and five 
unrelated individuals from the same population who sho"\ved no signs of POAG. 
For nine spouses who were deceased, haplotypes could be reconstructed with the 
help of data from their children. 
The age at diagnosis of the definite POAG patients ranged from 49 to 82 years 
(mean 68.5, median 72 years), and in the probable patients from SO to 84 years 
(mean 63.3, median 64 years). The exact age of onset of the disease was not known, 
because the disease has an insidious character, not causing symptoms until in a 
most progressed stage. The mean age at the time of ascertainment was both in 
definite patients and controls 71.3 years, and in probable patients, 71.7 years. The 
proportion of males was 7/11 (64%) in the definite patients and 8/15 (53%) in the 
probable ones. An elevated lOP was present in 10/11 definite patients and 10/15 
probables, with a mean IOP 27.1 mm Hg and 24.5 mm Hg, respectively. 
All26 probable and definite POAG patients were related (Figure 1, chapter 5.1). 
A common founder could be identified \Vho lived in the 16th century, which is 13 to 
14 generations back. 
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Table 1 
Clinical features of patients with definite and probable primary open-angle 
laucoma 
Individual~ Sexb Age at Intraocular Glaucomatous Glaucomatous Therapy 
diagnosis pressure optic visual field 
(ns)' (mm Hg)cl neuroEathyt defectf 
OD OS OD OS OD OS 
Patientr }))ith definite prima!)! open-angle l!,laucoma 
3 i\l 73 28 3S + + + + medical, laser 
4 F 73 21 18 + + + medical 
8 :VI 49 28 32 + + medical 
12 F 82 19 22 + + + medical 
15 M 56 23 24 + + + medical 
16 M 76 23 23 + + + + medical 
21 M 60 40 40 + + + + surgery, laser 
22 F 68 26 26 + + + medical 
23 F 78 25 26 + + + + medical 
24 M 67 22 22 + + + + medical 
26 M 72 27 27 + + medical 
Patien!J Jvith probable primao' open-OilJ!/e xlaucoma 
1 F 74 22 29 + + medical, laser, 
suro-cry b • 
2 :VI 65 30 30 + medical 
5 M 53 33 33 + medical, laser 
6 F 51 19 22 + medical 
7 :VI 50 14 13 + 
9 lvl 84 13 14 + 
10 F 65 21 21 + medical 
11 F 63 16 16 + 
13 M 72 20 29 + medical 
14 :VI 62 28 28 + medical 
17 F 56 26 23 + medical 
18 11 74 33 22 + + medical, laser 
19 F 64 21 22 + +1' H medical, laser 
20 J\I 69 33 30 + medical, laser 
25 F 52 16 17 + medical 
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= "Kumbers of individuals refer to numbers in the pedigree in Figure 1, chapter 5.1 
b F = female; lvi = male 
cAge at diagnosis 'vas defined as the age of detection of a GVFD in the definite patients and 
GOl\1 in the probable patients 
d The intraocular pressure represents the maximum level of intraocular pressure ever measured in 
a patient's history; OD = right eye; OS = left eye 
~ + = present; - = absent 
f + = present; - ::::: absent 
g Early visual field defects, could not be confirmed because patient died 
Genome scan results 
Lod scores = 0 were produced in 82°/o of markers, both under the narrow and 
broad phenotype. The proportion of markers with lod scores between 0 and 0.5 
was similar under both phenotypes (15% versus 14%). Markers with lod scores> 1 
under either the narrow or broad phenotype are shown in Table 2. 
In total, a strong indication for combined linkage and association bet\:veen 
POAG and two markers was found (lod scores ~ 1.5). The highest result under 
either phenotype was observed with marker D2S123, located on 2p21 at 77 eM. 
Table 2 
Markers with lodscores 2: 1 for primary open-ang_le g:laucorna 
1Jarker Probable and definite POAG• Definite POAG Locationb 
Lodscore Lambda Lodscore Lambda ( ciV!) 
D2S123 2.25 0.83 1.32 1.00 77.1 
D12S97 1.63 0.44 0.70 0.51 160.9 
D4S3042 125 0.69 0.59 0.78 81.9 
D21S1908 0.45 0.63 1.15 1.00 31.4 
D1S252 0.97 0.50 0.98 0.69 155.1 
Shmvn are maximum lod scores using a combined analysis for linkage and association calculated by a 
modified version of ILI::-\K. Lambda represents the proportion of disease chromosomes with the 
associated allele. 
a POAG =primary open-angle glaucoma. Definite POAG was defined as a glaucomatous visual field 
defect together ·w-ith a possible or probable glaucomatous optic neuropathy (see text for cut-off 
points). Probable POAG "\Vas defined as a probable glaucomatous optic neuropathy "\Vith a normal 
visual field. 
b Location indicates the position of the marker in cencimorgans from the top of the relevant 
chromosome on the \'1/hitehead genetic map (w>.vv.'-genome.\vi.mit.edu). 
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lvlarker (position in dvl") 
lndividua!c D2s2294 D2s11'J D2s2298 D2S2378 D2s2LI6" D2s123" D2sm1 D2s2251 D2S378 D2S393 
13 
16 17 2 5 5 2 
7 15 2 5 5 2 6 2 13 
12 17 5 2 4 12 
23 11 3 8 5 2 3 7 14 
26 11 7 5 2 8 4 13 
20 16 3 16 4 2 7 4 12 
14 16 4 4 I 2 2 5 11 
6 16 7 13 1 2 2 11 
15 16 6 16 7 
24 16 6 4 
25 16 2 3 3 
22 16 7 10 2 
21 16 6 16 8 
iliinimol region qflinkage disequilibrillll/ 
J\1aximal region of linkage disequilib;ilti!J 
Figure 1 
Haplotype sh:1ring in the D2S123 region among probable and definite primary open-angle glaucoma patients. Different dc.t:,rrces of shading represent 
haplotype sharing by subsets of patients. Data in bold are from definite POAG patients, data in regular font style an.: from probable POAG patients 
a Position of marker in ccntimorgans from the top of the rdcvant chromosome on the \\.Thitehead genetic map (w\V\v-genorne.wi.mit.edu) 
b i\farh:rs D2S2l56 and D2S123 yielded high lodscores 
eN umbers ofinclividuals correspond to numbers in the pedigree (rigure 1 in chapter 5.1) 
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The lod score was 1.6 (A = 1.0) in the group of only definite patients and 2.25 (A = 
0.8), when probably and definitely affected patients were included. Tvlarker D12S97 
on chromosome 12g at 161 eM yielded the second-highest lod score of 0.7 (A = 
0.5) under the narrow phenotype and 1.6 (A = 0.8) under the broad phenotype. 
Further interesting lod scores were obtained for markers D4S3042 and D21S1908, 
with lod scores 1.25 (A = 0.69) and 1.15 (A = 1), respectively, under the broad 
phenotype. 
Fine mapping and haplotype analysis in the regions 1vith the highest lod scores 
Around the two markers with the highest lod scores, D2S123 and D12S97, 
additional markers were screened (Fig. 2 and 3). In the D2S123 flanking region, 
D2S2156 also yielded a high lod score in the analysis of the definite POAG patient 
group (lod score = 1.53, A = 1), but a low lod score in the group with definite and 
probable patients (lod score = 0.2, A = 0.44). The other, additionally screened, 
markers resulted in lod scores = 0 with A = 0. Haplotype analysis revealed that a 
region up to 3.1 clvl between D2S2378 and D2Sm1 is most likely in LD with the 
disease-associated allele. This region is completely shared by 14 out of 26 definite 
and 15 probable patients and by eight out of 28 controls. 
Among the markers screened in the D12S97 region, marker D12S343 also 
yielded high lod scores. Lod scores were 0.6 (A = 0.45) under the narrowly defined 
phenotype and 1.25 (A = 0.57) under the broadly defined phenotype. The other 
markers tested around D12S97 resulted in lod scores = 0 with A= 0. A large region 
(11.3 clvl) between D12S1609 and D12S343 appeared robe in LD and was shared 
among nine out of 26 patients and by t\VO out of 28 controls. 
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D12S395 D12S324 
lnclividuaJc 
3 
19 7 
4 8 
25 7 
11 9 
7 7 
2 
HI 7 
21 8 
i\llinilllal rej!,ion o_flinkage di-reqNilibtittlll 
J\1axil!lal region of linkaJ!,e disequili!JiiNJJI 
Figure 2 
11arkcr (positiot1 in cMn) 
D12S1609 D12S367b D12S97b D12S343 
(165.7) 
1 
1 
1 
D12S357 
(169.1) 
15 
15 
15 
15 
15 
Haplotype sharing among probable and definite primary open-angle glaucoma patients. D.ifferenl Jegrees of shading represent haplolype sharing 
by subsets of patients. Data in hold are data from definite POAG patients, data in regular fool style are probable P01\G patients 
"Position of the marker in centimorgans from the top of the relevant chromosome on the \'X-'h.itebead genetic map (www-gcnome.wi.mit.edu). 
b Markers D12S367 and D 12S97 yiddccl h.igh lodscorcs 
"Nu111bcrs of incliv.iduals correspond to numbers in the pedigree (Figure 1 in chapter 5.1) 
tlfndividmds 3 and 4 are siblings 
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Discussion 
We performed a whole genome scan in 11 definite and 15 probable POAG patients 
from a genetically isolated population. Although based on subjective criteria, the 
type of POt\G observed in our sample of patients could be described as moderate 
to severe, "\Vith a relatively late age of diagnosis, various levels of lOP, and the use 
of medical therapy in most patients, with a few surgical interventions. A combined 
test for linkage and LD yielded lod scores of> 1.5 in two regions on chromosome 
2p21 and 12q24, and lod scores > 1.0 on chromosome 4q13 and 21q21. In the two 
loci most significantly associated with POAG, haplotype sharing was present 
among patients. 
Suitability of study population 
Our isolated population has proven successful in identifying genes for rare 
monogenic eye disorders. 25.28 Ho"\vever, the genetic heterogeneous character of 
POAG complicates genetic research. Although it is expected that this heterogeneity 
is reduced in a genetic isolate due to the limited number of founders, there is 
considerable debate whether such populations as ours are suitable to map common 
multifactorial diseases.33,38,39 It has been suggested by simulation studies41l-42 and by 
observational studics43 that the extent of LD is similar in older isolated populations 
and mixed populations. As a consequence, the former populations would not be 
more useful for mapping genes for complex diseases than the latter. Other studies 
provide evidence for an increased extent of LD in recently isolated populations.44-46 
Our population is relatively young, was founded by a few ancestors, and increased 
dramatically after 1830. Therefore, we expect that the extent of LD is considerable. 
Since, in a genome scan, the probability to detect LD is determined by the extent of 
LD, our genetic isolate is most suitable for finding potential gene loci. A disadvan-
tage of this substantial LD may be the difficulty to narrow down the region of 
interest at a later stage of the study. 
Patients 
The lack of a conclusive and worldwide-applied clinical definition of POAG 
complicates research as well as valid comparison of results from different genetic 
POAG studies. The heterogenous molecular etiology of POAG necessitates an 
exact description of the phenotype. Unfortunately, in many genetic studies, the 
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phenotype is not reported in detail. The clinical definition we used was based on 
the Rotterdam Study,4 a population-based prospective cohort study among persons 
55 years and older. An elevated lOP was not part of the definition, since it is rather 
considered a risk factor for POAG than a criterion required for diagnosis by most 
studies.6.47.48 Compared to other genetic studies, our definition was rather strict, 
because the cut-off points for a glaucomatous optic neuropathy \vere set at a high 
level, and because the lOP was not used as a criterion for POAG. For example, if 
Wirtz' criteria15 would be applied to our data, 21 of our patients (probable or 
definite) would also be assigned as affected. However, five of our probable patients 
would not be assigned as affected because they had an lOP ,; 21 mm Hg. In 
contrast, 18 additional individuals of our study would be classified as POAG, while 
by our criteria, they were classified as having ocular hypertension or unaffected 
(data not shown). A strict clinical definition of POAG decreases the number of 
patients. It may seem that this reduces the power of the analyses to yield an 
interesting lod score. However, the opposite may also occur if a strict definition 
reduces misclassification of POAG patients: in that case, the power of the analyses 
may increase strongly. 
Statistical analysis 
POAG frequently does not show a simple inheritance pattern, as is seen in classical 
Evfendelian genetics. In contrast, incomplete penetrance, a variable phenotype, as 
well as phenocopies are observed with POAG. Since statistical analyses have to take 
these observations into account, simple 11endelian models are not appropriate. In a 
genetically isolated population, it is possible to perform a combined test for linkage 
and association, where A allows the presence of genetic heterogeneity, phenocopies, 
and allelic heterogeneity. 
The region around marker D2S123, which yielded our highest result (lod score 
= 2.25 with A = 0.8), was recently also reported by Suriyapperuma49 to be involved 
in POAG. This group found linkage with 2p14-p16 in a large British family. The 
affected individuals shared a haplotype from D2S123 to D2S329, a region of 
approximately 27 cJ\.1. Recombination occurred in individuals with ocular hyperten-
sion, potentially restricting this locus to less than 8 eM. Our interval extended from 
D2S2378 to D2Sm1 (3 cl\1) and possibly to D2S2251, since half of the patients 
shared an allele at this marker. Therefore, our interval overlaps the interval reported 
by Suriyapperuma only for the 70kb part between D2S123 and D2Sm1, possibly 
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extending 2.8 c1'1 to D2S2251. Since the overlap bet\veen the two regions is rather 
small (70 kb) compared to their respective sizes, the most likely explanation of our 
results combined with those of the literature, is that there are t\:VO genes located on 
2p14. 
In our study, multiple markers with multiple alleles \Vere tested, as it was not 
kno"\vn a priori which allele of which marker would be in LD with the disease. This 
procedure will lead to an increased probability for false-positive findings 24 There-
fore, a higher level of significance would be required before definite evidence of 
linkage or association can be considered as definitive. As our genome scan findings 
are only used to give an initial indication for localization of disease susceptibility 
genes, \Ve considered lod scores > 1 interesting for further exploration. 
Candidate genes 
In the 3.1 eM region between D2S2378 and D2Sm1, at least 15 genes and 18 EST's 
are located, such as the potassium channel (KCNK12), the gene similar to solute 
carrier family 13 (LOC115211), and the matrilin gene. It is not known whether 
KCNK12, LOC115211 or the matrilin genes are expressed in eye tissues. 
Ion transporters are involved in the production of aqueous humor in the ciliary 
body. Therefore, although there is no conclusive clinical or scientifical evidence that 
PO£\G is caused by hypersecretion of aqueous humour, KCNK12 and LOC115211 
are interesting candidate genes. The matrilin gene is a member of a family of 
proteins that are thought to be involved in the extracellular matrix of various 
tissues. Since it is hypothesized that extracellular deposits in the trabecular mesh-
work obstruct the outflow of aqueous humor, leading to POAG,9 matrilin is an 
interesting candidate gene for POAG. 
In the region between D12S1609 and D2S343 on chromosome 12, screening of 
UDB revealed the presence of the genes GOLGA3 and ZNF26, three EST's, and 
two eDNA clones, moderately similar to zinc finger protein 84. In addition, J'viap 
view showed also two Drosophila homologous genes (PIWI L1 and FZD1 0). 
Ho"\vever, none of these genes are obvious candidate genes for POAG. 
Clinical evaluation of first- and second-degree relatives of patients may reveal 
additional affected individuals. Genealogical data may help in the formation of 
clusters based on the degree of kinship. In such clusters, conventional linkage 
analysis may be feasible, with the assumption of a reduced penetrance. Further-
more, clinical data in close relatives gives information on clinical variability within a 
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phenotype, because close relatives share many genes including the disease gene(s) 
identical by descent. The identification of additional distantly related patients in the 
population may be useful to narrow do\\rn the region of interest based on haplotype 
sharing. A larger sample size generally leads to higher power. In addition, a large 
sample size may enable additional sub-analyses after stratification according to 
specific clinical characteristics, such as lOP or age of onset of the disease. 
Our findings provide an indication of rtvo ne\v POAG loci on chromosome 
2p21 and 12q24. These regions contain several interesting candidate genes for 
POAG. Further molecular analysis of these candidate genes is needed to identify a 
susceptibility gene involved in POi\. G. 
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General discussion 
The aim of this thesis "\vas to investigate and identify determinants for primary 
open-angle glaucoma (PO A G) in order to increase our knowledge of the etiology 
of this multifactorial disorder. Several approaches were used in different types of 
populations, including a genetically outbrcd one, families of pro bands derived from 
this outbred population, and a genetically isolated population. 
In this chapter, the main findings of these studies together with their methodo-
logical considerations will be discussed. Furthermore, recommendations for future 
research will be provided. 
Epidemiological studies in tbe Rotterdam 5 tudy 
Epidemiologic studies ·were carried out in the genetically outbred Rotterdam popu-
lation, representative of the general Dutch population, aged 55 years and over. In 
this cohort study, ophthalmological, cardiovascular, neurological, and locomotor 
diseases are studied, which enables us to evaluate new risk factors for POAG, and 
to analyse genetic and non-genetic risk factors that have been proposed before. The 
criteria we used to define POAG and the prevalence of POAG according to this 
definition in the Rotterdam Study was described in chapter 1. 
\\le found that \vomen with an early natural menopause had a 2.6 times 
increased risk of POAG (chapter 2.2). Furthermore, a high systolic blood pressure, 
a high systemic pulse pressure, a low diastolic blood and perfusion pressure, as well 
as arterial stiffness were associated \Vith an increased risk of high-tension POAG, 
while no significant association was found between these factors and normal-
tension POAG (chapter 2.3). 
Selection bias occurs when the relation between determinant and outcome is 
different for responders and non-responders. The non-responders of the 
Rotterdam Study were older. Therefore, it is likely that they had more exposure to 
risk factors and more diseases than the responders. Since the prevalence of POAG 
increases with age, exclusion of an older set of individuals probably causes under-
estimation of the prevalence of the disease. However, since it is not likely that the 
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relation ben~veen any of the determinants studied (age at menopause, blood pres-
sure, arterial stiffness) was different in responders and non-responders, \VC think 
non-response had no serious bias on the results of our study. 
In the study into age at menopause (chapter 2.2), data on age and cause of 
menopause \Vtre self-reported. ivfisclassification could have occurred because of the 
time period between the occurrence of age at menopause and the reporting. 
However, the distribution of ages at menopause in our study \vas comparable to the 
distributions reported by t\vo leading studies on age at menopause in the 0Jcther-
lands.1·2 Furthermore, since we have no reason to assume that women \.Vith POAG 
\vould have reported an earlier age at menopause, misclassification \\lould have been 
non-differential, and this would have given an underestimation of the true effect. 
The studies into age at menopause and blood pressure parameters described in 
this thesis \Vere cross-sectional. LAJ.l parameters of the outcome measure (PO/\.G) 
and all determinants, except arterial stiffness, \Vcre assessed in the baseline phase of 
the Rotterdam Study. In general, a cause-effect relation is difficult to establish in a 
cross-sectional design. Bias may occur when the determinant changes over time and 
w-hen the determinant is affected by the outcome. In case of POAG, one can 
imat,rine that glaucomatous loss of nerve tissue in the optic nerve and retina may 
have influence on local processes in the eye. However, it is unlikely in our studies 
that our results are explained by an influence of POAG on systemic factors such as 
age at menopause, systemic blood pressure, and arterial stiffness. Since \Ve have no 
reason to assume a change of any of these determinants due to the occurrence of 
POAG, we think that such bias is minimal. 
In our study of blood pressure parameters (chapter 2.3), we classified POAG 
cases into those with and without an lOP > 21 mm Hg (high-tension POAG and 
normal-tension POAG, respectively), despite the limited number of lOP measure-
ments and the time span in which they were taken. The value of 21 mm Hg was 
chosen because this value represents the 97.5t11 centile in our population, and 
because it is generally used as cut-off point.3 There is much debate about the ques-
tion whether the two types of POAG should be considered separate entities. 
Opinions differ on whether they have a different clinical course and a different 
etiology. Although we realize that any cut-off point creates an artificial distinction, 
\VC chose to stratify our POAG cases according to lOP for the following reason: it 
is o-enerallv accepted that POAG is considered a multifactorial disease, where b • 
different combinations of factors are responsible for the different phenotypes of 
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the disease. Therefore, it is likely that normal tension POAG and high tension 
POAG are subtypes along the continuum of lOP. Stratification for lOP facilitates 
the search for other risk factors than lOP for POAG. Therefore, risk factors that 
are involved in a subset of the heterogeneous group of POAG may better be identi-
fied when analysing these subsets, instead of analysing the total group. 
Each risk factor may in itself, at least partly, be influenced by genetic and non-
genetic factors. In chapter 2.3, we hypothesized that blood pressure parameters and 
arterial stiffness may lead to POAG if the lOP is elevated (at the upper end of the 
lOP continuum). Like\\rise, mutations in any gene involved in blood pressure or 
arterial stiffness may lead to POAG. We did not find any association between the 
determinants we examined and normal tension POAG (at the lower end of the lOP 
continuum). Risk factors reported in the literature involved in normal tension 
POAG include vasospasmic disorders such as migraine and Raynaud disease.4 
_;'\{utations in any gene involved in these disorders may lead to normal tension 
P01\G. 
Mutation analysis in a genetically outbred population 
:Vlyocilin (l'vfYOC) is the first, and, so far, only gene found to be involved 1n 
POAG. Despite an immense increase in studies of lviYOC since its discovery 10 
1997, the function in normal individuals and the mechanism by which this gene 
causes POAG re1nain largely unkno\vn. 1lYOC is expressed in multiple eye tissues, 
including the trabecular meshwork,s ciliary body and sclera,6 axons of ganglion cells 
and several parts of the optic nerve head,7 as \Vell as in many nonocular tissues.f' It 
is hypothesized that the outflo\v of aqueous humour is obstructed. a The mutated 
protein may either disturb the normal cytoskeletal function,9 or contribute to the 
extracellular matrix. 10 Increased lvrYOC expression in the trabecular meshwork was 
found in POAG and pseudoexfoliative glaucomaJ1 
It has been established that the contribution of the iYfYOC gene to adult onset 
POAG is 3-5°/o in large, clinic-based samples of patients.8,l2-14 \\le tested a popula-
tion-based sample of 47 POAG cases from the Rotterdam Study for mutations in 
this gene (chapter 3). One disease-causing mutation (Asn480Lys) and six polymor-
phisms \vere found. Although our numbers are relatively small, this prevalence 
(1/47) was similar to the 3-5% found in clinic-based studies. 
The number of patients included in our study \vas limited by the prevalence of 
the disease in the population and the rather strict criteria used to define definite 
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POAG. Both a glaucomatous optic neuropathy and a glaucomatous visual field 
defect were required for the definition of definite POAG, and the threshold values 
for a glaucomatous optic neuropathy were high, compared to other studies. An 
important advantage of our population-based approach "\Vas the minimalization of 
selection bias to\vards a specific type of POAG, such as that with an elevated IOP 
or progressed stages. 
\'\le examined the relatives of the POAG case in whom "\VC identified the 
Asn480Lys mutation in J'viYOC, and identified one individual with probable and 
one with definite POAG, who carried the same mutation, \Vhile four unaffected 
relatives did not carry the mutation. The phenotypes of the three patients within 
this family varied widely, ranging from a glaucomatous optic neuropathy' but no 
visual field damage in a 70-year old patient to a severely excayated optic disc and a 
remaining temporal rest in a 34-year old patient. Apparently, even in this family, 
where POAG is inherited as a simple autosomal dominant trait, other factors must 
be present to cause these differences in phenotypes. 
The family derived from our population study demonstrates that knowledge of 
genetic factors may be useful for POAG patients and their relatives. By screening 
for the presence of this specific mutation, future relatives \vho carry the mutation 
may be put under more strict control of the ophthalmologist. At the same time, 
relatives negative for this mutation run no higher risk of POAG than an individual 
\vith the same age from the general population. 
Family study in a population-based setting 
A positive family history of POAG has been established as a major risk factor of 
POAG. This risk factor is often indicated as presence or absence of a positive 
family history for a given individual. In chapter 4, we applied a new statistical 
method to quantify the familial risk for an individual, by calculating her/his family 
score (FS) based on all data obtained by examination of their family. This FS 
accounted for the age, gender, number, kinship, and presence or absence of POAG 
in relatives. To test whether this FS could be used as a risk factor for POAG, we 
examined "\vhether FS was associated with POAG. Case and control individuals 
were derived from the population-based Rotterdam Study and their relatives were 
examined. FS's were calculated from these relatives, and logistic regression \vas 
performed to examine whether FS was associated with POAG. We found that indi-
viduals \vith a high FS had an increased risk of POAG. This association was 
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independent of the presence of an elevated lOP. 
Cases and controls, further noted as case and control pro bands to discern them 
from their relatives, were derived from the population~based Rotterdam Study. 
Relatives undenvent the same standardized ophthalmological examination as the 
probands, and response rates were high. Features of POAG were assessed 
separately in a masked fashion to ensure an unbiased diagnosis. As a result, 
selection and ascertainment bias were minimized. Examining relatives instead of 
taking a family history from the probands reduced misclassification of disease 
status. J\fisclassification of POAG could otherwise easily occur due to the insidious 
course of the disease, lack of knowledge of the disease status in proband or relative, 
and different and changing definitions ofPOAG.JS 
A positive FS indicated that in a family, more cases were present than would be 
expected from the age- and gender-specific prevalence in the general population. A 
high FS therefore points to an increased genetic risk for individuals in that family 
and vice versa. An FS = 0 meant that the number of cases was equal to that 
expected from the age- and gender-specific prevalence in the general population. 
However, many pro bands had an FS of 0, because they had small and/ or young 
families, which did not contain much information about the genetic risk. In indi-
viduals of these families, FS could not be used as a risk factor. 
In larger families, the FS can be used as risk factor of POAG of an individual. It 
can be used by the clinician to identify individuals with a high familial risk for 
follow up and for further genetic analysis. For research purposes, the FS can be 
used to represent the genetic risk of an individual in multifactorial models of 
POAG. 
Localization of genes in a genetically isolated population 
In chapter 5, we aimed to localize one or more genetic susceptibility loci for 
POAG. We identified 11 definite and 15 probable POAG patients, and 23 indi~ 
vi duals with ocular hypertension in a genetically isolated population in the North of 
the Netherlands. In chapter 5.1 we first excluded all candidate POAG regions 
known from Uterature, including lvfiOC (GLC1A),12 regions on chromosome 
2cen~q13 (GLC1B),16 3q21~q24 (GLCJC),n 8q23 (GLClD),lS 10p15~p14 
(GLC1E),19 and 7q35 (GLC1F)."1 In addition, we excluded five regions that were 
described in a genome scan in a large, heterogeneous sample of POAG families 
(chromosome 2p, 14p, 17p, 17q, and 19g).21 In chapter 5.2, we present the results 
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of a whole genome scan in this sample. Lod scores > 1.5 were obtained in t\VO 
regions on chromosome 2p21 and 12q24, and lod scores > 1.0 on chromosome 
4q13 and 21q21. In the two loci most significandy associated with POAG, haplo-
type sharing was present among patients. 
The POAG loci GLCJA to GLCJF were identified using linkage analysis in a 
subset of unrelated POAG families. In these families, POAG segregated as an 
autosomal dominant trait. However, in the majority of families, PO_AG does not 
follow a clear-cut J\.Iendelian inheritance pattern and the inheritance pattern is 
unknown. Conventional linkage analysis has limited value in localizing loci and 
genes for POAG in the latter group of families, because of several reasons. The 
power of linkage analysis decreases rapidly if the mode of inheritance is not exactly 
known. Furthermore, POAG is genetically heterogeneous. It is hypothesized that 
many genes are involved in POAG, each contributing for a small part to the occur-
rence of the disease. 22 Linkage analysis has limited power to detect modest effects 
of susceptibility loci contributing to a complex disease. Finally, linkage analysis 
requires large families with a considerable number of affected individuals. Due to 
the relatively late age of onset of POAG, parents of patients are often diseased, 
while the children have not reached the age of onset yet, resulting in limited 
numbers of affected individuals per family. \Xle chose a genetically isolated popula-
tion to deal with these problems. 
In a genetically isolated population, the current generation has arisen from a 
limited number of founders, \Vhich reduces genetic complexity. Therefore, it is 
plausible that many patients of the current generation share the same genetic factor, 
inherited from a common ancestor. Linkage disequilibrium (LD) mapping is based 
on the assumption that these patients also share a genomic region spanning this 
genetic factor. These chromosomal regions of LD may be used to localize a disease 
gene. These regions are detected by comparing allele and haplotype frequencies 
bet\veen patients and controls, and are confirmed by haplotyping of markers in the 
chromosomal region. In our studies, we used a combined test for linkage and L.D. 
This test is appropriate to exclude or localize chromosomal regions of interest for 
multifactorial disorders in a genetically isolated population, where the inheritance 
pattern is not exactly known. Sampling from a genetic isolate enabled us to indi-
vidually collect a considerable number of patients.23 Genealogical research revealed 
that the majority of patients \vas related and a pedigree could be constructed. 
The probability to detect LD is determined by the extent of LD. If the extent of 
134 
General dzSmssion 
LD is small, and the distance between the markers used in the genome scan is large, 
the region of LD will be missed. The extent of LD decreases as the number of 
generations since the common ancestor increases. Isolated populations have often 
been proposed as suitable populations for LD mapping, because it was expected 
that they have larger regions of LD than mixed populations.24,25 Recently, though, 
simulation26-29 and observational studies3°-32 suggested that LD in older genetic 
isolates would not be larger than in outbred populations. However, it has been 
argued by others33 that the assumptions used in these studies about the demo-
graphic history and the expansion of a population were not realistic. A continuous 
decrease of LD was assumed, while genomic regions of lower recombination and 
hotspots of recombination exist, as well as expansion, contraction, and bottlenecks 
in population growth. Finally, investigators provided empirical evidence for exten-
sive LD in recently isolated populations, founded by a small number of individuals. 
LD would be especially large in populations, which had undergone rapid growth 
after a considerable period of constant size.34-3"7 
Our studies into the identification of genes for monogenic eye disorders showed 
that the extent of LD was approximately 3-5 cM.38,39 This size was expected from 
the history of the population, because it was relatively recently founded by only a 
few ancestors, and the population increased dramatically after the year 1830. As a 
consequence of the recent isolation, this population may resemble the general 
population more than older genetic isolates. The latter increases the probability that 
a POAG susceptibility gene identified in our population may also play a role in 
POAG in the general population. 
In our study, multiple markers with multiple alleles were tested, because it was 
not known a priori which allele of which marker would be in LD with the disease. 
This increases the probability of false-positive findings. A higher level of signifi-
cance is required before the results can be considered as conclusive evidence, but 
there is debate on the exact threshold that should be used in a genome wide LD 
screen for a complex disease. The highest lod scores reported in chapter 5.2 (2.25 
and 1.6) were not corrected for multiple testing and correspond to uncorrected p-
values of 0.006 and 0.02, respectively. However, the lod scores shown in chapter 
5.2 should not be interpreted as conclusive evidence, but as an initial indication of 
regions interesting for further exploration. 
Spouses of patients and elderly, unrelated, individuals without any signs of 
POAG were included as controls. The choice of a control group may generate false 
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positive findings if unaffected controls and affected individuals are chosen from 
different populations because of a potential difference in population allele frequen-
cies. Our patients and controls \Vere derived from the same population, which 
minimized selection bias. In the analyses, the disease status of the controls was 
assigned as unkno\vn. A disease gene freguency of 1 °/o accounted for a possible 
prevalence of POAG among the control individuals of 1%. This prevalence was 
based on the assumption that we have identified nearly all POAG patients in this 
community through general practitioners and ophthalmologists in the region, since 
response rates were high. 
In our combined analysis of linkage and LD, A (the proportion of disease chro-
mosomes with the associated allele) allows the presence of a few phenocopies. In 
the exclusion analysis of POAG candidate genes, fixed A's of 0.8 and 0.9 were used, 
allowing for 10 to 20% of phenocopies. If in the analyses of the genome scan, a few 
phenocopies are present among the patients, the power of analyses and A are 
reduced, but this effect will be minimal. 
Our criteria for the presence of definite POAG were strict, compared to other 
definitions of POAG from genetic studies. The cut-off points for a glaucomatous 
optic neuropathy were high, and the level of IOP was not used as a criterion for 
inclusion. 40 These strict criteria reduced the number of patients. \Xlhat are the 
possible consequences of this reduction? 
The consequences of reduction depend upon the question which individuals are 
excluded from the study by using a strict clinical definition. In general, decreasing 
the sample of patients lowers the overall power to yield positive results. The latter is 
the case, if the exclusion leads to lowering the number of patients, who share the 
same genetic cause. In contrast, if the exclusion decreases the number of individuals 
wrongly classified as POAG (misclassification) or if it decreases the number of 
phenocopies (diagnosis of POAG is right, but the disease results from a different 
genetic cause), the power of the analyses increases strongly. \Xle excluded a consid-
erable number of individuals, compared to, for example, \N'irtz' study (see chapter 
5.2). Using strict clinical criteria likely results in more homogeneity of the pheno-
type, and thus we think that the gain in power caused by decreasing rills-
classification and phenocopies is larger than the loss of power due to the reduction 
of patients, who shared the same genetic cause. 
136 
General discNssion 
Strategies for future research 
Epidemiologic studies 
To evaluate a causal-effect relation of a determinant on the outcome, longitudinal 
studies are preferred. The determinant is then measured before occurrence of the 
outcome. The Rotterdam Study has a prospective cohort design. Soon, incidence 
data on POAG will become available from the third examination phase, which has 
taken place between 1997 and 1999, resulting in follow up time of about 7 years. 
Then, it will be possible to study the effect of determinants measured in the first 
phase on the occurrence of POAG, determined in the third phase. 
For both etiologic and therapeutic reasons, further research into the effects of 
endogenous and exogenous exposure to female sex hormones would be of interest. 
The Rotterdam Study recently started a new study phase, including again individuals 
age 55 years and older. The use of hormone replacement therapy has increased 
largely in the last decade. Therefore, newly included women may have used 
hormonal replacement therapy more often than those from the original baseline 
cohort, leading to more power in analyses regarding hormone replacement therapy. 
Myocilin mutation analysis in a genetically outbred population 
Differences in phenotype among carriers of the same mutation in 1fYOC have 
been reported in several large families, including ours. It is unknown which factors 
influence the intrafamiliar differences in the phenotype. One patient may not have 
any damage, while another patient from the same family, carrying the same muta-
tion, suffers from severe visual field loss. This leads to the conclusion that other 
factors must be present to explain these differences. Genotype-phenotype research 
in families with POAG caused by mutations in :\fYOC remains necessar:y to iden-
tify possible influencing factors. Furthermore, such studies may be helpful to eluci-
date the mechanism by which mutations in j\;JYQC cause POAG. The Glu368Stop 
mutation leads to a considerably shorter protein, lacking a domain of fvfYOC that is 
hypothesized to be important for its function. It is the most prevalent (40%) of the 
approximately 30 mutations known at present. However, it is unknown why this 
mutation causes a much milder phenotype than mutations with a more subtle 
effect.4 1 Furthermore, it is unknown why patients heterozygous for a mutation are 
affected, and patients homozygous for the same mutation do not display any signs 
of POAG.41 Apart from these family studies, research in transgenic animal models 
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may aid in examining the function of normal and mutated :0.~IYOC. These studies 
may be useful to study genetics of individual glaucoma genes and to identify inter-
action berureen genes and thus help in the identification of modifier genes.24 
Family study in a population-based setting 
In a complex disease, the number of affected individuals per family is relatively 
small. This complicates segregation analysis. To further identify and quantify the 
attribution of genetic and environmental risk factors, families \Vith high FS could be 
followed up, and examination of families could be extended to 2nd degree relatives 
and spouses. 
Furthermore, the inheritance of features of POAG could be investigated 
separately. These can be quantitative measures, such as vertical cup-to-disc ratio 
and minimal neuroretinal rim, and categorical measures, such as the presence of a 
glaucomatous visual field defect. In addition, the FS could be used to examine more 
thoroughly the inheritance ofiOP and its role in the inheritance ofPOAG. 
Localization of genes in a genetically isolated population 
Further clinical follow up of the patients from the genetically isolated population 
may be useful to define the phenotype more accurately. This follow up could 
include assessing the rate of excavation of the optic disk, visual field deterioration, 
and response to treatment. 
Follow up of close relatives of previously identified patients may reveal 
additional affected individuals. A higher number of patients may increase the power 
of the analyses. A higher number of patients may also be useful to perform 
additional detailed analyses. Genealogical data may be used to form clusters based 
on the degree of kinship. In such clusters, conventional linkage analysis may be 
feasible, with the assumption of a reduced penetrance. Furthermore, clinical data in 
close relatives gives information on clinical variability within a phenotype, because 
close relatives share the disease gene identical by descent. 
The identification of additional distantly related patients in the population may 
be useful to narrow down the region of interest based on haplotype sharing. A 
larger sample size generally· also leads to higher po\ver. In addition, a large sample 
size may enable additional analyses after stratification according to specific clinical 
characteristics, such as IOP or age of onset of the disease. 
Candidate genes in the ultimately identified chromosomal regions may· be 
138 
General discussion 
screened for mutations. Sequence alterations may be compared bet\veen cases and 
controls of the isolated population, and, subsequently, bet\veen cases and controls 
from the general population. Selection of candidate genes is based on several 
criteria. Genes may show homology \vith genes already known to be involved in 
POAG. Since 1fYOC is the only gene known for POAG, genes showing homology 
with 1\fYOC may be interesting candidates. Furthermore, genes are selected 
because of the function of the protein they encode. For POAG, a large number of 
genes would be appropriate according to this criterion, because multiple 
mechanisms are thought to be involved in its pathogenesis. In addition, selection of 
genes is based on the expression of the gene. In case of POAG, many tissues in the 
eye are involved, including retinal ganglion cells and their axons, but also the lamina 
cribrosa, ciliary body, and trabecular meshwork. Finally, the phenotype may aid the 
selection of candidate genes. For example, if an elevated lOP is an important 
feature in the phenotype, genes involved in aqueous humor dynamics could be 
appropriate. 
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7 
SUMMARY 

7.1 
Summary 
This thesis describes our research into risk factors of primary open-angle glaucoma 
(POAG). POAG is a clinically and genetically heterogeneous eye disorder, which 
mostly affects people aged 55 years and older. The clinical features are an excava-
tion of the optic nerve, so called glaucomatous optic neuropathy (GON) and a 
glaucomatous visual field defect (GVFD). Important risk factors include age, an 
elevated intraocular pressure (IOP), black race, and the presence of POAG in 
relatives. The epidemiological part and one family study described in this thesis 
took place in the Rotterdam Study, a population-based cohort study of subjects 
aged 55 years and older. Data were derived from the baseline phase of this study 
(1990-1993), when 6,872 subjects participated in the eye examination. The other 
genetic studies described in this thesis were performed in a genetically isolated 
population in the Netherlands. 
Chapter 1 describes the aim of our studies on POAG. A brief introduction is 
given of POAG, its risk factors, and the problems encountered when examining a 
complex disease such as POAG, using an epidemiologic and genetic approach. 
In chapter 2.1, we present a proposal for an international classification system 
and we give the prevalence of POAG in the Rotterdam Study according to this 
system. POAG is classified in three categories: definite, probable, and possible. 
Definite POAG is defined as a probable or possible GON based on the 99.5<h and 
97.5<h percentile, respectively for this population, together with a GVFD. Probable 
POAG is either a GVFD without GON or a probable GON without a GVFD or a 
visual field test. Possible POAG is defined as a possible GON without a GVFD or 
visual field test. The overall prevalence of definite POAG was 0.8% (50 cases). The 
prevalence of POAG in men was double that in women. \X/ben criteria used by 
other population-based studies were applied to data of the Rotterdam Study, the 
prevalence differed by a factor of 12. 
\Xle examined whether an early age at menopause was associated with POAG in 
2,469 women "\vho experienced a natural menopause and 609 women who 
experienced menopause after surgery or irradiation therapy (chapter 2.2). Definite 
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or probable POAG \Vas diagnosed in 78 women with a natural menopause and 15 
\vith an artificial menopause. \"Xlomen \Vho \Vent through natural menopause before 
reaching the age of 45 had a 2.6 times higher risk of POAG than those \Vith their 
menopause at or after age 50. The number of ·women with an artificial menopause 
and women \Vho used hormonal replacement therapy \vas too small to draw 
conclusions. 
In chapter 2.3, we studied the relation between blood pressure, arterial stiffness 
and the risk of POAG. We analyzed separately POAG cases with and without an 
elevated IOP (high-tension POAG and normal-tension POAG, respectively) and 
subjects \Vith and without systemic antihypertensive therapy. Subjects \.Vith a high 
systolic blood pressure, a high difference between systolic and diastolic blood 
pressure, and a high arterial stiffness, had an increased risk of high-tension POAG, 
in the group without antihypertensive therapy. Subjects \Vith a low diastolic blood 
pressure also had an increased risk of high-tension POAG, in those with treatment 
for systemic hypertension. 
The prevalence of mutations in myocilin, the only gene known to be associated 
with POAG, were investigated in the population-based sample of 47 POAG cases 
from the Rotterdam Study (chapter 3). In one case, a disease-causing mutation was 
found, which prevalence was expected from the prevalence in clinic-based studies 
(2-4°/o). "Cpon investigating the family of this case, mutations were present in two 
affected, and absent in four unaffected relatives. The clinical features differed 
largely among the patients carrying the mutation, suggesting the presence of other 
factors influencing the expression of POAG. 
In chapter 4, the family score method (FS), which is a new statistical method, is 
described to assess the genetic risk of an individual for POAG, based on the infor-
mation in his/her relatives. The FS accounts not only for the disease status of 
relatives, but also for their total number, age, gender, and degree of kinship. An 
increase in FS was significantly associated with an increased risk of POAG 1n a 
given individual. The presence of an elevated IOP did not influence this 
association. 
In chapter 5, a sample of 11 definite and 15 probable POAG patients is 
described, derived from a genetically isolated population. This population has arisen 
from a limited number of founders, and has been isolated during many generations 
for cultural and religious reasons. As a result, the genetic complexity of the 
population and the number of genes possibly involved in POAG is most likely 
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decreased, \\rhich is an advantage for genetic research into the genetic causes of 
POAG. In chapter 5.1, POAG candidate loci known from literature were excluded 
·with a combined test for linkage and association. The test was based on the 
assumption that most patients identified in this population share the same genetic 
cause and a larger genomic region around it. Unrelated spouses and elderly subjects 
from the same population were included as controls. 
Chapter 5.2 describes a genome scan performed in this sample of POAG 
patients, using 347 markers distributed oYer the total genome. Analyses were 
performed including both the group of definite and probable POAG patients, and 
the group of definite patients only. Two regions on chromosome 2 and 12, most 
likely involved in POAG, ·were further examined with additional markers. Haplo-
type sharing in these regions \Vas obsen.red bertveen patients. Potential candidate 
genes, such as KCNK12, a gene for a potassium channel, and matrilin, an extracel-
lular matrix protein, were discussed. 
In chapter 6, the main findings of the studies described in this thesis are 
discussed, together with their methodological considerations. Furthermore, 
recommendations for future research are provided. 
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7.2 
Samenvatting 
Primair open kamer (angle) hoekglaucoom (PO A G) is een oogziekte, die vooral bij 
ouderen voorkomt. De klinische verschijnselen zijn een glaucomateuze exca\Tatie 
van de gezichtszenuw, ook glaucomateuze opticus neuropathic (GON) genoemd, 
en bijpassende gezichtsvelddefecten. Belangrijke risicofactoren voor het ontstaan 
van POAG zijn: leeftijd, een verhoogde oogdruk, bijziendheid, en negrolde ras. 
Naast deze factoren spelen genetische oorzaken een belangrijke rol. In dit 
proefschrift worden determinanten van POAG onderzocht met verschillende 
benaderingen. De studies vonden plaats in een algemene populatie, die genetisch 
gemengd is, in families van POAG patienten en controles, afkomstig uit deze 
algemene populatie, en in een genetisch gelsoleerde populatie. Het Erasmus 
Gezondheid en Ouderen (ERGO) onderzoek \Verd uitgevoerd in een populatie die 
representatief was voor de algemene Nederlandse Caucasische bevolking. In de 
ERGO studie zijn 7983 personen van 55 jaar en ouder onderzocht op oogziekten, 
hart-en vaatziekten, aandoeningen van het bewegingsapparaat, en neurologische 
ziekten. De genetische studies werden verricht in een genetisch g6soleerde 
bevolkingsgroep in Noord-1\:ederland. 
Hoofdstuk 1 beschrijft het doe! van de studies naar POAG. Hierin wordt een 
korte introductie gegeven over het klinische beeld en de risicofactoren van POAG. 
Verder worden de problemen die men tegenkomt bij het onderzoeken van POAG 
vanuit de verschillende benaderingen besproken, zoals het ontbreken van een 
wereldwijd toegepaste klinische definitie of classificatiesysteem, het feit dat er 
"\vaarschijnlijk meerdere genen betrokken zijn bij POAG, de complexe manier van 
overerving, en de late leeftijd van ontstaan of manifest worden van POAG. 
In hoofdstuk 2.1 doen wij een voorstel voor een internationale classificatie van 
POAG en bcschrijven we de prevalentie van POAG in de ERGO populatie 
volgens dit classificatiesysteem. POAG wordt ingedeeld in drie categorieen: 
definitief, waarschijnlijk en mogelijk. Dcfinitief POAG wordt gedefinieerd als een 
waarschijnlijke of mogelijke GON, gebaseerd op de 99.5 respectievelijk 97.5' 
percentiel in deze populatie, samen met glaucomateus gezichtsveldverlies (GGV). 
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Waarschijnlijk POAG wordt gedefinieerd als GGV zonder GON of een 
waarschijnlijke GON zonder GGV of zonder gezichtsveldonderzoek. l\!logelijk 
POAG tenslotte berust op een mogelijke GON zonder GGV of 
gezichtsveldonderzoek. De totale prevalentie van definitief POAG was 0.8% (50 
personen). De prevalentie van POAG onder mannen was 2x zo hoog als die onder 
vrou\-ven. \Xlanneer de criteria uit andere populatiestudies "\verden toegepast op data 
uit het ERGO onderzoek, verschilde de prevalentie met factor 12. 
In hoofdstuk 2.2 onderzochten we of er een verband bestond tussen het op 
jonge leeftijd doormaken van de menopauze en POAG in 2469 vrouwen met een 
spontane menopauze en 609 vrouwen die in de menopauze k\vamen na een 
operatic of na bestraling (artificiele menopauze). POAG was aanwezig in 78 
vrouwen met een spontane menopauze en 15 met een artificidc menopauze. 
Vrouwen die voor hun 45e spontaan in de menopauze geraakten, hadden een 2.6 
zo hoog risico op POAG als degenen die na hun SOc menopauzaal werden. 
Analyses bij vrouwen met een artificide menopauze en vrouwen die hormonale 
substitutie gebruikten wezen ook op een verhoogd risico voor hen die voor hun 45c 
in de menopauze kwamen, maar aantallen waren te laag om definitieve conclusies 
uit te trekken. Deze resultaten konden vanuit de literatuur verklaard worden door 
het WCg"'ailen van een beschermend effect van vrouwelijke geslachtshormonen, 
zoals oestrogenen en progestagenen. 
In hoofdstuk 2.3 bestudeerden we de relatie tussen bloeddruk, vaatwand-
stijfheid en het risico van PQj\G. Eerdere studies rapporteerden verschillende 
resultaten met betrekking tot bloeddmk en POAG. Personen met POAG met en 
zonder verhoogde oogdruk (hoge drukglaucoom en lage drukglaucoom) en 
personen met en zonder bloeddrukverlagende therapie werden apart geanalyseerd. 
In de groep zonder bloeddrukverlagende therapie hadden individuen met een hoge 
systolische bloeddruk een boger risico op hoge drukglaucoom. Dit gold eveneens 
voor individuen met een groat verschil tussen systolische en diastolische bloeddruk 
(polsdruk) en voor individuen met een hoge vaatwandstijfheid. De diastolische 
bloeddruk werd apart geanalyseerd in de groep die bloeddrukverlagende medicatie 
gebruikten. Individuen met een lage diastolische bloeddruk hadden een verhoogd 
risico op hoge drukglaucoom. Dit gold ook voor individuen met een laag verschil 
tussen diastolische bloeddruk en oogdruk. Deze resultaten zouden verklaard 
kunnen worden door een verminderde doorbloeding van bet oog met schade van 
de gezichtszenuw als gevolg. 
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In hoofdstuk 3 wordt de frequentie van mutaties in het myociline gen in 
respondenten met POAG uit de ERGO studie beschreven. Het myociline gen is 
betrokken bij de meeste gevallen van POAG op kinder- en jong volwassen leeftijd, 
en bij 3-5% van de patienten bij wie POAG zich manifesteert op volwassen leeftijd. 
De normale functie van het myociline gen en het mechanisme waarop mutaties in 
dit gen POAG kunnen veroorzaken, zijn nog onduidelijk. Een hypothese is, dat 
mutaties in het myociline gen kunnen leiden tot een verhoogde afzetting ervan in 
het trabekelsysteem, dat zorgt voor de afvoer van het kamerwater uit het oog. Als 
gevolg zou de afvoer verminderd worden, de oogdruk oplopen en zo POAG 
kunnen veroorzaken. Het v66rkomen van mutaties in myociline bij glaucoom-
patienten is uitgebreid onderzocht in grate aantallen patienten die verzameld 
werden vanuit ziekenhuizen. Het was echter nooit onderzocht bij een groep 
personen met POAG die verzameld zijn vanuit een bevolkingsonderzoek. \Xlij 
onderzochten 47 personen met POAG afkomstig uit bet ERGO onderzoek op 
mutaties in dit gen. In een van hen werd een ziekte-veroorzakende mutatie 
gevonden, een frequentie die verwacht was op basis van de klinische studies. Bij het 
nakijken van de familie van deze persoon, werd de mutatie aangetroffen in t\vee 
familieleden die eveneens POAG hadden en was de mutatie af\vezig bij vier 
gezonde familieleden. Het klinisch beeld onder degenen met de mutatie varieerde 
sterk, van geen gezichtsveldverlies bij een 70-jarige man tot ernstige defecten bij een 
28-jarige vrouw. Dit wijst op het bestaan van andere, nog onbekende, factoren voor 
de manifestatie van POAG. Dit kunnen zowel genetische als omgevingsfactoren 
zijn. Voor de familieleden van deze familie is het nuttig te weten of zij de mutatie 
hebben. Als blijkt dat zij die dragen, is frequente controle gewenst. Degenen die de 
mutatie niet hebben lopen geen hager risico dan een -willekeurig indivi.du met 
dezelfde leeftijd uit de algemene populatie. 
In hoofdstuk 4 wordt de familiescore (FS) beschreven, een statistisch nieuwe 
methode om het genetisch risico voor een individu op een ziekte te bepalen, op 
basis van infonnatie van familieleden. Deze FS houdt niet aileen rekening met de 
ziektestatus van familieleden, maar ook met het totaal aantal familieleden, hun 
leeftijd, geslacht, en graad van verwantschap. Wij pasten deze methode toe op de 
POAG data uit de familiestudie van ERGO. In deze studie zijn van de 50 
individuen met definitief POAG en 150 personen zonder POAG de 
eerstegraadsfamilieleden oogheelkundig onderzocht. FS's werden berekend en 
getest werd of de verdeling van FS verschilde tussen de individuen met en zonder 
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POi\.G. FS bleek positief geassocieerd met POAG, wat inhield dat het risico van 
POAG boger werd naarmate de FS steeg. Deze associatie tussen FS en POAG 
verschilde niet tussen POAG met een verhoogde oogdruk en POAG zonder 
verhoogde oogdruk. De FS methode is nuttig voor het selecteren van individuen 
met een verhoogd genecisch risico. V oor de onderzoeker is de FS een bruikbare 
maat voor genetisch risico in POAG modellen met meerdere factoren. 
In hoofdstuk 5 wordt beschreven hoe 11 definitieve en 15 waarschijnlijke 
POAG patienten uit een genetisch isolaat werden onderzocht. Deze populatie is 
afkomstig van een beperkt aantal voorouders en is gedurende vele generaties 
gelsoleerd door vanwege culturele en religieuze redenen. Daardoor is de genetische 
complexiteit en daarmee het aantal genen dat mogelijk betrokken is bij POAG 
gereduceerd, \Vat een voordeel is voor genetisch onderzoek naar POAG. De 
structuur van een genetisch isolaat biedt ook de mogelijkheid voor het uitvoeren 
van alternatieve analyses voor het lokaliseren van een gen. Conventionele 
koppelingsanalyse gaat uit van een duidelijke manier van overerving, wat bij de 
meeste POAG families niet het geval is. In een genetisch isolaat moet een ander 
type analyse worden gebruikt, dat veel minder afhankelijk is van aannames over de 
precieze overerving van POAG. Een laatste voordeel van een genetisch isolaat is 
dat niet hoeft te worden gezocht naar grote POAG families, wat moeilijk is gezien 
de late leeftijd van ontstaan van de ziekte. In deze populatie kunnen POi\.G 
patienten individueel opgespoord worden omdat de kans groot is dat zij ver 
verwant blijken te zijn bij genealogisch onderzoek. 
In hoofdstuk 5.1 zijn de 11 definitieve POi\.G patienten onderzocht op 
kandidaat regio's voor POAG, bekend uit de literatuur. De gebruikte test gaat 
ervanuit dat de meeste POAG patienten dezelfde genetische oorzaak (mutatie in 
een gen) hebben, geerfd van een gemeenschappelijke voorouder, met een groter 
gedeelte D:N"A eromheen. Getest wordt of zo'n deel DNA vaker voorkomt bij 
POi\.G patienten dan bij controlepersonen uit dezelfde populatie. Geen van de 
onderzochte POAG kandidaatregio's bleek significant vaker voor te komen bij 
patienten dan bij controles. Dit betekent dat er een ander gen kan zijn dat 
verantwoordelijk is voor POi\.G bij deze patienten. 
In hoofdstuk 5.2 wordt een volledige genoom scan beschreven met 347 merkers 
verdeeld over het gehele genoom. Deze scan is uitgevoerd bij 11 definitieve en 15 
waarschijnlijke POi\.G patienten, 38 familieleden en 28 controle personen. Voor de 
analyses werd dezelfde test gebruikt als in hoofdstuk 5.1. Analyses werden gedaan 
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met definitieve en waarschijnlijke patienten samen, en met aileen definitieve 
patienten. Lod scores (waarschijnlijkheidsquotient) werden berekend voor elke 
merker. De hoge lod scores op chremeseom 2 and 12 "\vijzen erep dat bet zeer 
"\Vaarschijnlijk is dat er genen veer POAG ep deze chromeseemgedeelten liggen. 
Dus werden er in deze regie's extra merkers getest. Het bleek dat de meeste 
patitnten een identiek stuk D~A, aH::emstig van een verre voorouder, gezamenlijk 
bezaten. Dit is een aanwijzing dat het ziekte-gen hierop zou kunnen liggen. 
1\fogelijke kandidaatgenen voor POAG in die regie's werden bediscussieerd, zeals 
KCNK12, een gen voor een kalium kanaal, evenals matriline, een extraceilulair 
matrix eiwit. 
In hoofdstuk 6 worden de belangrijkste resultaten van aile studies kort 
bespreken samen met enkele voor- en nadelen van de toegepaste benaderingen. 
Daarna worden aanbevelingen veer vervolgonderzoek besproken. 
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7.2 
Dankwoord 
Iedereen weet dat een proefschrift nooit door een persoon tot stand komt. Er zijn 
veel mensen bij betrokken die een hoop "\Vcrk hebben verricht, meegedacht, en van 
wie ik heb geleerd. lviet ru.ree onderzoeksprojecten neemt die hoeveelheid aileen 
maar toe, wat zich uit in de lange rij namen boven de geschreven artikelen. 
Dit gedeelte is vooral ook voor degenen die daar niet staan. 
:vlijn beide promotoren, professor de J ong en professor Hofman, wil ik 
allereerst bedanken. Paulus, ik had het gevoel dat je uiteindelijk altijd achter me 
stond. Ik "\vaardeer het zeer dat de deur altijd voor me open ging hoe druk je bet 
ook had. Bert, jouw enthousiasme was erg motiverend en je aanwijzingen 
"\vaardevol. 
lvfijn co-promoter Arthur Bergen wil ik bedanken voor de dagelijkse begeleiding. 
Arthur, met jouw ervaring haalde je meteen de belangrijke resultaten naar boven en 
gaf je daarmee de richting aan het genetisch onderzoek. 
De commissieleden Prof van Duijn, Prof de Smet en Prof Niermeijer wil ik zeer 
danken voor de bereidheid in de commissie plaats te nemen en kritisch naar mijn 
proefschrift te kijken. Hans Lemij wil ik eveens danken voor het plaatsnemen in de 
commissie, en nog wel als deskundigc. Lodewijk Sandkuijl, bedankt voor de 
plezierige samenwerking en voor de tijd die je nam om al mijn vragen te 
beant\voorden en weer tegenvragen te stellen. 
De ERGO groep oogheelkunde: ik wil jullie bedanken voor de stimulerende 
samenwerking, want dat is de kracht van deze groep. Ik zal jullie missen. 
Ada en Carina, dank voor al jullie werk op het ERGO centrum, het verrichten van 
de extra gezichtsvelden en het uitbreiden van het familieonderzoek. Het is 
ontzettend veel waard dat jullie iedereen en alles van en op ERGO kennen. Raph, 
Dolinda en Siamand dank ik voor het inlezen en beoordelen van de grote 
hoeveelheid papildia's. 11ijn voorbeelden Caroline, Roger en Hans, hebben me niet 
alleen het nodige epidemiologische advies voor analyses gegeven, 1naar ook mij 
aangestoken met hun enthousiasme. Petra en Redmer wens ik veel succes in hun 
resterende onderzoekstijd. 
155 
Dank1voord 
Jacqueline, als mijn directe voorganger heb jij me overal de weg geleerd. Hoe had ik 
bijvoorbeeld anders ooit aile adressen in ons dorp kunnen vinden? :0Joem de 
tuinkabouters en de groene gordijnen, en wij "\Veten de weg! 
Petra, ik ben verheugd dat jij naast me staat, 6 maart. Dank voor je steun op aile 
vlakl.;;::en, met je gezonde manier van denken. 
Anneke Korving wil ik speciaal bedanken. Van verre gekomen voelde ik me 's 
ochtends vroeg altijd meteen thuis op het ERGO centrum. lk heb met 
bewondering toegekeken hoe jij met aile verschillende respondenten omgaat. 
J canine Houwing wil ik bedanken voor de stimulerende en nuttige 
samenwerking. Van jouw vakgebied wist ik weinig maar het boeide me enorm. Ik 
had nog veel meer van je willen leren. Oak Jacqueline \Xlitteman wil ik danken voor 
de samenwerking. Jacqueline, bet bespreken van analyses en papers met jou was 
zeer waardevol. Hoewel je "aileen" hoefde te zorgen dat bet cardiovasculair 
verant\voord was wat ik opschreef, beb ik juist ook veel aan je algemene 
aanwijzingen gehad over het scbrijven en de opbouw van een artikel. 
Dan bet IOI, dat altijd in beweging is. 
lvfarjolein, dank voor je inzet en betrokkenheid bij bet genetiscb onderzoek. Het 
was een enorme steun te weten dat "\Ve er met zijn t\veeen aan \Verkten. 
Jacqueline Bruins, met jou op pad werkte erg goed. De juiste toon, een extra 
hand en een extra oor. Elles en Ria, dank voor bet uitzoeken van de genealogie. 
Ton, heel erg bedankt voor je hulp bij de dia's en later natuurlijk de stambo(o)m(en) 
in aile variaties . .iYiarcia, \\Til en Ernita voor jullie geregel, waardoor alles altijd goed 
komt. 
J'viarsba, Simone, Xiao Feng, en Jacoline wil ik bedanken voor de gezelligheid 
van de afdeling en de ant\:voorden op alle genetische vragen van de dokter. 
Antonella, John, 11ariClle voor de overige gezellige uurtjes; J\ntonella natuurlijk 
voor het functioneren als help~desk voor allerhande computer problemen 
(misschien had je dat beter moeten verbergen). 
Willem Kamphuis bedank ik voor zijn onzichtbare begeleiding. Willem, als 
leider van de glaucoomgroep ben je zo divers en breed inzetbaar als de 
glaucoomgroep zelf. Het verbaasde mij telkens hoeveel je "\vist, maar ook hoe snel je 
onderzoek en analyses uit een ander veld snapte en er ook nog iets zinnigs over kon 
zeggen, nee zelfs lastige vragen kon stellen. 
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En dan \Xrillems glaucoom-angels: Andrea en Frederike. 
\"'Vrat is er allemaal niet besproken bij ons? Er is geen betere marrier om jezelf niet 
serieus te nemen dan met jullie op een kamer te zitten. De befaamde 
kamergenotendag: ik zal me de tractaties, dansjes en liedjes nog lang blijven 
herinneren. Dankzij jullie ben ik me ervan bewust hoe belangrijk collega's en de 
sfeer op bet werk zijn. Ik zal jullie erg missen, maar wij zullen elkaar zeker blijven 
zien. Frederike, ik \Vil je bedanken voor het feit dat je ook nog mijn paranimf wil 
ZlJn. 
lviarijn, jou wil ik danken voor je steun en vriendschap door de jaren been. 
Mijn familie dank ik voor al hun steun. Casper en Michie!, ondanks het feit dat 
jullie zo verschillend zijn worden jullie toch weer samen genoemd: dank voor het 
luisteren, meedenken en de logische en niet eens altijd zo makkelijk te 
beant\:voorden lekenvragen. Lieve pap en mam, ik ben jullie oneindig dankbaar dat 
jullie altijd achter me hebben gestaan en gestimuleerd, terwijl jullie me tegelijkertijd 
vrijlieten. lk dank jullie voor alles, maar vooral voor het gevoel dat jullie mij geven 
mijn grootste fans te zijn. 
Lieve Bert-Jan, \vat wij hebben kan tegen een stootje . .0/Iet jou wil ik samen zijn. 
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